Prof. dr. A. (Ton) de Boer

Publications

2022

Scholarly publications

the Trials@Home Consortium (Accepted/In press). Opportunities and Challenges for Decentralized Clinical Trials: European Regulators’ Perspective. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.2628
Ismail, R. K., van Breeschoten, J., van der Flier, S., van Loosen, C., Pasmooij, A. M. G., van Dartel, M., van den Eertwegh, A., de Boer, A., Wouters, M., & Hilarius, D. (2022). Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis. Journal of Medical Internet Research, 24(6), e33446. https://doi.org/10.2196/33446
ESCAPE-NET Investigators (2022). Acetylsalicylic acid use is associated with reduced risk of out-of-hospital cardiac arrest in the general population: Real-world data from a population-based study. PLoS One, 17(6), 1-12. [e0267016]. https://doi.org/10.1371/journal.pone.0267016
Ismail, R. K., Suijkerbuijk, K. P. M., de Boer, A., van Dartel, M., Hilarius, D. L., Pasmooij, A. M. J., van Zeijl, M. C. T., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Blank, C. U., Boers-Sonderen, M. J., de Groot, J. W. B., Haanen, J. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., van der Veldt, A. A. M., Vreugdenhil, A., ... Wouters, M. W. J. M. (2022). Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors. Melanoma Research. https://doi.org/10.1097/CMR.0000000000000832
Trials@Home Consortium (2022). Opportunities and Challenges for Decentralized Clinical Trials: European Regulators' Perspective. Clinical Pharmacology and Therapeutics. https://doi.org/10.1002/cpt.2628
Ismail, R. K., van Breeschoten, J., Wouters, M. W. J. M., van Dartel, M., van der Flier, S., Reyners, A. K. L., de Graeff, P., Pasmooij, A. M. G., de Boer, A., Broekman, K. E., & Hilarius, D. L. (2022). Response to: Effect of dose reductions on clinical outcomes, or of outcomes on dose reductions? Breast, 62, 180. https://doi.org/10.1016/j.breast.2022.01.011

2021

Scholarly publications

Mulder, J., van Rossum, T., Mariz, S., Magrelli, A., de Boer, A., Pasmooij, A. M. G., & Stoyanova-Beninska, V. (2021). Orphan Medicinal Products for the Treatment of Pancreatic Cancer: Lessons Learned From Two Decades of Orphan Designation. Frontiers in Oncology, 11, 1-7. [809035]. https://doi.org/10.3389/fonc.2021.809035
Mulder, J., Verjans, R., Verbaanderd, C., Pean, E., Weemers, J., Leufkens, H. G. M., Pignatti, F., de Boer, A., Voest, E. E., Stoyanova-Beninska, V. V., & Pasmooij, A. M. G. (2021). Extension of Indication for Authorised Oncology Products in the European Union: A Joint Effort of Multiple Stakeholders. Frontiers in Medicine, 8, 1-5. [790782]. https://doi.org/10.3389/fmed.2021.790782
ESCAPE-NET Investigators (2021). Opioid use is associated with increased out-of-hospital cardiac arrest risk among 40,000-cases across two countries. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15157
Ismail, R. K., van Breeschoten, J., Wouters, M. W. J. M., van Dartel, M., van der Flier, S., Reyners, A. K. L., de Graeff, P., Pasmooij, A. M. G., de Boer, A., Broekman, K. E., & Hilarius, D. L. (2021). Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer. Breast, 60, 263-271. https://doi.org/10.1016/j.breast.2021.11.013
Eroglu, T. E., Blom, M. T., Souverein, P. C., de Boer, A., & Tan, H. L. (2021). Multiple categories of non-cardiac QT-prolonging drugs are associated with increased risk of out-of-hospital cardiac arrest: real-world data from a population-based study. Europace, 1-9. https://doi.org/10.1093/europace/euab251
for the ESCAPE-NET Investigators (2021). Out-of-hospital cardiac arrest and differential risk of cardiac and non-cardiac QT-prolonging drugs in 37 000 cases. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15030
de Meza, M. M., Ismail, R. K., Rauwerdink, D., van Not, O. J., van Breeschoten, J., Blokx, W. A. M., de Boer, A., van Dartel, M., Hilarius, D. L., Ellebaek, E., Bonenkamp, H. J., Blank, C. U., Aarts, M. J. B., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., Boers-Sonderen, M. J., de Groot, J. W. B., Haanen, J. B., Hospers, G. A. P., ... Wouters, M. W. J. M. (2021). Adjuvant treatment for melanoma in clinical practice – Trial versus reality. European Journal of Cancer, 158, 234-245. https://doi.org/10.1016/j.ejca.2021.08.044
Hempenius, M., Groenwold, R. H. H., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2021). Drug exposure misclassification in pharmacoepidemiology: sources and relative impact. Pharmacoepidemiology and Drug Safety, 30(12), 1703-1715. https://doi.org/10.1002/pds.5346
Eroglu, T. E., Jia, L., Blom, M. T., Verkerk, A. O., Devalla, H. D., Boink, G. J. J., Souverein, P. C., de Boer, A., & Tan, H. L. (2021). Sulfonylurea antidiabetics are associated with lower risk of out-of-hospital cardiac arrest: Real-world data from a population-based study. British Journal of Clinical Pharmacology, 87(9), 3588-3598. https://doi.org/10.1111/bcp.14774
Abedian, S., Abbasi, A., de Boer, A., Stricker, B. H., Bakker, S. J. L., van der Harst, P., Sedaghat, S., Darvishian, M., Ikram, M. A., Navis, G., Dehghan, A., Pen, I., Stolk, R. P., Snieder, H., Klungel, O. H., Souverein, P., & Alizadeh, B. Z. (2021). Effect of metabolic genetic variants on long-term disease comorbidity in patients with type 2 diabetes. Scientific Reports, 11(1), [2794]. https://doi.org/10.1038/s41598-021-82276-3
Lefeber, G. J., Knol, W., Souverein, P. C., Bouvy, M. L., de Boer, A., & Koek, H. L. (2021). Statins After Ischemic Stroke in the Oldest: A Cohort Study Using the Clinical Practice Research Datalink Database. Stroke, 52(4), 1244-1252. https://doi.org/10.1161/STROKEAHA.120.030755
Hempenius, M., Groenwold, R. H. H., Souverein, P. C., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2021). Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. British Journal of Clinical Pharmacology, 87(9), 3508-3517. https://doi.org/10.1111/bcp.14764
Trials@Home Consortium (2021). COVID-19 and the Emerging Regulatory Guidance for Ongoing Clinical Trials in the European Union. Clinical Pharmacology and Therapeutics, 109(6), 1517-1527. https://doi.org/10.1002/cpt.2225
Ismail, R. K., Sikkes, N. O., Wouters, M. W. J. M., Hilarius, D. L., Pasmooij, A. M. G., van den Eertwegh, A. J. M., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Boers-Sonderen, M. J., de Groot, J. W. B., Haanen, J. B. A. G., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Ten Tije, B-J., van der Veldt, A. A. M., Vreugdenhil, A., ... de Boer, A. (2021). Postapproval trials versus patient registries: comparability of advanced melanoma patients with brain metastases. Melanoma Research, 31(1), 58-66. https://doi.org/10.1097/CMR.0000000000000707
Houwen, J. P. A., Egberts, A. C. G., de Boer, A., van Maarseveen, E. M., Houwen, R. H. J., & Lalmohamed, A. (2021). Influence of allopurinol on thiopurine associated toxicity: A retrospective population-based cohort study. British Journal of Clinical Pharmacology, 87(5), 2333-2340. https://doi.org/10.1111/bcp.14625

2020

Scholarly publications

Rustem Gulluoglu, F., Souverein, P. C., van den Ham, H. A., de Boer, A., & Komen, J. (2020). Comparative effectiveness and safety of direct oral anticoagulants versus warfarin in UK patients with atrial fibrillation and type 2 diabetes: a retrospective cohort study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5181
Cohen, A. F., van Gerven, J., Burgos, J. G., de Boer, A., Foucher, R. A. M., Flore, H., Teitelbaum, Z., van Eden, W., Webb, A., & Cremers, S. (2020). COVID-19 vaccines: the importance of transparency and fact-based education. British Journal of Clinical Pharmacology, 86(11), 2107-2110. https://doi.org/10.1111/bcp.14581
Bergmeijer, T. O., Yasmina, A., Vos, G. J. A., Janssen, P. W. A., Hackeng, C. M., Kelder, J. C., Verma, S. S., Ritchie, M. D., Gong, L., Klein, T. E., de Boer, A., Klungel, O. H., Berg, J. M. T., & Deneer, V. H. M. (2020). Effect of CYP3A4*22 and PPAR-α genetic variants on platelet reactivity in patients treated with clopidogrel and lipid-lowering drugs undergoing elective percutaneous coronary intervention. Genes, 11(9), 1-13. [1068]. https://doi.org/10.3390/genes11091068
Stegemann, S., van Riet-Nales, D., & de Boer, A. (2020). Demographics in the 2020s—Longevity as a challenge for pharmaceutical drug development, prescribing, dispensing, patient care and quality of life. British Journal of Clinical Pharmacology, 86(10), 1899-1903. https://doi.org/10.1111/bcp.14511
Ismail, R. K., Schramel, F. M. N. H., van Dartel, M., Hilarius, D. L., de Boer, A., Wouters, M. W. J. M., & Smit, H. J. M. (2020). The Dutch Lung Cancer Audit: Nationwide quality of care evaluation of lung cancer patients. Lung Cancer, 149, 68-77. https://doi.org/10.1016/j.lungcan.2020.08.011
Althunian, T. A., de Boer, A., Mantel-Teeuwisse, A. K., Groenwold, R. H. H., Gispen-de Wied, C. C., Leufkens, H. G. M., & Klungel, O. H. (2020). Assessment of the Regulatory Dialogue Between Pharmaceutical Companies and the European Medicines Agency on the Choice of Noninferiority Margins. Clinical Therapeutics, 42(8), 1588-1594. https://doi.org/10.1016/j.clinthera.2020.06.004
van Riet-Nales, D. A., Sundberg, K., de Boer, A., & Hirschlérova, B. (2020). Developing patient centric medicines for older people: reflections from the draft EMA paper on the pharmaceutical development of medicines for use in the older population. British Journal of Clinical Pharmacology, 86, 2008-2013. https://doi.org/10.1111/bcp.14530
Barcella, C. A., Eroglu, T. E., Hulleman, M., Granfeldt, A., Souverein, P. C., Mohr, G. H., Koster, R. W., Wissenberg, M., de Boer, A., Torp-Pedersen, C., Folke, F., Blom, M. T., Gislason, G. H., & Tan, H. L. (2020). Association of beta-blockers and first-registered heart rhythm in out-of-hospital cardiac arrest: real-world data from population-based cohorts across two European countries. Europace, [euaa124]. https://doi.org/10.1093/europace/euaa124
van Zeijl, M. C. T., Ismail, R. K., de Wreede, L. C., van den Eertwegh, A. J. M., de Boer, A., van Dartel, M., Hilarius, D. L., Aarts, M. J. B., van den Berkmortel, F. W. P. J., Boers-Sonderen, M. J., de Groot, J. W. B., Hospers, G. A. P., Kapiteijn, E., Piersma, D., van Rijn, R. S., Suijkerbuijk, K. P. M., Ten Tije, A. J., van der Veldt, A. A. M., Vreugdenhil, G., ... Wouters, M. W. J. M. (2020). Real-world outcomes of advanced melanoma patients not represented in phase III trials. International Journal of Cancer, 147(12), 3461-3470. https://doi.org/10.1002/ijc.33162
Althunian, T. A., de Boer, A., Groenwold, R. H. H., Rengerink, K. O., Souverein, P. C., & Klungel, O. H. (2020). Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5065
Hempenius, M., Luijken, K., de Boer, A., Klungel, O., Groenwold, R., & Gardarsdottir, H. (2020). Quality of reporting of drug exposure in pharmacoepidemiological studies. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.5020
Dal Ré, R., de Boer, A., & James, S. K. (2020). The design can limit PRECIS─2 retrospective assessment of the clinical trial explanatory/pragmatic features. Journal of Clinical Epidemiology. https://doi.org/10.1016/j.jclinepi.2020.03.027
Zhang, Y., Souverein, P. C., Gardarsdottir, H., van den Ham, H. A., Maitland-van der Zee, A. H., & de Boer, A. (2020). Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: a population-based nested case-control study. British Journal of Clinical Pharmacology, 86(6), 1150-1164. https://doi.org/10.1111/bcp.14227
Oshagbemi, O. A., Franssen, F. M. E., Wouters, E. F. M., Maitland-van der Zee, A. H., Driessen, J. H. M., de Boer, A., & de Vries, F. (2020). C-reactive protein as a biomarker of response to inhaled corticosteroids among patients with COPD. Pulmonary Pharmacology & Therapeutics, 60, [101870]. https://doi.org/10.1016/j.pupt.2019.101870
Riet-Nales, D. A., Donkerbroek, L., Nicia, A., Oussoren, C., de Boer, A., & van den Bemt, B. (2020). The development of a test battery to assess the hand-eye functions relevant in predicting easy and accurate tablet subdivision in older people: a pilot study. British Journal of Clinical Pharmacology, 86(10), 1969-1981. https://doi.org/10.1111/bcp.14201
Weersink, R. A., Abadier, M., de Boer, A., Taxis, K., & Borgsteede, S. D. (2020). Medication safety in patients with hepatic impairment: a survey of community pharmacists' knowledge level and their practice in caring for these patients. British Journal of Clinical Pharmacology, 86(4), 763-770. https://doi.org/10.1111/bcp.14177
Lefeber, G. J., Koek, H. L., Souverein, P. C., Bouvy, M. L., de Boer, A., & Knol, W. (2020). Statins After Myocardial Infarction in the Oldest: A Cohort Study in the Clinical Practice Research Datalink Database. Journal of the American Geriatrics Society, 68(2), 329-336. https://doi.org/10.1111/jgs.16227
Eroglu, T. E., Mohr, G. H., Blom, M. T., Verkerk, A. O., Souverein, P. C., Torp-Pedersen, C., Folke, F., Wissenberg, M., van den Brink, L., Davis, R. P., de Boer, A., Gislason, G. H., & Tan, H. L. (2020). Differential effects on out-of-hospital cardiac arrest of dihydropyridines: real-world data from population-based cohorts across two European countries. European heart journal. Cardiovascular pharmacotherapy, 6, 347-355. https://doi.org/10.1093/ehjcvp/pvz038

Professional publications

Visser, B. J., Korevaar, D. A., Mokhles, M. M., Vermeer-Pragt, W., de Boer, A., & Giezen, T. J. (2020). Hoe bereikt een nieuw geneesmiddel de patiënt? Nederlands Tijdschrift voor Geneeskunde, 164.

2019

Scholarly publications

Hempenius, M., Luijken, K., De Boer, A., Klungel, O. H., Groenwold, R. H. H., & Gardarsdottir, H. (2019). Current practice in reporting exposure in pharmacoepidemiological studies. 428. Abstract from 35th International conference on Pharmacoepidemiology & therapeutic risk management., Philapdelphia, Pennsylvania, United States. https://doi.org/10.1002/pds.4864
Gieling, E., de Vries, F., Williams, R., van Onzenoort, H. A. W., de Boer, A., Ten Cate, V., Kramers, C., & Burden, A. (2019). Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists. International Journal of Clinical Pharmacy, 2019(41), 1536–1544. https://doi.org/10.1007/s11096-019-00916-1
Althunian, T. A. I., De Boer, A., Groenwold, R. H. H., Rengerink, K. O., Souverein, P. C., & Klungel, O. H. (2019). Replication of rivaroxaban once daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation in a cohort study using electronic primary care database. Pharmacoepidemiology and Drug Safety, 28(S2), 57-58. https://doi.org/10.1002/pds.4864
Claassens, D. M. F., Vos, G. J. A., Bergmeijer, T. O., Hermanides, R. S., van 't Hof, A. W. J., van der Harst, P., Barbato, E., Morisco, C., Tjon Joe Gin, R. M., Asselbergs, F. W., Mosterd, A., Herrman, J-P. R., Dewilde, W. J. M., Janssen, P. W. A., Kelder, J. C., Postma, M. J., de Boer, A., Boersma, C., Deneer, V. H. M., & Ten Berg, J. M. (2019). A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. New England Journal of Medicine, 381, 1621-1631. https://doi.org/10.1056/NEJMoa1907096
Bakhriansyah, M., Souverein, P. C., van den Hoogen, M. W. F., de Boer, A., & Klungel, O. H. (2019). Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users. Clinical journal of the American Society of Nephrology : CJASN, 14(9), 1355-1362. https://doi.org/10.2215/CJN.14331218
van Hunsel, F., Gardarsdottir, H., de Boer, A., & Kant, A. (2019). Measuring the impact of pharmacovigilance activities, challenging but important. British Journal of Clinical Pharmacology, 85(10), 2235-2237. https://doi.org/10.1111/bcp.14042
Hempenius, M., Groenwold, R. H. H., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2019). Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions. Pharmacoepidemiology and Drug Safety, 28(12), 1563-1571. https://doi.org/10.1002/pds.4851
Dal Ré, R., Avendaño Solà, C., de Boer, A., James, S. K., Rosendaal, F. R., Stephens, R., & Pa Ioannidis, J. (2019). A limited number of medicines pragmatic trials had potential for waived informed consent following the 2016 CIOMS ethical guidelines. Journal of Clinical Epidemiology, 114, 60-71. https://doi.org/10.1016/j.jclinepi.2019.06.007
Eroglu, T. E., Mohr, G. H., Blom, M. T., Torp-Pedersen, C., Souverein, P. C., De Boer, A., Gislason, G. H., & Tan, H. L. (2019). High-dose nifedipine use is associated with increased risk of out-of-hospital cardiac arrest: Multi-country case-control study. Europace, 21(suppl 2), [P568]. https://esc365.escardio.org/Congress/EHRA-2019/Young-EP-poster-session-Young-meets-Experienced/188365-high-dose-nifedipine-use-is-associated-with-increased-risk-of-out-of-hospital-cardiac-arrest-multi-country-case-control-study
Makady, A., van Acker, S., Nijmeijer, H., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2019). Conditional Financing of Drugs in the Netherlands: Past, Present, and Future-Results From Stakeholder Interviews. Value in Health, 22(4), 399-407. https://doi.org/10.1016/j.jval.2018.11.016
Bakhriansyah, M., Meyboom, R. H. B., Souverein, P. C., de Boer, A., & Klungel, O. H. (2019). Cyclooxygenase selectivity and chemical groups of non-steroidal anti-inflammatory drugs and the frequency of reporting hypersensitivity reactions: a case/non-case study in VigiBase. Fundamental and Clinical Pharmacology, 33(5), 589-600. https://doi.org/10.1111/fcp.12463
Bakhriansyah, M., Souverein, P. C., de Boer, A., & Klungel, O. H. (2019). Risk of myocardial infarction associated with non-steroidal anti-inflammatory drugs: Impact of additional confounding control for variables collected from self-reported data. Journal of Clinical Pharmacy and Therapeutics, 44(4), 623-631. https://doi.org/10.1111/jcpt.12836
Dal-Ré, R., Avendaño-Solà, C., Bloechl-Daum, B., De Boer, A., Eriksson, S., Fuhr, U., Holm, S., James, S. K., Mentz, R. J., Perucca, E., Rosendaal, F. R., & Treweek, S. (2019). Low risk pragmatic trials do not always require participants' informed consent. British Medical Journal, 364, [1092]. https://doi.org/10.1136/bmj.l1092
Henricks, L. M., van Merendonk, L. N., Meulendijks, D., Deenen, M. J., Beijnen, J. H., de Boer, A., Cats, A., & Schellens, J. H. M. (2019). Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis. International Journal of Cancer, 144(9), 2347-2354. https://doi.org/10.1002/ijc.32022
Danese, E., Raimondi, S., Montagnana, M., Tagetti, A., Langaee, T., Borgiani, P., Ciccacci, C., Carcas, A. J., Borobia, A. M., Tong, H. Y., Dávila-Fajardo, C., Botton, M. R., Bourgeois, S., Deloukas, P., Caldwell, M. D., Burmester, J. K., Berg, R. L., Cavallari, L. H., Drozda, K., ... de Boer, A. (2019). Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. Clinical Pharmacology and Therapeutics, 105(6), 1477-1491. https://doi.org/10.1002/cpt.1323
Makady, A., van Veelen, A., de Boer, A., Hillege, H., Klungel, O. H., & Goettsch, W. (2019). Implementing managed entry agreements in practice: The Dutch reality check. Health Policy, 123(3), 267-274. https://doi.org/10.1016/j.healthpol.2018.09.016
Tran-Duy, A., Connell, N. J., Vanmolkot, F. H., Souverein, P. C., de Wit, N. J., Stehouwer, C. D. A., Hoes, A. W., de Vries, F., & de Boer, A. (2019). Use of proton pump inhibitor and risk of iron deficiency: a population-based case-control study. Journal of Internal Medicine, 285(2), 205-214. https://doi.org/10.1111/joim.12826
Bakhriansyah, M., Souverein, P. C., Klungel, O. H., de Boer, A., Blom, M. T., & Tan, H. L. (2019). Non-steroidal anti-inflammatory drugs and the risk of out-of-hospital cardiac arrest: a case-control study. Europace, 21(1), 99-105. https://doi.org/10.1093/europace/euy180

2018

Scholarly publications

Makady, A., De Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). What is real-world data? A review of definitions based on literature and stakeholder interviews. 410. Abstract from 34th International conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czech Republic. https://doi.org/10.1002/pds.4629
Makady, A., Kalf, R. R. J., Ryll, B., Spurrier, G., De Boer, A., Hillege, H., Klungel, O. H., & Goettsch, W. (2018). Social media as a tool for assessing patient perspectives on quality of life in metastatic melanoma: A feasibility study 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis. Health and Quality of Life Outcomes, 16(1), [222]. https://doi.org/10.1186/s12955-018-1047-z
Klungel, O., Bakhriansyah, M., Meijboom, R., Souverein, P., & De Boer, A. (2018). Cox selectivity and chemical subgroup of non-steroidal anti-inflammatory drugs and frequency of spontaneous reporting of hypersensitivity reactions. Drug Safety, 41(11), 1166. https://doi.org/10.1007/s40264-018-0719-2
Klungel, O., Alharbi, F., De Boer, A., & Kholod, A. (2018). The impact of sex on the associations between ace inhibitors and cough and angioedema: A systematic review and meta-analysis. Drug Safety, 41(11), 1165. https://doi.org/10.1007/s40264-018-0719-2
Maagdenberg, H., Bierings, M. B., Van Ommen, C. H., Van Der Meer, F. J. M., Appel, I. M., Tamminga, R. Y. J., Cessie, S. L., Swen, J. J., Van Der Straaten, T., De Boer, A., & Maitland-Van Der Zee, A. H. (2018). Effects of age and genetic variations in VKORC1, CYP2C9 and CYP3A4 on the phenprocoumon dose in pediatric patients. Pharmacogenomics, 19(15), 1195-1202. https://doi.org/10.2217/pgs-2018-0095
Oshagbemi, O. A., Keene, S. J., Driessen, J. H. M., Jordan, R., Wouters, E. F. M., de Boer, A., de Vries, F., & Franssen, F. M. E. (2018). Trends in moderate and severe exacerbations among COPD patients in the UK from 2005 to 2013. Respiratory Medicine, 144, 1-6. https://doi.org/10.1016/j.rmed.2018.09.010
Zhang, Y., De Boer, A., Gardarsdottir, H., Van Den Ham, H. A., Maitland-Van Der Zee, A. H., & Souverein, P. C. (2018). Concurrent use of DOACs and pharmacodynamic interacting drugs is associated with an increased risk of major bleeding compared with patients using DOACs alone: Nested case-control study in UK CPRD. Pharmacoepidemiology and Drug Safety, 27, 465-466. https://doi.org/10.1002/pds.4629
Makady, A., Kalf, R., Ryll, B., Spurrier, G., De Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). Using social media to collect patient perspectives on quality of life: A feasibility study. Pharmacoepidemiology and Drug Safety, 27, 56. https://doi.org/10.1002/pds.4629
Bakhriansyah, M., Meyboom, R. H. B., Souverein, P. C., De Boer, A., & Klungel, O. H. (2018). Cyclooxygenase selectivity and chemical subgroup of non-steroidal anti-inflammatory drugs and frequency of spontaneous reporting of hypersensitivity reactions: A case/non-case study in Vigibase. Pharmacoepidemiology and Drug Safety, 27(S2), 264. https://doi.org/10.1002/pds.4629
Hempenius, M., Gardarsdottir, H., De Boer, A., Klungel, O., & Groenwold, R. (2018). Amiodarone use and the risk of acute pancreatitis: Influence of different exposure definitions on risk estimation. Pharmacoepidemiology and Drug Safety, 27, 7. https://doi.org/10.1002/pds.4629
Alharbi, F., Kholod, A., De Boer, A. A., & Klungel, O. (2018). The impact of sex on the associations between ace inhibitors and cough and angioedema: A systematic review and metaanalysis. Pharmacoepidemiology and Drug Safety, 27(S2), 466. https://doi.org/10.1002/pds.4629
Althunian, T., De Boer, A., Mantel-Teeuwisse, A. K., Groenwold, R. H. H., Gispen-De Wied, C. C., Leufkens, H. G. M., Elferink, A., & Klungel, O. H. (2018). Regulatory challenges in the design of non-inferiority trials: Evaluating scientific advice letters from the European Medicines Agency (EMA). Pharmacoepidemiology and Drug Safety, 27(S2), 149. https://doi.org/10.1002/pds.4629
Althunian, T., De Boer, A., Groenwold, R. H. H., & Klungel, O. H. (2018). Using a single non-inferiority margin or a single preserved fraction for an entire pharmacological class may be invalid for the analysis of non-inferiority: A case study of statin non-inferiority trials. Pharmacoepidemiology and Drug Safety, 27(S2), 149. https://doi.org/10.1002/pds.4629
SMART Study Group (2018). Combined use of polypill components in patients with type 2 diabetes mellitus. European Journal of Preventive Cardiology, 25(14), 1523-1531. https://doi.org/10.1177/2047487318789494
Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. (2018). Using a single non-inferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate. Journal of Clinical Epidemiology, 104, 15-23. https://doi.org/10.1016/j.jclinepi.2018.07.004
Maagdenberg, H., Bierings, M. B., van Ommen, C. H., van der Meer, F. J. M., Appel, I. M., Tamminga, R. Y. J., Le Cessie, S., Swen, J. J., van der Straaten, T., de Boer, A., & Maitland-van der Zee, A. H. (2018). The pediatric acenocoumarol dosing algorithm: The Children Anticoagulation and Pharmacogenetics Study. Journal of Thrombosis and Haemostasis. https://doi.org/10.1111/jth.14211
Taghipour Bazargani, Y., Ugurlu, M., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2018). Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. BMC Cardiovascular Disorders, 18(1), [126]. https://doi.org/10.1186/s12872-018-0858-5
Mahmoudpour, S. H., Asselbergs, F. W., Souverein, P. C., de Boer, A., & Maitland-van der Zee, A. H. (2018). Prescription Patterns of Angiotensin-Converting Enzyme Inhibitors for Various Indications: A UK Population-based Study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.13692
Gispen-De Wied, C. C., & de Boer, A. (2018). Commentary on the article 'Gender differences in clinical registration trials; is there a real problem? by Labots et al. BJCP January 2018. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.13620
van den Heuvel, J. M., Hövels, A. M., Büller, H. R., Mantel-Teeuwisse, A. K., de Boer, A., & Maitland-van der Zee, A. H. (2018). NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands. Thrombosis Journal, 16(7). https://doi.org/10.1186/s12959-017-0156-y
Sharon, L., de Boer, A., Croiset, G., Kusurkar, R. A., & Koster, A. S. (2018). A longitudinal approach to changes in the motivation of dutch pharmacists in the current continuing education system. American Journal of Pharmaceutical Education, 82(2), 135-143. [6199]. https://doi.org/10.5688/ajpe6199
Bronsveld, H. K., De Bruin, M. L., Wesseling, J., Sanders, J., Hofland, I., Jensen, V. F., Bazelier, M. T., ter Braak, B., de Boer, A., Vestergaard, P., & Schmidt, M. K. (2018). The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. BMC Cancer, 18(1), [224]. https://doi.org/10.1186/s12885-018-4072-8
Tjin A Tsoi, S. L. N. M., Croiset, G., De Boer, A., Kusurkar, R. A., & Koster, A. S. (2018). Longitudinal changes in autonomous and controlled motivation of pharmacists in the Dutch continuing education system. Pharmacy Education, 18(1), 25-26.
Tjin A Tsoi, S. L. N. M., de Boer, A., Croiset, G., Koster, A. S., van der Burgt, S., & Kusurkar, R. A. (2018). How basic psychological needs and motivation affect vitality and lifelong learning adaptability of pharmacists: a structural equation model. Advances in Health Sciences Education, 23(3), 549-566. https://doi.org/10.1007/s10459-018-9812-7
Stam-Slob, M. C., van der Graaf, Y., de Boer, A., Greving, J. P., & Visseren, F. L. J. (2018). Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. International Journal of Cardiology, 253, 148-154. https://doi.org/10.1016/j.ijcard.2017.10.080
Makady, A., van Veelen, A., Jonsson, P., Moseley, O., d'Andon, A., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2018). Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies. PharmacoEconomics, 36(3), 359–368. https://doi.org/10.1007/s40273-017-0596-z
Ahmadizar, F., Souverein, P., de Boer, A., & Maitland-van der Zee, A. H. (2018). Under-treatment of hypertension and hypercholesterolemia in children and adolescents with type 1 diabetes- Long term follow-up on time trends in the occurrence of cardiovascular disease, risk factors and medications use. British Journal of Clinical Pharmacology, 84(4), 776-785. https://doi.org/10.1111/bcp.13482
Maagdenberg, H., Bierings, M. B., van Ommen, C. H., van der Meer, F. J. M., Appel, I. M., Tamminga, R. Y. J., de Boer, A., & Maitland-van der Zee, A. H. (2018). Characteristics and quality of oral anticoagulation treatment in pediatric patients in the Netherlands based on the CAPS cohort. Journal of Thrombosis and Haemostasis, 16(1), 116-124. https://doi.org/10.1111/jth.13897
Ahmadizar, F., Vijverberg, S. J. H., Arets, H. G. M., de Boer, A., Lang, J. E., Garssen, J., Kraneveld, A., & Maitland-van der Zee, A. H. (2018). Early life antibiotic exposure increases the risk of developing allergic symptoms later in life: A meta-analysis. Allergy, 73(5), 971-986. https://doi.org/10.1111/all.13332
Fazeli Farsani, S., Abdullah-Koolmees, H., Souverein, P. C., de Boer, A., & Mantel-Teeuwisse, A. K. (2018). Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study. Pediatric Diabetes, 19(1), 121-128. https://doi.org/10.1111/pedi.12529

Professional publications

Nales, D. A., Nijholt-Faber, E. D., & de Boer, A. (2018). Druppels: onveilige of onhandige toedieningsvorm? Nederlands Tijdschrift voor Geneeskunde, 162(11), [D2577].

2017

Scholarly publications

Nijmeijer, H., van Veelen, A., De Boer, A., Hillege, H., Klungel, O., Goettsch, W., & Makady, A. (2017). Conditional financing in health technology assessment practice: The Dutch experience. International Journal of Technology Assessment in Health Care, 33, 42-43. https://search.proquest.com/openview/aa071a295fbfb195bcda188c62313717/1?pq-origsite=gscholar&cbl=36708
Baranova, E. V., Geenen, J. W., Asselbergs, F. W., Palmer, C. N., De Boer, A., Maitland-Van Der Zee, A-H., & Hövels, A. M. (2017). Early HTA in pharmacogenomics: A case example in cardiovascular drugs. Pharmacoepidemiology and Drug Safety, 26(S2), 264-265. https://doi.org/10.1002/pds.4275
Yasmina, A., Bergmeijer, T. O., Janssen, P. W. A., Vos, G. J. A., Hackeng, C. M., De Boer, A., Klungel, O. H., Ten Berg, J. M., & Deneer, V. H. M. (2017). PPAR-α genetic variants influence on-treatment platelet reactivity in patients treated with clopidogrel and lipid-lowering drugs and undergoing non-urgent percutaneous coronary intervention with stent implantation. Pharmacoepidemiology and Drug Safety, 26(S2), 261-262. https://doi.org/10.1002/pds.4275
Bakhriansyah, M., Souverein, P., De Boer, A., & Klungel, O. H. (2017). The risk of acute myocardial infarction associated with non-steroidal anti-inflammatory drugs users: Impact of additional confounding control for variables collected from self-reported data. Pharmacoepidemiology and Drug Safety, 26(S2), 89. https://doi.org/10.1002/pds.4275
Maagdenberg, H., Souverein, P. C., Bierings, M. B., De Boer, A., & Maitland-Van Der Zee, A. H. (2017). Incidence of bleeding and thrombotic events in non-institutionalized paediatric patients using warfarin in the united kingdom. Pharmacoepidemiology and Drug Safety, 26(S2), 273-274. https://doi.org/10.1002/pds.4275
Rahman, N. A. B., Yasmina, A., De Boer, A., Deneer, V. H. M., Souverein, P. C., & Klungel, O. H. (2017). Patterns of antiplatelet therapy in patients with ischaemic stroke or transient ischaemic attack. Pharmacoepidemiology and Drug Safety, 26, 495. https://doi.org/10.1002/pds.4275
Maagdenberg, H., Bierings, M. B., De Boer, A., & Maitland-Van Der Zee, A. H. (2017). The children anticoagulation and pharmacogenetics study (CAPS): Developing a dosing algorithm for acencocoumarol in paediatric patients. Pharmacoepidemiology and Drug Safety, 26, 270-271. https://doi.org/10.1002/pds.4275
Makady, A., van Veelen, P. A., Jonsson, P. V., Moseley, O., d'Andon, A., De Boer, A., Hillege, J. L., Klungel, O., & Goettsch, W. (2017). Using real-world data (RWD) in health technology assessment (HTA) practice: A comparative study of 5 HTA agencies. Value in Health, 20(9), 401. https://doi.org/10.1016/j.jval.2017.08.017
Van Den Heuvel, J. M., Hövels, A. M., Büller, H. R., Mantel-Teeuwisse, A. K., De Boer, A., & Maitland-Van Der Zee, A. H. (2017). Noacs replace VKA as preferred oral anticoagulant among new patients. Pharmacoepidemiology and Drug Safety, 26, 565-566. https://doi.org/10.1002/pds.4275
Geenen, J. W., Baranova, E. V., Asselbergs, F. W., de Boer, A., Vreman, R. A., Palmer, C. N., Maitland-van der Zee, A. H., & Hövels, A. M. (2017). Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs. Pharmacogenomics, 18(12), 1143-1153. https://doi.org/10.2217/pgs-2017-0063
Alharbi, F. F., Kholod, A. A. V., Souverein, P. C., Meijboom, R., de Groot, M. C. H., de Boer, A., & Klungel, O. H. (2017). The impact of age and sex on the reporting of cough and angioedema with renin-angiotensin system inhibitors: a case/noncase study in VigiBase. Fundamental and Clinical Pharmacology, 31(6), 676-684. https://doi.org/10.1111/fcp.12313
Ahmadizar, F., Vijverberg, S. J. H., Arets, H. G. M., de Boer, A., Garssen, J., Kraneveld, A. D., & Maitland-van der Zee, A. H. (2017). Breastfeeding is associated with a decreased risk of childhood asthma exacerbations later in life. Pediatric Allergy and Immunology, 28(7), 649-654. https://doi.org/10.1111/pai.12760
Alharbi, F. F., Souverein, P. C., de Groot, M. C. H., Blom, M. T., de Boer, A., Klungel, O. H., & Tan, H. L. (2017). The Impact of Serum Potassium-Influencing Antihypertensive Drugs on the Risk of Out-of-Hospital Cardiac Arrest: A Case Control Study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.13356
van Brummelen, E. M. J., de Boer, A., Beijnen, J. H., & Schellens, J. H. M. (2017). BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies. Oncologist. https://doi.org/10.1634/theoncologist.2017-0031
Makady, A., de Boer, A., Hillege, H., Klungel, O., & Goettsch, W. (2017). What Is Real-World Data (RWD)? A Review of Definitions Based on Literature and Stakeholder Interviews. Value in Health, 20(7), 858-865. https://doi.org/10.1016/j.jval.2017.03.008
Meulendijks, D., Henricks, L. M., Jacobs, B. A. W., Aliev, A., Deenen, M. J., de Vries, N., Rosing, H., van Werkhoven, E., de Boer, A., Beijnen, J. H., Mandigers, C. M. P. W., Soesan, M., Cats, A., & Schellens, J. H. M. (2017). Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. British Journal of Cancer, 116, 1415–1424. https://doi.org/10.1038/bjc.2017.94
Kleijnen, S., Meneses Leonardo Alves, T., Meijboom, K., Lipska, I., De Boer, A., Leufkens, H. G., & Goettsch, W. G. (2017). The impact of quality-of-life data in relative effectiveness assessments of new anti-cancer drugs in European countries. Quality of Life Research, 26(9), 2479-2488. https://doi.org/10.1007/s11136-017-1574-9
Makady, A., Ham, R. T., de Boer, A., Hillege, H., Klungel, O., Goettsch, W., & GetReal Workpackage 1 (2017). Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies. Value in Health, 20(4), 520-532. https://doi.org/10.1016/j.jval.2016.12.003
Ahmadizar, F., Vijverberg, S. J. H., Arets, H. G. M., de Boer, A., Turner, S., Devereux, G., Arabkhazaeli, A., Soares, P., Mukhopadhyay, S., Garssen, J., Palmer, C. N. A., de Jongste, J. C., Jaddoe, V. W., Duijts, L., van Meel, E. R., Kraneveld, A. D., & Maitland-van der Zee, A. H. (2017). Early life antibiotic use and the risk of asthma and asthma exacerbations in children. Pediatric Allergy and Immunology, 28(5), 430-437. https://doi.org/10.1111/pai.12725
Bakhriansyah, M., Souverein, P. C., de Boer, A., & Klungel, O. H. (2017). Gastrointestinal toxicity among patients taking selective COX-2 inhibitors or conventional NSAIDs, alone or combined with proton pump inhibitors: a case-control study. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.4183
Mahmoudpour, S. H., Veluchamy, A., Siddiqui, M. K., Asselbergs, F. W., Souverein, P. C., De Keyser, C. E., Hofman, A., Lang, C. C., Doney, A. S. F., Stricker, B. H., De Boer, A., Maitland-Van Der Zee, A. H., & Palmer, C. N. A. (2017). Meta-analysis of genome-wide association studies on the intolerance of angiotensin-converting enzyme inhibitors. Pharmacogenetics and Genomics, 27(3), 112-119. https://doi.org/10.1097/FPC.0000000000000264
Stolk, L. M., de Vries, F., Ebbelaar, C., de Boer, A., Schalekamp, T., Souverein, P., Ten Cate-Hoek, A., & Burden, A. M. (2017). Risk of myocardial infarction in patients with atrial fibrillation using vitamin K antagonists, aspirin or direct acting oral anticoagulants. British Journal of Clinical Pharmacology, 83(8), 1835-1843. https://doi.org/10.1111/bcp.13264
Alharbi, F. F., Souverein, P. C., de Groot, M. C., Maitland-van der Zee, A. H., de Boer, A., & Klungel, O. H. (2017). Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study. Journal of Human Hypertension. https://doi.org/10.1038/jhh.2017.1
Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. (2017). Defining the non-inferiority margin and analyzing non-inferiority: An overview. British Journal of Clinical Pharmacology, 83(8), 1636-1642. https://doi.org/10.1111/bcp.13280
Althunian, T. A., de Boer, A., Klungel, O. H., Insani, W. N., & Groenwold, R. H. H. (2017). Methods of defining the non-inferiority margin in randomized, double-blind controlled trials: a systematic review. Trials, 18(107), 1-9. https://doi.org/10.1186/s13063-017-1859-x
Gieling, E., van den Ham, H. A., van Onzenoort, H., Bos, J., Kramers, C., de Boer, A., de Vries, F., & Burden, A. M. (2017). Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study: a cohort study. British Journal of Clinical Pharmacology, 83(8), 1844-1859. https://doi.org/10.1111/bcp.13265
Bronsveld, H. K., Peeters, P. J. H. L., de Groot, M. C. H., de Boer, A., Schmidt, M. K., & De Bruin, M. L. (2017). Trends in breast cancer incidence among women with type-2 diabetes in British general practice. Primary Care Diabetes. https://doi.org/10.1016/j.pcd.2017.02.001
Bezin, J., Groenwold, R., Ali, M. S., Lassalle, R., Robinson, P., de Boer, A., Moore, N., Klungel, O. H., & Pariente, A. (2017). Comparative effectiveness of recommended versus less intensive drug combinations in secondary prevention of acute coronary syndrome. Pharmacoepidemiology and Drug Safety, 26(3), 285-293. https://doi.org/10.1002/pds.4171
Baranova, E. V., Verhoef, T., Ragia, G., Cessie, S. L., Asselbergs, F. W., de Boer, A., Manolopoulos, V. G., Maitland-van der Zee, A. H., & EU-PACT Group (2017). Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. Journal of Thrombosis and Haemostasis, 15(3), 465-472. https://doi.org/10.1111/jth.13615
Zhang, Y., de Boer, A., Verhoef, T. I., van der Meer, F. J., Le Cessie, S., Manolopoulos, V. G., Maitland-van der Zee, A. H., & EU-PACT Group (2017). Age-stratified outcome of genotype-guided dosing algorithm for acenocoumarol and phenprocoumon. Journal of Thrombosis and Haemostasis, 15(3), 454–464. https://doi.org/10.1111/jth.13601
Yasmina, A., de Boer, A., Deneer, V. H. M., Souverein, P. C., & Klungel, O. H. (2017). Patterns of antiplatelet drug use after a first myocardial infarction during a 10-years period. British Journal of Clinical Pharmacology, 83(3), 632-641. https://doi.org/10.1111/bcp.13139

Other output

Yasmina, A., De Boer, A., Deneer, V. H. M., Ten Berg, J. M., Groenwold, R. H. H., Souverein, P. C., & Klungel, O. H. (2017). Comparative effectiveness and safety of antiplatelet drug regimens as secondary prevention after ischemic stroke or transient ischemic attack. 490-491. Abstract from 33rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management. https://doi.org/10.1002/pds.4275

2016

Scholarly publications

Nielen, J. T. H., Emans, P. J., Dagnelie, P. C., Boonen, A., Lalmohamed, A., De Boer, A., Van Den Bemt, B. J. F., & De Vries, F. (2016). Severity of Diabetes Mellitus and Total Hip or Knee Replacement. Medicine (United States). https://doi.org/10.1097/MD.0000000000003739
Geenen, J. W., Baranova, E. V., Asselbergs, F. W., De Boer, A., Maitland-van der Zee, A., & Hövels, A. (2016). Early HTA in pharmacogenomics: A case example in cardiovascular drugs. Value in Health, 19(7), A636. https://doi.org/10.1016/j.jval.2016.09.1668
Althunian, T. A. I., De Boer, A., Klungel, O. H., Insani, W. N., & Groenwold, R. H. H. (2016). Methods of defining the noninferiority margin: A systematic review. Pharmacoepidemiology and Drug Safety, 25, 139-140. https://doi.org/10.1002/pds.4070
van der Aa, M. P., Hoving, V., van de Garde, E. M. W., de Boer, A., Knibbe, C. A. J., & van der Vorst, M. M. J. (2016). The Effect of Eighteen-Month Metformin Treatment in Obese Adolescents: Comparison of Results Obtained in Daily Practice with Results from a Clinical Trial. Journal of Obesity, 2016, [7852648]. https://doi.org/10.1155/2016/7852648
Mahmoud Pour, S. H., Siddiqui, M. K., Veluchamy, A., Asselbergs, F. W., Souverein, P. C., De Keyser, C. E., Hofman, A., Stricker, B. H., De Boer, A., Maitland-Van Der Zee, A-H., & Palmer, C. N. A. (2016). Meta-analysis of the Genome Wide Association Studies (GWAS) on the intolerance of Angiotensin Converting Enzyme Inhibitors (ACEIs). Pharmacoepidemiology and Drug Safety, 25, 383. https://doi.org/10.1002/pds.4070
Alharbi, F. F., Kholod, A. A. V., Souverein, P. C., Meyboom, R. H., de Groot, M., De Boer, A., & Klungel, O. H. (2016). A novel approach to study the impact of ethnicity on reporting of cough/angioedema with RAS inhibitors in VigiBase. Pharmacoepidemiology and Drug Safety, 25(S3), 443-44. [763]. https://doi.org/10.1002/pds.4070
Alharbi, F. F., Kholod, A. A. V., Souverein, P. C., Meyboom, R. H., de Groot, M., De Boer, A., & Klungel, O. H. (2016). The impact of age and gender on reporting of cough and angioedema with RAS inhibitors: A case/non-case in VigiBase. Pharmacoepidemiology and Drug Safety, 25, 442. [762]. https://doi.org/10.1002/pds.4070
Ahmadizar, F., Vijverberg, S., Arets, H., de Boer, A., Garssen, J., Kraneveld, A. D., & Maitland-Van Der Zee, A-H. (2016). Early life antibiotic exposure is associated with an increased risk of atopic eczema and hay fever. Allergy: European Journal of Allergy and Clinical Immunology, 71, 319. https://doi.org/10.1111/all.12974
Mahmoud Pour, S. H., Baranova, E. V., Souverein, P. C., Asselbergs, F. W., de Boer, A., Maitland-van der Zee, A. H., & PREDICTION-ADR Consortium (2016). Determinants of angiotensin converting enzyme-inhibitor (ACEI) intolerance and angioedema in the UK clinical practice research datalink. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.13090
Tjin A Tsoi, S. L. N. M., de Boer, A., Croiset, G., Koster, A. S., & Kusurkar, R. A. (2016). Factors Influencing Participation in Continuing Professional Development: A Focus on Motivation Among Pharmacists. Journal of Continuing Education in the Health Profession, 36(3), 144-150. https://doi.org/10.1097/CEH.0000000000000081
Ahmadizar, F., Vijverberg, S. J. H., Arets, H. G. M., de Boer, A., Lang, J. E., Kattan, M., Palmer, C. N. A., Mukhopadhyay, S., Turner, S., & Maitland-van der Zee, A. H. (2016). Childhood obesity in relation to poor asthma control and exacerbation: a meta-analysis. European Respiratory Journal. https://doi.org/10.1183/13993003.00766-2016
Klungel, O. H., Kurz, X., de Groot, M. C. H., Schlienger, R. G., Tcherny-Lessenot, S., Grimaldi, L., Ibáñez, L., Groenwold, R. H. H., Reynolds, R. F., Alvarez, Y., Candore, G., Durand, J., Slattery, J., Hasford, J., Rottenkolber, M., Schmiedl, S., de Abajo Iglesias, F., Gil, M., Gonzalez, R., ... On behalf of the members of work-package 2 of PROTECT (2016). Multi-centre, multi-database studies with common protocols: Lessons learnt from the IMI PROTECT project. Pharmacoepidemiology and Drug Safety, 25(supplement S1), 156-165. https://doi.org/10.1002/pds.3968
De Groot, M. C. H., Candore, G., Uddin, J., Souverein, P., Ali, M. S., Belitser, S., Huerta, C., Groenwold, R. H. H., Alvarez, Y., Slattery, J., Korevaar, J., Hoes, A. W., Roes, K. C. B., de Boer, A., Douglas, I. J., Schlienger, R. G., Reynolds, R., Klungel, O. H., & Gardarsdottir, H. (2016). Case-only designs for studying the association of antidepressants and hip or femur fracture. Pharmacoepidemiology and Drug Safety, 25(Supplement S1), 103-113. https://doi.org/10.1002/pds.3850
Kleijnen, S., Lipska, I., Leonardo Alves, T., Meijboom, K., Elsada, A., Vervölgyi, V., d'Andon, A., Timoney, A., Leufkens, H. G., De Boer, A., & Goettsch, W. G. (2016). Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. Annals of Oncology. https://doi.org/10.1093/annonc/mdw233
Leusink, M., Leusink, M., Maitland-Van Der Zee, A. H., Ding, B., Drenos, F., Drenos, F., Van Iperen, E. P. A., Van Iperen, E. P. A., Warren, H. R., Warren, H. R., Caulfield, M. J., Caulfield, M. J., Cupples, L. A., Cupples, L. A., Cushman, M., Hingorani, A. D., Hoogeveen, R. C., Hovingh, G. K., Kumari, M., ... Onland-Moret, N. C. (2016). A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. Pharmacogenomics, 17(6), 583-591. https://doi.org/10.2217/pgs.16.8
Cohen, A., Pattanaik, S., Kumar, P., Bies, R. R., De Boer, A., Ferro, A., Gilchrist, A., Isbister, G. K., Ross, S., & Webb, A. J. (2016). Organised crime against the academic peer review system. British Journal of Clinical Pharmacology, 81(6), 1012-1017. https://doi.org/10.1111/bcp.12992
Ahmadizar, F., Souverein, P. C., Arets, H. G. M., de Boer, A., & Maitland-van der Zee, A. H. (Accepted/In press). Asthma related medication use and exacerbations in children and adolescents with type 1 diabetes. Pediatric Pulmonology. https://doi.org/10.1002/ppul.23428
Lalmohamed, A., van Staa, T. P., Vestergaard, P., Leufkens, H. G. M., de Boer, A., Emans, P., Cooper, C., & de Vries, F. (2016). Statins and Risk of Lower Limb Revision Surgery: The Influence of Differences in Study Design Using Electronic Health Records From the United Kingdom and Denmark. American Journal of Epidemiology, 184(1), 58-66. https://doi.org/10.1093/aje/kwv311
Ali, M. S., Groenwold, R. H. H., Belitser, S., Souverein, P. C., Martín, E., Gatto, N. M., Huerta, C., Gardarsdottir, H., Roes, K. C. B., Hoes, A. W., de Boer, A., & Klungel, O. H. (2016). Methodological comparison of marginal structural model, time-varying Cox regression, and propensity score methods: the example of antidepressant use and the risk of hip fracture. Pharmacoepidemiology and Drug Safety, 25(Suppl 1), 114-121. https://doi.org/10.1002/pds.3864
Uddin, M. J., Groenwold, R. H. H., de Boer, A., Afonso, A. S. M., Primatesta, P., Becker, C., Belitser, S., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2016). Evaluating different physician's prescribing preference based instrumental variables in two primary care databases: A study of inhaled long-acting beta2-agonist use and the risk of myocardial infarction. Pharmacoepidemiology and Drug Safety, 25(Supplement 1), 132-141. https://doi.org/10.1002/pds.3860
Uddin, M. J., Groenwold, R. H. H., de Boer, A., Gardarsdottir, H., Martin, E., Candore, G., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2016). Instrumental variables analysis using multiple databases: An example of antidepressant use and risk of hip fracture. Pharmacoepidemiology and Drug Safety, 25(Supplement S1), 122-131. https://doi.org/10.1002/pds.3863
Uddin, M. J., Groenwold, R. H. H., Ali, M. S., de Boer, A., Roes, K. C. B., Chowdhury, M. A. B., & Klungel, O. H. (2016). Methods to control for unmeasured confounding in pharmacoepidemiology: an overview. International Journal of Clinical Pharmacy, 38(3), 714-723. https://doi.org/10.1007/s11096-016-0299-0
Nielen, J. T. H., Emans, P. J., Dagnelie, P. C., Boonen, A., Lalmohamed, A., de Boer, A., van den Bemt, B. J. F., & de Vries, F. (2016). Severity of Diabetes Mellitus and Total Hip or Knee Replacement: A Population-Based Case-Control Study. Medicine, 95(20), [e3739]. https://doi.org/10.1097/MD.0000000000003739
Maagdenberg, H., Vijverberg, S. J. H., Bierings, M. B., Carleton, B. C., Arets, H. G. M., de Boer, A., & Maitland-van der Zee, A. H. (2016). Pharmacogenomics in Pediatric Patients: Towards Personalized Medicine. Pediatric Drugs, 1-10. https://doi.org/10.1007/s40272-016-0176-2
Verhaegh, B. P. M., de Vries, F., Masclee, A. A. M., Keshavarzian, A., de Boer, A., Souverein, P. C., Pierik, M. J., & Jonkers, D. M. A. E. (2016). High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 43(9), 1004-1013. https://doi.org/10.1111/apt.13583
Tjin A Tsoi, S. L. N. M., de Boer, A., Croiset, G., Koster, A. S., & Kusurkar, R. A. (2016). Unraveling Motivational Profiles of Health Care Professionals for Continuing Education: The Example of Pharmacists in the Netherlands. Journal of Continuing Education in the Health Profession, 36(1), 46-54. https://doi.org/10.1097/CEH.0000000000000026
Schmidt, A. F., Klungel, O. H., Nielen, M., de Boer, A., Groenwold, R. H. H., & Hoes, A. W. (2016). Tailoring treatments using treatment effect modification. Pharmacoepidemiology and Drug Safety, 25(4), 355-362. https://doi.org/10.1002/pds.3965
Meulendijks, D., Henricks, L. M., Amstutz, U., Froehlich, T. K., Largiadèr, C. R., Beijnen, J. H., de Boer, A., Deenen, M. J., Cats, A., & Schellens, J. H. M. (2016). Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity. International Journal of Cancer, 138(11), 2752-2761. https://doi.org/10.1002/ijc.30014
De Boer, A., & Cohen, A. F. (2016). Digoxin and mortality: Lessons for observational studies. British Journal of Clinical Pharmacology, 81(1), 4-5. https://doi.org/10.1111/bcp.12791
De Boer, A., Cohen, A. F., Ferro, A., Flockhart, D. A., Gilchrist, A., Isbister, G., Loke, Y. K., Ross, S., Somogyi, A. A., & Webb, A. J. (2016). Editors' report for 2015, December 2015. British Journal of Clinical Pharmacology, 81(1), 6-7. https://doi.org/10.1111/bcp.12865
Schmidt, A. F., Groenwold, R. H. H., Amsellem, P., Bacon, N., Klungel, O. H., Hoes, A. W., de Boer, A., Kow, K., Maritato, K., Kirpensteijn, J., & Nielen, M. (2016). Which dogs with appendicular osteosarcoma benefit most from chemotherapy after surgery? Results from an individual patient data meta-analysis. Preventive Veterinary Medicine, 125, 116–125. https://doi.org/10.1016/j.prevetmed.2015.10.016
Ahmadizar, F., Fazeli Farsani, S., Souverein, P. C., van der Vorst, M. M., de Boer, A., & Maitland-van der Zee, A. H. (2016). Cardiovascular medication use and cardiovascular disease in children and adolescents with type 1 diabetes: a population-based cohort study. Pediatric Diabetes, 17(6), 433–440. https://doi.org/10.1111/pedi.12302
Leusink, M., Vijverberg, S. J. H., Koenderman, L., Raaijmakers, J. A. M., de Jongste, J. C., Sterk, P. J., Duiverman, E. J., Onland-Moret, N. C., Postma, D. S., de Boer, A., de Bakker, P. I. W., Koppelman, G. H., & Maitland-van der Zee, A. H. (2016). Genetic variation in uncontrolled childhood asthma despite ICS treatment. The Pharmacogenomics Journal, 16, 158–163. https://doi.org/10.1038/tpj.2015.36
Leusink, M., Onland-Moret, N. C., De Bakker, P. I. W., De Boer, A., & Maitland-Van Der Zee, A. H. (2016). Seventeen years of statin pharmacogenetics: A systematic review. Pharmacogenomics, 17(2), 163-180. https://doi.org/10.2217/pgs.15.158
Boef, A. G. C., Souverein, P. C., Vandenbroucke, J. P., van Hylckama Vlieg, A., de Boer, A., le Cessie, S., & Dekkers, O. M. (2016). Instrumental variable analysis as a complementary analysis in studies of adverse effects: venous thromboembolism and second-generation versus third-generation oral contraceptives. Pharmacoepidemiology and Drug Safety, 25(3), 317-324. https://doi.org/10.1002/pds.3956
Nielen, J. T. H., de Vries, F., Dagnelie, P. C., van den Bemt, B. J. F., Emans, P. J., Lalmohamed, A., de Boer, A., & Boonen, A. E. R. C. H. (2016). Use of thiazolidinediones and the risk of elective hip or knee replacement: a population based case-control study. British Journal of Clinical Pharmacology, 81(2), 370–378. https://doi.org/10.1111/bcp.12786
Fazeli Farsani, S., Souverein, P. C., van der Vorst, M. M. J., Knibbe, C. A. J., Herings, R. M. C., de Boer, A., & Mantel-Teeuwisse, A. K. (2016). Increasing trends in the incidence and prevalence rates of type 1 diabetes among children and adolescents in the Netherlands. Pediatric Diabetes, 17(1), 44–52. https://doi.org/10.1111/pedi.12232

Other output

Blom, M. T., Eke, E., van Hoeijen, D. A., Souverein, P. C., De Boer, A., & Tan, H. L. (2016). Sudden cardiac arrest risk of non-cardiac depolarization-blocking drugs. Circulation, 134(Suppl 1), [A19626].
Fazeli Farsani, S., Abdullah-Koolmees, H., Souverein, P. C., De Boer, A., & Mantel-Teeuwisse, A. K. (2016). Psychiatric medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study. Pharmacoepidemiology and Drug Safety, 25(S3), 175-176. https://doi.org/10.1002/pds.4070
Mahmoud Pour, S. H., Baranova, E. V., Souverein, P. C., Asselbergs, F. W., De Boer, A., & Maitland-Van Der Zee, A. (2016). Associations of comorbidities and co-medications with angioedema during the use of angiotensin converting enzyme-inhibitors within the United Kingdom clinical practice research Datalink. Value in Health, 19(3), A39. https://doi.org/10.1016/j.jval.2016.03.067
Noorsyahdy, A., De Boer, A., Deneer, V. H. M., Ten Berg, J. M., Souverein, P. C., & Klungel, O. H. (2016). Population-based effectiveness and safety of different antiplatelet regimens as secondary prevention for ischemic stroke/Transient ischemic attack. Pharmacoepidemiology and Drug Safety, 25(S3), 570. https://doi.org/10.1002/pds.4070
Bezin, J., Groenwold, R., Ali, S., Lassalle, R., De Boer, A., Moore, N., Klungel, O., & Pariente, A. (2016). Effectiveness of recommended drug classes in secondary prevention of acute coronary syndrome in France. Pharmacoepidemiology and Drug Safety, 25(S3), 258-259. https://doi.org/10.1002/pds.4070
Makady, A., Nijmeijer, H., De Boer, A., Hillege, J. L., Klungel, O., & Goettsch, W. (2016). Implementation of conditional reimbursement schemes in HTA practice: Experiences from the Netherlands. Value in Health, 19(7), A348. https://doi.org/10.1016/j.jval.2016.09.011
Ahmadizar, F., Vijverberg, S. J. H., Arets, H. G. M., De Boer, A., Lang, J. E., Garssen, J., Kraneveld, A., & Maitland-van der Zee, A. H. (2016). Early life antibiotic exposure is associated with an increased risk of allergy. European Respiratory Journal, 48(S60). https://doi.org/10.1183/13993003.congress-2016.PA3639
Ahmadizar, F., Vijverberg, S., Arets, H., De Boer, A., Lang, J., Kattan, M., Palmer, C., Mukhopadhyay, S., Turner, S., & Van Der Zee, A-H. M. (2016). Childhood obesity in relation to poor asthma control and exacerbations. Pharmacoepidemiology and Drug Safety, 25, 179-180. https://doi.org/10.1002/pds.4070
Makady, A. A. M. A., ten Ham, R. M. T., de Boer, A., Hillege, H., Klungel, O. H., & Goettsch, W. G. (2016). Policies for use of Real-World Data in Health Technology Assessment: A comparative study of 6 HTA agencies. https://doi.org/10.1016/j.jval.2016.12.003

2015

Scholarly publications

Tran-Duy, A., Vanmolkot, F. H., Souverein, P. C., Hoes, A. W., de Boer, A., Stehower, C. D., de Wit, N. J., Joore, M. A., & de Vries, F. (2015). CO-ADMINISTRATION OF PROTON PUMP INHIBITORS IN CHRONIC ASPIRIN USERS AND THE RISK OF ADVERSE CARDIOVASCULAR EVENTS: A POPULATION-BASED COHORT STUDY. Value in Health, 18(7), A378-A378.
R.W., D. Z., F., D. V., A., L., J.H.M., D., A., D. B., G., R., & C., N. (2015). Use of dipeptidyl-peptidase-4 inhibitors and the risk of pneumonia: A population-based cohort study. PLoS One, 10(10), 1-12. [e0139367]. https://doi.org/10.1371/journal.pone.0139367
Nielen, J. T. H., Van Den Bemt, B., Lalmohamed, A., De Boer, A., Boonen, A., Dagnelie, P. C., Emans, P. J., & De Vries, F. (2015). Use of glitazones and the risk of elective HIP or knee replacement: A population based case-control study. Annals of the Rheumatic Diseases, 74, 779-780. https://doi.org/10.1136/annrheumdis-2015-eular.3886
van Schie, R. M. F., Verhoef, T. I., de Boer, A., van der Meer, F. J. M., Redekop, W. K., Schalekamp, T., & Maitland-Van der Zee, A-H. (2015). Pharmacogenetics of coumarin anticoagulant therapy. In G. Grech (Ed.), Preventive and Predictive Genetics: Towards Personalised Medicine (pp. 307-328). (Advances in Predictive, Preventive and Personalised Medicine ; Vol. 9). Kluwer Academic Publishers, UK. https://doi.org/10.1007/978-3-319-15344-5_11
Ali, S., Groenwold, R. H. H., Belitser, S., Roes, K. C. B., Hoes, A. W., De Boer, A., & Klungel, O. H. (2015). Covariate balance assessment, model selection and bias in propensity score matching: A simulation study. Pharmacoepidemiology and Drug Safety, 24, 22. https://doi.org/10.1002/pds.3838
Uddin, J., Groenwold, R. H. H., Ali, M. S., Candore, G., De Groot, M. C. H., Souverein, P. C., Alvarez, Y., Belitser, S., Hoes, A. W., De Boer, A., Roes, K. C. B., Klungel, O. H., & Gardarsdottir, H. (2015). Application of the self-controlled case series design in pharmacoepidemiological studies: A cautionary note. European Journal of Epidemiology, 30(8), 903. https://doi.org/10.1007/s10654-015-0072-z
Bronsveld, H. K., Ter Braak, B., Karlstad, Ø., Vestergaard, P., Starup-Linde, J., Bazelier, M. T., de Bruin, M., De Boer, A., Siezen, C. L. E., Van De Water, B., Van Der Laan, J. W., & Schmidt, M. K. (2015). Insulin treatment and breast cancer risk; A systematic review of in vitro, animal and epidemiological evidence. Pharmacoepidemiology and Drug Safety, 24, 51-52. https://doi.org/10.1002/pds.3838
Mahmoud Pour, S. H., Asselbergs, F. W., Souverein, P. C., De Boer, A., & Maitland - van der Zee, A-H. (2015). Patterns of angiotensin converting enzyme inhibitor prescriptions for different indications: A population-based study. Pharmacoepidemiology and Drug Safety, 24, 202-203. https://doi.org/10.1002/pds.3838
Alharbi, F. F., Souverein, P. C., Blom, M. T., Tan, H. L., De Boer, A., & Klungel, O. H. (2015). Use of antihypertensive agents and the risk of out-of-hospital cardiac arrest: A case control study. Pharmacoepidemiology and Drug Safety, 24, 200. https://doi.org/10.1002/pds.3838
Yasmina, A., De Boer, A., Klungel, O. H., & Souverein, P. C. (2015). Patterns of antiplatelet use in patients with myocardial infarction and subsequent acute coronary syndrome events. Pharmacoepidemiology and Drug Safety, 24, 119. https://doi.org/10.1002/pds.3838
Alharbi, F. F., Souverein, P. C., De Groot, M. C. H., Der Zee, A. H. M-V., De Boer, A., & Klungel, O. H. (2015). The risk of acute myocardial infarction after discontinuation of antihypertensive agents. Pharmacoepidemiology and Drug Safety, 24, 199-200. https://doi.org/10.1002/pds.3838
Uddin, M. J., Groenwold, R. H. H., Ali, M. S., Candore, G., De Groot, M. C. H., Souverein, P. C., Alvarez, Y., Belitser, S., Hoes, A. W., De Boer, A., Roes, K. C. B., Klungel, O., & Gardarsdottir, H. (2015). Impact of violations of the assumptions of the self-controlled case series design in pharmacoepidemiological studies: An example of antidepressants use and the risk of hip fracture. Pharmacoepidemiology and Drug Safety, 24, 2-3. https://doi.org/10.1002/pds.3838
Ahmadizar, F., Maitland-Van Der Zee, A-H., De Boer, A., Souverein, P., & Arets, H. (2015). Asthma medication use before and after the onset of type 1 diabetes in children and adolescents: A population-based cohort study. Pharmacoepidemiology and Drug Safety, 24(S1), 275. https://doi.org/10.1002/pds.3838
Van Der Aa, M. P., Fazeli Farsani, S., Knibbe, C. A. J., De Boer, A., & Van Der Vorst, M. M. J. (Accepted/In press). Population-based studies on the epidemiology of insulin resistance in children. Journal of Diabetes Research, 2015, [362375]. https://doi.org/10.1155/2015/362375
Van Hoeijen, D. A., Blom, M. T., Bardai, A., Souverein, P. C., De Boer, A., & Tan, H. L. (2015). Reduced pre-hospital and in-hospital survival rates after out-of-hospital cardiac arrest of patients with type-2 diabetes mellitus: An observational prospective community-based study. Europace, 17(5), 753-760. https://doi.org/10.1093/europace/euv014
De Boer, A. (2015). Increased mortality by digoxin in patients with atrial fibrillation? Journal of the American College of Cardiology, 65(2), 220-221. https://doi.org/10.1016/j.jacc.2014.09.081
Blom, M. T., Jansen, S., de Jonghe, A., van Munster, B. C., de Boer, A., de Rooij, S. E., Tan, H. L., & van der Velde, N. (2015). In-hospital haloperidol use and perioperative changes in QTc-duration. The Journal of Nutrition, Health & Aging, 19(5), 583-589. https://doi.org/10.1007/s12603-015-0465-4
Fazeli Farsani, S., Souverein, P. C., Overbeek, J. A., van der Vorst, M. M. J., Knibbe, C. A. J., Herings, R. M. C., de Boer, A., & Mantel-Teeuwisse, A. K. (2015). Long term trends in oral antidiabetic drug use among children and adolescents in the Netherlands. British Journal of Clinical Pharmacology, 80(2), 294-303. https://doi.org/10.1111/bcp.12608
Bazargani, Y. T., de Boer, A., Schellens, J. H. M., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2015). Essential medicines for breast cancer in low and middle income countries. BMC Cancer, 15(591). https://doi.org/10.1186/s12885-015-1583-4
Fazelifarsani, S., Souverein, P. C., van der Vorst, M. M. J., Knibbe, C. A. J., de Boer, A., & Mantel-Teeuwisse, A. K. (2015). Chronic comorbidities in children with type 1 diabetes: a population-based cohort study. Archives of Disease in Childhood, 100(8), 763-8. https://doi.org/10.1136/archdischild-2014-307654
Warnier, M. J., Rutten, F. H., Souverein, P. C., de Boer, A., Hoes, A. W., & De Bruin, M. L. (2015). Are ECG monitoring recommendations before prescription of QT-prolonging drugs applied in daily practice? The example of haloperidol. Pharmacoepidemiology and Drug Safety, 24(7), 701-8. https://doi.org/10.1002/pds.3792
Bronsveld, H. K., ter Braak, B., Karlstad, Ø., Vestergaard, P., Starup-Linde, J., Bazelier, M. T., De Bruin, M. L., de Boer, A., Siezen, C. L. E., van de Water, B., van der Laan, J. W., & Schmidt, M. K. (2015). Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Research, 17(1), [100]. https://doi.org/10.1186/s13058-015-0611-2
Kleijnen, S., Fathallah, M., van der Linden, M. W., Vancraeynest, P., Dahmani, B., Timoney, A., De Boer, A., Leufkens, H. G., & Goettsch, W. G. (2015). Can a Joint Assessment Provide Relevant Information for National/Local Relative Effectiveness Assessments? An In-Depth Comparison of Pazopanib Assessments. Value in Health, 18(5), 663-72. https://doi.org/10.1016/j.jval.2015.03.1790
Mahmoud Pour, S. H., Asselbergs, F. W., Souverein, P., de Boer, A., & Maitland - van der Zee, A-H. (2015). Angiotensin converting enzyme inhibitors prescribing pattern for different indications: A population based study. Value in Health, 18(7), 402.
Verhoef, T. I., Redekop, W. K., de Boer, A., Maitland-van der Zee, A. H., & EU-PACT Group (2015). Economic evaluation of a pharmacogenetic dosing algorithm for coumarin anticoagulants in The Netherlands. Pharmacogenomics, 16(2), 101-14. https://doi.org/10.2217/pgs.14.149
Ahmadizar, F., Onland-Moret, N. C., de Boer, A., Liu, G., & Maitland-van der Zee, A. H. (2015). Correction: Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One, 10(10), e0141704. https://doi.org/10.1371/journal.pone.0141704
Zhang, Y., De Boer, A., Verhoef, T. I., Van Der Meer, F. J. M., Le Cessie, S., Maitland-Van Der Zee, A. H., Barallon, R., Daly, A., Maitland-Van Der Zee, A-H., Redekop, K., Stingl, J., Manolopoulos, V. G., Rosendaal, F. R., & Wadelius, M. (2015). Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. Thrombosis Research, 136(1), 94-100. https://doi.org/10.1016/j.thromres.2015.04.034
Baranova, E. V., Verhoef, T. I., Asselbergs, F. W., De Boer, A., & Maitland-Van Der Zee, A-H. (2015). Genotype-guided coumarin dosing: Where are we now and where do we need to go next? Expert Opinion on Drug Metabolism and Toxicology, 11(4), 509-522. https://doi.org/10.1517/17425255.2015.1004053
Ahmadizar, F., Onland-Moret, N. C., De Boer, A., Liu, G., & Maitland-Van Der Zee, A. H. (2015). Efficacy and safety assessment of the addition of bevacizumab to adjuvant therapy agents in cancer patients: A systematic review and meta-analysis of randomized controlled trials. PLoS One, 10(9), [e0136324]. https://doi.org/10.1371/journal.pone.0136324
Mahmoud Pour, S. H., Asselbergs, F. W., Terreehorst, I., Souverein, P. C., De Boer, A., & Maitland-Van Der Zee, A. H. (2015). Continuation of angiotensin converting enzyme inhibitor therapy, in spite of occurrence of angioedema. International Journal of Cardiology, 201, 644-645. https://doi.org/10.1016/j.ijcard.2015.08.185
Ali, M. S., Groenwold, R. H. H., Belitser, S., Pestman, W. R., Hoes, A. W., Roes, K. C. B., Boer, A. D., & Klungel, O. H. (2015). Reporting of covariate selection and balance assessment in propensity score analysis is suboptimal: A systematic review. Journal of Clinical Epidemiology, 68(2), 112-121. https://doi.org/10.1016/j.jclinepi.2014.08.011
Hazelbag, C. M., Klungel, O. H., van Staa, T. P., de Boer, A., & Groenwold, R. H. H. (2015). Left truncation results in substantial bias of the relation between time-dependent exposures and adverse events. International Journal of Epidemiology, 25(8), 590-6. https://doi.org/10.1016/j.annepidem.2015.03.019
Yska, J. P., van Roon, E. N., de Boer, A., Leufkens, H. G. M., Wilffert, B., de Heide, L. J. M., de Vries, F., & Lalmohamed, A. (2015). Remission of Type 2 Diabetes Mellitus in Patients After Different Types of Bariatric Surgery: A Population-Based Cohort Study in the United Kingdom. JAMA Surgery, 1-8. https://doi.org/10.1001/jamasurg.2015.2398
van der Zanden, R., de Vries, F., Lalmohamed, A., Driessen, J. H. M., de Boer, A., Rohde, G., Neef, C., & den Heijer, C. (2015). Use of Dipeptidyl-Peptidase-4 Inhibitors and the Risk of Pneumonia: A Population-Based Cohort Study. PLoS One, 10(10), e0139367. https://doi.org/10.1371/journal.pone.0139367
Marvig, C. L., Verhoef, T. I., De Boer, A., Kamali, F., Redekop, K., Pirmohamed, M., Daly, A. K., Manolopoulos, V. G., Wadelius, M., Bouvy, M., & Maitland-Van Der Zee, A. H. (2015). Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. Thrombosis Research, 136(1), 69-75. https://doi.org/10.1016/j.thromres.2015.04.026
Mahmoud Pour, S. H., Asselbergs, F. W., de Keyser, C. E., Souverein, P. C., Hofman, A., Stricker, B. H. C., de Boer, A., & van der Zee, A. H. (2015). Change in prescription pattern as a potential marker for adverse drug reactions of angiotensin converting enzyme inhibitors. International Journal of Clinical Pharmacy. http://www.ncbi.nlm.nih.gov/pubmed/26159317
Veldhuis-Vlug, A. G., Oei, L., Souverein, P. C., Tanck, M. W. T., Rivadeneira, F., Zillikens, M. C., Kamphuisen, P. W., Maitland-van der Zee, A. H., de Groot, M. C. H., Hofman, A., Uitterlinden, A. G., Fliers, E., de Boer, A., & Bisschop, P. H. (2015). Association of polymorphisms in the beta-2 adrenergic receptor gene with fracture risk and bone mineral density. Osteoporosis International, 26(7), 2019-2027. https://doi.org/10.1007/s00198-015-3087-0
Franken, M., Stolk, E., Scharringhausen, T., de Boer, A., & Koopmanschap, M. (2015). A comparative study of the role of disease severity in drug reimbursement decision making in four European countries. Health Policy, 119(2), 195–202. https://doi.org/10.1016/j.healthpol.2014.10.007
Uddin, M. J., Groenwold, R. H. H., van Staa, T. P., de Boer, A., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2015). Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study. Pharmacoepidemiology and Drug Safety, 24(5), 468-477. https://doi.org/10.1002/pds.3724

Other output

Verhaegh, B. P. M., De Vries, F., Masclee, A. A., Keshavarzian, A., De Boer, A., Souverein, P., Jonkers, D. M., & Pierik, M. J. (2015). Medication-induced microscopic colitis: Do recency and duration of use matter? Journal of Crohn's and Colitis, 9, 6-7. [OP010]. https://doi.org/10.1093/ecco-jcc/jju027.010
Nielen, J. T. H., Van Den Bemt, B., Lalmohamed, A., De Boer, A., Boonen, A., Dagnelie, P. C., Emans, P., & De Vries, F. (2015). Severity of diabetes mellitus and risk of total hip or knee replacement: A population based case-control study. 316. https://doi.org/10.1136/annrheumdis-2015-eular.3919
Tran-Duy, A., Vanmolkot, F. H., Souverein, P. C., Hoes, A. W., de Boer, A., Stehower, C. D., de Wit, N. J., Joore, M. A., & de Vries, F. (2015). Co-Administration of Proton Pump Inhibitors in Chronic Aspirin Users and the Risk of Adverse Cardiovascular Events: a Population-Based Cohort Study. Value in Health, 18(7), 378. [PCV28]. https://doi.org/10.1016/j.jval.2015.09.796

2014

Scholarly publications

Maitland-Van Der Zee, A. H., Daly, A. K., Kamali, F., Manolopoulous, V. G., Verhoef, T. I., Wadelius, M., De Boer, A., & Pirmohamed, M. (2014). Erratum: Patients benefit from genetics-guided coumarin anticoagulant therapy (Clinical Pharmacology and Therapeutics (2014) 96:1 (15-17) DOI:10.1038/clpt.2014.44). Clinical Pharmacology and Therapeutics, 96(3), 397. https://doi.org/10.1038/clpt.2014.142
Maitland-van Der Zee, A. H., De Boer, A., & Manolopoulos, V. G. (2014). Genotype-Guided Dosing of Vitamin K Antagonists (Dr. Maitland-Van Der Zee and colleagues reply). New England Journal of Medicine, 370(18), 1765-1766. https://doi.org/10.1056/NEJMc1402521
Baranova, E. V., Asselbergs, F. W., de Boer, A., & Maitland-van der Zee, A. H. (2014). The COAG and EU-PACT trials: What is the clinical benefit of pharmacogenetic-guided coumarin dosing during therapy initiation? Current Molecular Medicine, 14(7), 841-848. https://doi.org/10.2174/1566524014666140811114906
Koster, A. S., de Boer, A., & Tjin a Tsoi, S. (2014). Gender differences in motivation and learning preferences of pharmacists in lifelong learning. Journal of Pharmacy and Pharmacology, 2, 608-615.
Schmidt, A. F., Groenwold, R. H. H., Knol, M. J., Hoes, A. W., Nielen, M., Roes, K. C. B., De Boer, A., & Klungel, O. H. (2014). Exploring interaction effects in small samples increases rates of false-positive and false-negative findings: Results from a systematic review and simulation study. Journal of Clinical Epidemiology, 67(7), 821-829. https://doi.org/10.1016/j.jclinepi.2014.02.008
Lalmohamed, A., Vestergaard, P., de Boer, A., Leufkens, H. G. M., van Staa, T. P., & de Vries, F. (2014). Changes in mortality patterns following total hip or knee arthroplasty over the past two decades: a nationwide cohort study. Arthritis & Rheumatology, 66(2), 311-8. https://doi.org/10.1002/art.38232
Leusink, M., Onland-Moret, N. C., De Bakker, P. I. W., De Boer, A., & Maitland-Van Der Zee, A. H. (2014). Fifteen years of statin pharmacogenetics: A systematic review. European Heart Journal, 35, 42. https://doi.org/10.1093/eurheartj/ehu322
Bergmeijer, T. O., Janssen, P. W. A., Asselbergs, F. W., Schipper, J. C., Van 'T Hof, A. W., Dewilde, W. J. M., Postma, M. J., De Boer, A., Deneer, V. H. M., & Ten Berg, J. M. (2014). A tailored antiplatelet strategy in STEMI patients based on CYP2C19 genotyping is feasible in daily practice-POPular Genetics study. European Heart Journal, 35, 191-192. https://doi.org/10.1093/eurheartj/ehu323
Van Hoeijen, D. A., Blom, M. T., Bardai, A., Souverein, P. C., De Boer, A., & Tan, H. L. (2014). Reduced prehospital survival rate after out-of-hospital cardiac arrest in patients with diabetes mellitus type 2: A prospective community-based study. Circulation, 130.
Pouwels, S., de Boer, A., Leufkens, H. G. M., Weber, W. E. J., Cooper, C., van Onzenoort, H. A. W., & de Vries, F. (2014). Risk of fracture in patients with muscular dystrophies. Osteoporosis International, 25(2), 509-518. https://doi.org/10.1007/s00198-013-2442-2
van der Aa, M. P., Fazeli Farsani, S., Kromwijk, L. A. J., de Boer, A., Knibbe, C. A. J., & van der Vorst, M. M. J. (2014). How to screen obese children at risk for type 2 diabetes mellitus? Clinical Pediatrics, 53(4), 337-342. https://doi.org/10.1177/0009922813509480
Taghipour Bazargani, Y., de Boer, A., Schellens, J. H. M., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Selection of oncology medicines in low- and middle-income countries. Annals of Oncology, 25(1), 270-276. https://doi.org/10.1093/annonc/mdt514
Fazelifarsani, S., Souverein, P. C., van der Vorst, M. M. J., Mantel-Teeuwisse, A. K., Knibbe, C. A. J., & de Boer, A. (2014). Disease history and medication use as risk factors for the clinical manifestation of type 1 diabetes in children and young adults: an explorative case control study. PLoS One, 9(2), e87408. https://doi.org/10.1371/journal.pone.0087408
Taghipour Bazargani, Y., Ewen, M., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Essential medicines are more available than other medicines around the globe. PLoS One, 9(2), [e87576]. https://doi.org/10.1371/journal.pone.0087576
Yasmina Noorsyahdy, A., de Boer, A., Klungel, O. H., & Deneer, V. H. M. (2014). Pharmacogenomics of oral antiplatelet drugs. Pharmacogenomics, 15(4), 509-28. https://doi.org/10.2217/pgs.14.16
Pouwels, S., de Boer, A., Leufkens, H. G. M., Weber, W. E. J., Cooper, C., & de Vries, F. (2014). Risk of fracture in patients with Charcot-Marie-Tooth disease. Muscle & Nerve, 50(6), 919-24. https://doi.org/10.1002/mus.24240
van der Zee, P. A., & de Boer, A. (2014). Pheochromocytoma: a review on preoperative treatment with phenoxybenzamine or doxazosin. Netherlands Journal of Medicine, 72(4), 190-201.
https://dspace.library.uu.nl/bitstream/handle/1874/304261/getpdf.pdf?sequence=1
Bergmeijer, T. O., Janssen, P. W. A., Schipper, J. C., Qaderdan, K., Ishak, M., Ruitenbeek, R. S., Asselbergs, F. W., van 't Hof, A. W. J., Dewilde, W. J. M., Spanó, F., Herrman, J-P. R., Kelder, J. C., Postma, M. J., de Boer, A., Deneer, V. H. M., & ten Berg, J. M. (2014). CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. American Heart Journal, 168(1), 16-22.e1. https://doi.org/10.1016/j.ahj.2014.03.006
Warnier, M. J., Holtkamp, F. A., Rutten, F. H., Hoes, A. W., de Boer, A., Mol, P. G. M., & De Bruin, M. L. (2014). Safety information on QT-interval prolongation: comparison of European Union and United States drug labeling. Drug Discovery Today, 19(9), 1294-1297. https://doi.org/10.1016/j.drudis.2014.06.017
Kreeftmeijer-Vegter, A. R., de Boer, A., van der Vlugt-Meijer, R. H., & de Vries, P. J. (2014). The influence of the European paediatric regulation on marketing authorisation of orphan drugs for children. Orphanet Journal of Rare Diseases, 9, 120. https://doi.org/10.1186/s13023-014-0120-x
Maitland-Van Der Zee, A. H., Daly, A. K., Kamali, F., Manolopoulous, V. G., Verhoef, T. I., Wadelius, M., De Boer, A., & Pirmohamed, M. (2014). Patients benefit from genetics-guided coumarin anticoagulant therapy. Clinical Pharmacology and Therapeutics, 96(1), 15-17. https://doi.org/10.1038/clpt.2014.44
Leusink, M., De Keyser, C. E., Onland-Moret, N. C., Hofman, A., Visser, L. E., Stricker, B. H., De Bakker, P. I. W., De. Boer, A., Van Schaik, R. H. N., & Maitland-Van Der Zee, A. H. (2014). No association between CYP3A4∗22 and statin effectiveness in reducing the risk for myocardial infarction. Pharmacogenomics, 15(11), 1471-1477. https://doi.org/10.2217/pgs.14.90
van Schie, R. M. F., de Boer, A., & Maitland-van der Zee, A. H. (2014). Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses: Reply. Journal of Thrombosis and Haemostasis, 12(7), 1197-1198. https://doi.org/10.1111/jth.12603
Leusink, M., Onland-Moret, N. C., Asselbergs, F. W., Ding, B., Kotti, S., Van Zuydam, N. R., Papp, A. C., Danchin, N., Donnelly, L., Morris, A. D., Chasman, D. I., Doevendans, P. A. F. M., Klungel, O. H., Ridker, P. M., Van Gilst, W. H., Simon, T., Nyberg, F., Palmer, C. N. A., Sadee, W., ... Maitland-Van Der Zee, A. H. (2014). Cholesteryl ester transfer protein polymorphisms, statin use, and their impact on cholesterol levels and cardiovascular events. Clinical Pharmacology and Therapeutics, 95(3), 314-320.
Verhoef, T. I., Redekop, W. K., Daly, A. K., Van Schie, R. M. F., De Boer, A., & Maitland-Van Der Zee, A. H. (2014). Pharmacogenetic-guided dosing of coumarin anticoagulants: Algorithms for warfarin, acenocoumarol and phenprocoumon. British Journal of Clinical Pharmacology, 77(4), 626-641. https://doi.org/10.1111/bcp.12220
Taghipour Bazargani, Y., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Essential medicines for COPD and asthma in low and middle-income countries. Thorax, 69(12), 1149-51. https://doi.org/10.1136/thoraxjnl-2014-205249
Fazeli Farsani, S., Souverein, P. C., van der Vorst, M. M. J., Knibbe, C. A. J., de Boer, A., & Mantel - Teeuwisse, A. (2014). Population-based cohort study of anti-infective medication use before and after the onset of type 1 diabetes in children and adolescents. Antimicrobial Agents and Chemotherapy, 58(8), 4666-4674. https://doi.org/10.1128/AAC.03080-14
Taghipour Bazargani, Y., de Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists. PLoS One, 9(9), [e106072]. https://doi.org/10.1371/journal.pone.0106072
Prieto-Alhambra, D., Lalmohamed, A., Abrahamsen, B., Arden, N. K., de Boer, A., Vestergaard, P., & de Vries, F. (2014). Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. Arthritis & Rheumatology, 66(11), 3233-40. https://doi.org/10.1002/art.38789
Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., Leusink, M., Verweij, N., Sharp, S. J., Guo, Y., Giambartolomei, C., Chung, C., Peasey, A., Amuzu, A., Li, K., ... DIAGRAM Consortium, MAGIC Consortium, InterAct Consortium (2014). HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet. https://doi.org/10.1016/S0140-6736(14)61183-1
Verhoef, T. I., Redekop, W. K., Hasrat, F., de Boer, A., & Maitland-van der Zee, A. H. (2014). Cost effectiveness of new oral anticoagulants for stroke prevention in patients with atrial fibrillation in two different European healthcare settings. American journal of cardiovascular drugs : drugs, devices, and other interventions, 14(6), 451-62. https://doi.org/10.1007/s40256-014-0092-1
Schmidt, A. F., Klugkist, I., Klungel, O. H., Nielen, M., de Boer, A., Hoes, A. W., & Groenwold, R. H. H. (2014). Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs. Journal of Clinical Epidemiology, 68(4), 387-396. [8758]. https://doi.org/10.1016/j.jclinepi.2014.11.015
Yasmina, A., Deneer, V. H. M., Maitland-van der Zee, A. H., van Staa, T. P., de Boer, A., & Klungel, O. H. (2014). Application of routine electronic health record databases for pharmacogenetic research. Journal of Internal Medicine, 275(6), 590-604. https://doi.org/10.1111/joim.12226
Pouwels, S., de Boer, A., Leufkens, H. G. M., Weber, W. E. J., Cooper, C., van Staa, T. P., & de Vries, F. (2014). Risk of fracture in patients with Guillain-Barré syndrome. Osteoporosis International, 25(7), 1845-51. https://doi.org/10.1007/s00198-014-2705-6
Verhoef, T. I., Redekop, W. K., Bouvy, M. L., Dorenbos, B., Karwar, Z., van Schie, R. M. F., de Boer, A., Maitland-van der Zee, A-H., & EU-PACT Group (2014). Beliefs about medicines in Dutch acenocoumarol and phenprocoumon users. British Journal of Clinical Pharmacology, 78(2), 422-429. https://doi.org/10.1111/bcp.12346
Warnier, M. J., Rutten, F. H., De Boer, A., Hoes, A. W., & De Bruin, M. L. (2014). Resting heart rate is a risk factor for mortality in chronic obstructive pulmonary disease, but not for exacerbations or pneumonia. PLoS One, 9(8), [e105152]. https://doi.org/10.1371/journal.pone.0105152
Blom, M. T., van Hoeijen, D. A., Bardai, A., Berdowski, J., Souverein, P. C., De Bruin, M. L., Koster, R. W., de Boer, A., & Tan, H. L. (2014). Genetic, clinical and pharmacological determinants of out-of-hospital cardiac arrest: rationale and outline of the AmsteRdam Resuscitation Studies (ARREST) registry. Open Heart, 1(1), [e000112]. https://doi.org/10.1136/openhrt-2014-000112
Duijnhoven, R. G., Straus, S. M. J. M., Souverein, P. C., de Boer, A., Bosch, J. L. H. R., Hoes, A. W., & De Bruin, M. L. (2014). Long-term Use of 5α-Reductase Inhibitors and the Risk of Male Breast Cancer. Cancer Causes & Control, 25(11), 1577-1582. https://doi.org/10.1007/s10552-014-0455-6
Ali, M. S., Uddin, M. J., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., de Boer, A., Roes, K. C. B., & Klungel, O. H. (2014). Quantitative falsification of instrumental variables assumption using balance measures. Epidemiology, 25(5), 770-772. https://doi.org/10.1097/EDE.0000000000000152
Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Roes, K. C. B., Hoes, A. W., de Boer, A., & Klungel, O. H. (2014). Propensity score balance measures in pharmacoepidemiology: A simulation study. Pharmacoepidemiology and Drug Safety, 23(8), 802-811. https://doi.org/10.1002/pds.3574
Warnier, M. J., Holtkamp, F. A., Rutten, F. H., Hoes, A. W., de Boer, A., Mol, P. G. M., & de Bruin, M. L. (2014). Quality of drug label information on QT interval prolongation. International Journal of Risk and Safety in Medicine, 26(2), 89-98. https://doi.org/10.3233/JRS-140612
Uddin, M. J., Groenwold, R. H. H., de Boer, A., Belitser, S. V., Roes, K. C. B., Hoes, A. W., & Klungel, O. H. (2014). Performance of instrumental variable methods in cohort and nested case-control studies: A simulation study. Pharmacoepidemiology and Drug Safety, 23(2), 165-177. https://doi.org/10.1002/pds.3555
Maitland-van der Zee, A. H., de Boer, A., & Manolopoulos, V. G. (2014). Genotype-Guided Dosing of Vitamin K Antagonists. New England Journal of Medicine, 370(18), 1765-1766. https://doi.org/10.1056/NEJMc1402521#SA5
Baranova, E. V., Asselbergs, F. W., de Boer, A., & Maitland-van der Zee, A. H. (2014). The COAG and EU-PACT Trials: What is the Clinical Benefit of Pharmacogenetic-Guided Coumarin Dosing During Therapy Inititiation? Current Molecular Medicine, 14(7), 841-848.

Professional publications

Schouten, S., De Boer, A., & Koster, A. (2014). Autonomie-stimulerende leeromgeving maakt scholing effectief. Lifelong learning: Alles draait om de intrinsieke motivatie. Pharmaceutisch Weekblad, 149(27), 20-22.
Schouten, S. B., de Boer, A., & Koster, A. S. (2014). Lifelong learning: alles draait om de intrinsieke motivatie. Pharmaceutisch Weekblad, 149(27), 20-24.

Other output

Ali, M. S., De Groot, M., Candore, G., Groenwold, R. H. H., Souverein, P. C., Alvarez, Y., Uddin, M. J., Hoes, A. W., de Boer, A., Klungel, O. H., & Gardarsdottir, H. (2014). Antidepressant Use and the Risk of Hip Fracture: A Self-Controlled Case Series Approach in Two Primary Care Databases. Pharmacoepidemiology and Drug Safety, 23, 385-385.
Uddin, M. J., Groenwold, R. H. H., Van Staa, T. P., De Boer, A., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2014). The use of prior event rate ratio adjustment method for controlling unmeasured confounding in pharmacoepidemiologic studies: A cautionary note. Pharmacoepidemiology and Drug Safety, 23(S1), 182. [345]. https://doi.org/10.1002/pds.3701
Ali, M. S., Groenwold, R. H. H., Belitser, S. V., Hoes, A. W., De Boer, A., & Klungel, O. H. (2014). Propensity score matching and unmeasured covariate imbalance: A simulation study. Pharmacoepidemiology and Drug Safety, 23(S1), 12-13. [22]. https://doi.org/10.1002/pds.3701
Warnier, M., Rutten, F., Souverein, P., Hoes, A., De Boer, A., & De Bruin, M. (2014). Are ECG monitoring recommendations before prescription of QT prolonging drugs applied in daily practice? The example of haloperidol. Pharmacoepidemiology and Drug Safety, 23(S1), 228-229. [434]. https://doi.org/10.1002/pds.3701
Uddin, M. J., Groenwold, R. H. H., De Boer, A., Afonso, A., Primatesta, P., Becker, C., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2014). Evaluating different physician's prescribing preference based instrumental variables in the study of beta2-agonist use and the risk of acute myocardial infarction. Pharmacoepidemiology and Drug Safety, 23(S1), 32. [58]. https://doi.org/10.1002/pds.3701
Uddin, M. J., Groenwold, R. H. H., De Boer, A., Gardarsdottir, H., Martin, E., Candore, G., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2014). Instrumental variable analysis using multiple databases: An example of antidepressant use and risk of hip/femur fracture. Pharmacoepidemiology and Drug Safety, 23(S1), 30-31. [55]. https://doi.org/10.1002/pds.3701
Ali, M. S., Groenwold, R. H. H., Belitser, S. V., Souverein, P. C., Gardarsdottir, H., Hoes, A. W., De Boer, A., & Klungel, O. H. (2014). Antidepressant use and risk of hip fracture: A comparison of marginal structural models, conventional regression and propensity score methods. Pharmacoepidemiology and Drug Safety, 23(S1), 199. [377]. https://doi.org/10.1002/pds.3701
Fazelifarsani, S., Souverein, P. C., Van Der Vorst, M. M. J., Knibbe, C. A. J., De Boer, A., & Mantel-Teeuwisse, A. K. (2014). Chronic comorbidities in children and adolescents with type 1 diabetes. Pharmacoepidemiology and Drug Safety, 23(S1), 185. [351]. https://doi.org/10.1002/pds.3701
Taghipour Bazargani, Y., De Boer, A., Leufkens, H. G. M., & Mantel-Teeuwisse, A. K. (2014). Endocrine therapy for breast cancer patients in South Africa. Pharmacoepidemiology and Drug Safety, 23(S1), 70-71. [130]. https://doi.org/10.1002/pds.3701
Pour, S. H. M., De Keyser, C. E., Souverein, P. C., Asselbergs, F. W., Hofman, A., Stricker, B. H., De Boer, A., & Maitland-Van Der Zee, A-H. (2014). Discontinuation of angiotensin converting enzyme inhibitors (ACEIs) as a potential marker for adverse drug reactions (ADRs). Pharmacoepidemiology and Drug Safety, 23(S1), 379. https://doi.org/10.1002/pds.3701
Duijnhoven, R. G., Van Leeuwen, R., Straus, S. M., Imhof, S. M., Hoes, A. W., De Boer, A., & De Bruin, M. L. (2014). Effect of long-term aspirin use on the risk for neovascular age-related macular degeneration. Pharmacoepidemiology and Drug Safety, 23(S1), 323. https://doi.org/10.1002/pds.3701
Fazelifarsani, S., Souverein, P. C., Van Der Vorst, M. M. J., Knibbe, C. A. J., Herings, R. M. C., De Boer, A., & Mantel-Teeuwisse, A. K. (2014). Increasing trend of type 1 diabetes in Dutch children and adolescents (1998-2010). Pharmacoepidemiology and Drug Safety, 23(S1), 184. [349]. https://doi.org/10.1002/pds.3701

2013

Scholarly publications

Pouwels, S., Bazelier, M. T., de Boer, A., Weber, W. E., Neef, C., Cooper, C., & de Vries, F. (2013). Risk of fracture in patients with Parkinson's disease. Osteoporos Int. https://doi.org/10.1007/s00198-013-2300-2
Lalmohamed, A., Vestergaard, P., Javaid, M. K., de Boer, A., Leufkens, H. G., van Staa, T. P., & de Vries, F. (2013). Risk of gastrointestinal bleeding in patients undergoing total hip or knee replacement compared with matched controls: a nationwide cohort study. American Journal of Gastroenterology. https://doi.org/10.1038/ajg.2013.108
Van Schie, R. M. F., De Boer, A., Van Der Meer, F. J. M., & Maitland-van Der Zee, A. H. (2013). Beter balanceren dankzij armacogenetica: Op weg naar een optimale dosering van cumarinederivaten. Pharmaceutische Weekblad Wetenschappelijk Platform, 148(37).
Pouwels, S., Bazelier, M. T., de Boer, A., Weber, W. E. J., Neef, C., Cooper, C., & de Vries, F. (2013). Five-year fracture risk estimation in patients with Parkinson's disease. Bone, 56(2), 266-270. https://doi.org/10.1016/j.bone.2013.06.018
Prieto-Alhambra, D., Lalmohamed, A., Abrahamsen, B., Arden, N., De Boer, A., Vestergaard, P., & De Vries, F. (2013). Bisphosphonate use and improved implant survival: A nation-wide cohort study. Osteoarthritis and Cartilage, 21, 155-156.
Duijnhoven, R. G., Straus, S. M. J. M., Souverein, P. C., De Boer, A., Hoes, A. W., & De Bruin, M. L. (2013). Male breast cancer in users of finasteride and dutasteride: A case-control study. Pharmacoepidemiology and Drug Safety, 22, 355. https://doi.org/10.1002/pds.3512
Fazeli Farsani, S., Souverein, P. C., Van Der Vorst, M. M. J., Knibbe, C. A. J., & De Boer, A. (2013). Medication use and disease history as risk factors for the clinical manifestation of type 1 diabetes mellitus. Pharmacoepidemiology and Drug Safety, 22, 336-337. https://doi.org/10.1002/pds.3512
Fazeli Farsani, S., Souverein, P. C., Van Der Vorst, M. M. J., Knibbe, C. A. J., & De Boer, A. (2013). Prevalence and patterns of anti-infective medication use in children with type 1 diabetes mellitus. Pharmacoepidemiology and Drug Safety, 22, 336. https://doi.org/10.1002/pds.3512
Van Schie, R., Wessels, J., Aoussar, A., Verhoef, T., Schalekamp, T., Le Cessie, S., Van Der Meer, F., Rosendaal, F., De Boer, A., & Maitland-Van Der Zee, A-H. (2013). Evaluation of the effect of SNPS in CYP3A4 and CYP4F2 on the stable phenprocoumon and acenocoumarol maintenance dose. Pharmacoepidemiology and Drug Safety, 22, 327. https://doi.org/10.1002/pds.3512
Warnier, M., Holtkamp, F., Rutten, F., Hoes, A., De Boer, A., Mol, P., & De Bruin, M. (2013). Quality of label information on qt-interval prolongation of medicinal products registered in the EU. Drug Safety, 36(9), 827. https://doi.org/10.1007/s40264-013-0087-x
Warnier, M. J., Holtkamp, F. A., Rutten, F. H., Hoes, A. W., De Boer, A., Mol, P. G. M., & De Bruin, M. L. (2013). Information on QTc-interval prolongation in the summary of product characteristics. Pharmacoepidemiology and Drug Safety, 22, 248-249. https://doi.org/10.1002/pds.3512
Ali, S., Groenwold, R. H. H., Pestman, W. R., Belitser, S., Hoes, A. W., De Boer, A., & Klungel, O. H. (2013). Time-dependent propensity score and collider-stratification bias: An example of beta2-agonist use and the risk of coronary heart disease. European Journal of Epidemiology, 28(4), 291-299. https://doi.org/10.1007/s10654-013-9766-2
Alhambra, D. P., Lalmohamed, A., Abrahamsen, B., Arden, N., De Boer, A., Vestergaard, P., & De Vries, F. (2013). Bisphosphonate use and improved implant survival: A nationwide cohort study. Rheumatology, 52, 41. https://doi.org/10.1093/rheumatology/ket200
Warnier, M., Holtkamp, F., Rutten, F., Hoes, A., De Boer, A., Mol, P., & De Bruin, M. (2013). Information on QT-interval prolongation properties of medicinal products in the european and american drug label. Drug Safety, 36(9), 887. https://doi.org/10.1007/s40264-013-0087-x
Kooij, M., Van Wijk, B. L. G., Heerdink, E. R., De Boer, A., & Bouvy, M. L. (2013). Does the use of an electronic reminder device with or without counseling improve adherence to lipid-lowering treatment? The results of a randomized controlled trial. Frontiers in Pharmacology, 4 MAY. https://doi.org/10.3389/fphar.2013.00069
Jansen, S., Blom, M. T., De Jonghe, A., Van Munster, B. C., De Boer, A., De Rooij, S. E., Tan, H. L., & Van Der Velde, N. (2013). Haloperidol effects on perioperative changes in QTc-duration: A prospective in-hospital study. European Geriatric Medicine, 4, 187-188. https://doi.org/10.1016/j.eurger.2013.07.626
Starup-Linde, J., Vestergaard, P., Karlstad, O., Eriksen, S. A., Bronsveld, H. K., De Vries, F., De Boer, A., & De Bruin, M. L. (2013). CARING: Diabetes Mellitus and Risk of Cancer - A Systematic Review and Meta-Analysis. Pharmacoepidemiology and Drug Safety, 22, 402-403.
Wangge, G., De Boer, A., Klungel, O. H., Hoes, A. W., & Knol, M. J. (2013). Expert-opinion on non-inferiority margin: A case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery. Thrombosis Research, 131(4), 368-371. https://doi.org/10.1016/j.thromres.2013.01.013
Wangge, G., Klungel, O. H., Roes, K. C. B., De Boer, A., Hoes, A. W., & Knol, M. J. (2013). Should non-inferiority drug trials be banned altogether? Drug Discovery Today, 18(11-12), 601-604. https://doi.org/10.1016/j.drudis.2013.01.003
Uddin, M. J., Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., De Boer, A., Roes, K. C. B., & Klungel, O. H. (2013). Quantitative verification of instrumental variables assumption using balance measures. American Journal of Epidemiology, 177, 102. https://doi.org/10.1093/aje/kwt103
Schmidt, A. F., Groenwold, R. H. H., Pocock, S., Gueyffier, F., Hoes, A. W., De Boer, A., Nielen, M., & Klungel, O. H. (2013). Comparing effectiveness estimates from randomized and nonrandomized studies, using subgroup analyses and individual patient data. Pharmacoepidemiology and Drug Safety, 22, 29-30.
Starup-Linde, J., Karlstad, O., Eriksen, S. A., Vestergaard, P., Bronsveld, H. K., de Vries, F., Andersen, M., Auvinen, A., Haukka, J., Hjellvik, V., Bazelier, M. T., Boer, A. D., Furu, K., & De Bruin, M. L. (2013). CARING (CAncer Risk and INsulin analoGues): the association of diabetes mellitus and cancer risk with focus on possible determinants - a systematic review and a meta-analysis. Current Drug Safety, 8(5), 296-332.
Pouwels, S., de Boer, A., Javaid, M. K., Hilton-Jones, D., Verschuuren, J., Cooper, C., Leufkens, H. G., & de Vries, F. (2013). Fracture rate in patients with myasthenia gravis: the general practice research database. Osteoporosis International, 24(2), 467-76. https://doi.org/10.1007/s00198-012-1970-5
Wangge, G., Roes, K. C. B., de Boer, A., Hoes, A. W., & Knol, M. J. (2013). The challenges of determining noninferiority margins: a case study of noninferiority randomized controlled trials of novel oral anticoagulants. Canadian Medical Association Journal, 185(3), 222-227. https://doi.org/10.1503/cmaj.120142
Stuijver, D. J. F., Majoor, C. J., van Zaane, B., Souverein, P. C., de Boer, A., Dekkers, O. M., Büller, H. R., & Gerdes, V. E. A. (2013). Use of oral glucocorticoids and the risk of pulmonary embolism: a population-based case-control study. Chest, 143(5), 1337-1342. https://doi.org/10.1378/chest.12-1446
Mahmoudpour, S. H., Leusink, M., van der Putten, L., Terreehorst, I., Asselbergs, F. W., de Boer, A., & Maitland-van der Zee, A. H. (2013). Pharmacogenetics of ACE inhibitor-induced angioedema and cough: a systematic review and meta-analysis. Pharmacogenomics, 14(3), 249-60. https://doi.org/10.2217/pgs.12.206
Bardai, A., Amin, A. S., Blom, M. T., Bezzina, C. R., Berdowski, J., Langendijk, P. N. J., Beekman, L., Klemens, C. A., Souverein, P. C., Koster, R. W., de Boer, A., & Tan, H. L. (2013). Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. European Heart Journal, 34(20), 1506-16. https://doi.org/10.1093/eurheartj/eht054
Wangge, G., de Boer, A., Klungel, O. H., Hoes, A. W., & Knol, M. J. (2013). Expert-opinion on non-inferiority margin: a case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery. Thrombosis Research, 131(4), 368-71. https://doi.org/10.1016/j.thromres.2013.01.013
Sontoredjo, T. A. A., de Boer, A., & Maitland-van der Zee, A. H. (2013). Etnische farmacogenetica. Nederlands Tijdschrift voor Geneeskunde, 157(17), A6118.
Franken, M., Nilsson, F., Sandmann, F., de Boer, A., & Koopmanschap, M. (2013). Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision making. PharmacoEconomics, 31(9), 781-797. https://doi.org/10.1007/s40273-013-0074-1
Lalmohamed, A., Vestergaard, P., Javaid, M. K., de Boer, A., Leufkens, H. G. M., van Staa, T. P., & de Vries, F. (2013). Risk of gastrointestinal bleeding in patients undergoing total hip or knee replacement compared with matched controls: a nationwide cohort study. American Journal of Gastroenterology, 108(8), 1277-85. https://doi.org/10.1038/ajg.2013.108
Fazeli Farsani, S., van der Aa, M. P., van der Vorst, M. M. J., Knibbe, C. A. J., & de Boer, A. (2013). Global trends in the incidence and prevalence of type 2 diabetes in children and adolescents: a systematic review and evaluation of methodological approaches. Diabetologia, 56(7), 1471-88. https://doi.org/10.1007/s00125-013-2915-z
Duijnhoven, R. G., Straus, S. M. J. M., Raine, J. M., de Boer, A., Hoes, A. W., & De Bruin, M. L. (2013). Number of Patients Studied Prior to Approval of New Medicines: A Database Analysis. PLoS Medicine, 10(3), e1001407/1-e1001407/8. [e1001407]. https://doi.org/10.1371/journal.pmed.1001407
Donnelly, L. A., Van Zuydam, N. R., Zhou, K., Tavendale, R., Carr, F., Maitland-Van Der Zee, A. H., Leusink, M., De Boer, A., Doevendans, P. A., Asselbergs, F. W., Morris, A. D., Pearson, E. R., Klungel, O. H., Doney, A. S. F., & Palmer, C. N. A. (2013). Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenetics and Genomics, 23(10), 518-525. https://doi.org/10.1097/FPC.0b013e3283642fd6
Pouwels, S., Bazelier, M. T., de Boer, A., Weber, W. E. J., Neef, C., Cooper, C., & de Vries, F. (2013). Risk of fracture in patients with Parkinson's disease. Osteoporosis International, 24(8), 2283-90. https://doi.org/10.1007/s00198-013-2300-2
Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., de Boer, A., & Klungel, O. H. (2013). Time-dependent propensity score and collider-stratification bias: an example of beta(2)-agonist use and the risk of coronary heart disease. European Journal of Epidemiology, 28(4), 291-299.
Warnier, M. J., Blom, M. T., Bardai, A., Berdowksi, J., Souverein, P. C., Hoes, A. W., Rutten, F. H., de Boer, A., Koster, R. W., De Bruin, M. L., & Tan, H. L. (2013). Increased risk of sudden cardiac arrest in obstructive pulmonary disease: a case-control study. PLoS One, 8(6), 1-8. [e65638]. https://doi.org/10.1371/journal.pone.0065638
Lalmohamed, A., Vestergaard, P., Jansen, P. A. F., Grove, E. L., de Boer, A., Leufkens, H. G. M., van Staa, T. P., & de Vries, F. (2013). Prolonged outpatient vitamin K antagonist use and risk of venous thromboembolism in patients undergoing total hip or knee replacement. Journal of Thrombosis and Haemostasis, 11(4), 642-50. https://doi.org/10.1111/jth.12158
Verhoef, T. I., Redekop, W. K., Veenstra, D. L., Thariani, R., Beltman, P. A., van Schie, R. M., de Boer, A., Maitland-van der Zee, A-H., & EU-PACT Group (2013). Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. Pharmacogenomics, 14(8), 869-83. https://doi.org/10.2217/pgs.13.74
van Schie, R. M. F., Aoussar, A., van der Meer, F. J. M., de Boer, A., & Maitland-van der Zee, A. H. (2013). Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses. Journal of Thrombosis and Haemostasis, 11(6), 1200-3. https://doi.org/10.1111/jth.12195
for the V.S.S.O. Investigators (2013). Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: an individual patient data meta-analysis. Preventive Veterinary Medicine, 112(3-4), 414-422. https://doi.org/10.1016/j.prevetmed.2013.08.011
Blom, M. T., Warnier, M. J., Bardai, A., Berdowski, J., Koster, R. W., Souverein, P. C., Hoes, A. W., Rutten, F. H., de Boer, A., De Bruin, M. L., & Tan, H. L. (2013). Reduced in-hospital survival rates of out-of-hospital cardiac arrest victims with obstructive pulmonary disease. Resuscitation, 84(5), 569-74. https://doi.org/10.1016/j.resuscitation.2012.10.009
Bardai, A., Amin, A. S., Blom, M. T., Bezzina, C. R., Berdowski, J., Langendijk, P. N. J., Beekman, L., Klemens, C. A., Souverein, P. C., Koster, R. W., de Boer, A., & Tan, H. L. (2013). Sudden cardiac arrest associated with use of a non-cardiac drug that reduces cardiac excitability: evidence from bench, bedside, and community. European Heart Journal, 34(20), 1506-16.
Wangge, G., de Boer, A., Klungel, O. H., Hoes, A. W., & Knol, M. J. (2013). Expert-opinion on non-inferiority margin: a case study of oral anti-coagulant agents for prophylaxis of venous thromboembolic events after orthopedic surgery. Thrombosis Research, 131(4), 368-71. https://doi.org/10.1016/j.thromres.2013.01.013
van Schie, R. M. F., Wessels, J. A. M., le Cessie, S., de Boer, A., Schalekamp, T., van der Meer, F. J. M., Verhoef, T. I., van Meegen, E., Rosendaal, F. R., & Maitland-van der Zee, A. H. (2013). Corrigendum to: 'Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data' [Eur Heart J (2011) 32 (15): 1909-1917, doi:10.1093/eurheartj/ehr116]. European Heart Journal, 34(24).
Bernabe, R. D. L. C., Wangge, G., Knol, M. J., Klungel, O. H., van Delden, J. J. M., de Boer, A., Hoes, A. W., Raaijmakers, J. A. M., & van Thiel, G. J. M. W. (2013). Phase IV non-inferiority trials and additional claims of benefit. BMC Medical Research Methodology [E], 13, 70. https://doi.org/10.1186/1471-2288-13-70
Verhoef, T. I., Ragia, G., de Boer, A., Barallon, R., Kolovou, G., Kolovou, V., Konstantinides, S., Le Cessie, S., Maltezos, E., van der Meer, F. J. M., Redekop, W. K., Remkes, M., Rosendaal, F. R., van Schie, R. M. F., Tavridou, A., Tziakas, D., Wadelius, M., Manolopoulos, V. G., Maitland-van der Zee, A. H., & EU-PACT Group (2013). A Randomized Trial of Genotype-Guided Dosing of Acenocoumarol and Phenprocoumon. New England Journal of Medicine, 369(24), 2304-2312. https://doi.org/10.1056/NEJMoa1311388
Warnier, M. J., Rutten, F. H., Numans, M. E., Kors, J. A., Tan, H. L., de Boer, A., Hoes, A. W., & De Bruin, M. L. (2013). Electrocardiographic characteristics of patients with chronic obstructive pulmonary disease. COPD, 10(1), 62-71. https://doi.org/10.3109/15412555.2012.727918
Grutters, J. P., Sculpher, M., Briggs, A. H., Severens, J. L., Candel, M. J., Stahl, J. E., De Ruysscher, D., de Boer, A., Ramaekers, B. L., & Joore, M. A. (2013). Acknowledging patient heterogeneity in economic evaluation : a systematic literature review. PharmacoEconomics, 31(2), 111-23.
Biere-Rafi, S., Hutten, B. A., Squizzato, A., Ageno, W., Souverein, P. C., de Boer, A., Gerdes, V. E. A., Büller, H. R., Kamphuisen, P. W., & de Boer, A. (2013). Statin treatment and the risk of recurrent pulmonary embolism. European Heart Journal, 34(24), 1800-6. https://doi.org/10.1093/eurheartj/eht046
Wilffert, B., Swen, J. J., Mulder, H., van Schaik, R. H. N., Nijenhuis, M., Grandia, L., Maitland-van der Zee, A. H., Rongen, G. A., Schalekamp, T., van der Weide, J., de Boer, A., Guchelaar, H. J., Touw, D. J., & Deneer, V. H. M. (2013). Implementation of pharmacogenetics in evidence-based medicine: Toward advancing personalized medicine. In Handbook of personalized medicine. Advances in Nanotechnology, Drug Delivery and Theory (pp. 953-1116). Ioannis S. Vizirianakis Pan Stanford Publishing. https://doi.org/10.4032/9789814411202

Professional publications

Van Schie, R. M. F., De Boer, A., Van Der Meer, F. J. M., & Maitland-van Der Zee, A-H. (2013). Beter doseren van coumarines door farmacogenetica. Pharmaceutische Weekblad Wetenschappelijk Platform, 148(37).
Van Schie, R. M. F., De Boer, A., Van Der Meer, F. J. M., & Maitland - van der Zee, A-H. (2013). Coumarines en farmacogenetica. Pharmaceutisch Weekblad, 148(37), 24-27.
Sontoredjo, T. A. A., De Boer, A., & Maitland-Van Der Zee, A. H. (2013). Ethiek en farmacogenetica. Nederlands Tijdschrift voor Geneeskunde, 157(18).
Sontoredjo, T. A., de Boer, A., & Maitland-van der Zee, A. H. (2013). [Ethnicity in pharmacogenetics]. Nederlands Tijdschrift voor Geneeskunde, 157(17).

Other output

Kooij, M., Van Wijk, B., Heerdink, E. R., De Boer, A., & Bouvy, M. L. (2013). A community pharmacist-led intervention to improve adherence to lipid-lowering treatment by counseling and an electronic reminder device: Results of a randomized controlled trial in The Netherlands. International Journal of Clinical Pharmacy, 35(5), 879-880. https://doi.org/10.1007/s11096-013-9801-0
Verhoef, T. I., Redekop, W. K., Veenstra, D. L., Thariani, R., Beltman, P. A., Van Schie, R. M. F., De Boer, A., & Maitland-Van Der Zee, A-H. (2013). Cost-effectiveness of pharmacogenetic-guided dosing of phenprocoumon in atrial fibrillation. Pharmacoepidemiology and Drug Safety, 22, 328-329. https://doi.org/10.1002/pds.3512
Starup-Linde, J., Vestergaard, P., Karlstad, O., Eriksen, S. A., Bronsveld, H. K., De Vries, F., de Boer, A., & De Bruin, M. L. (2013). CARING: Diabetes mellitus and risk of cancer: A systematic review and meta-analysis. 183. https://doi.org/10.1007/s00125-013-3012-z
Leusink, M., Onland, N. C., Asselbergs, F. W., Ding, B., Kotti, S., Van Zuydam, N. R., Papp, A. C., Danchin, N., Donnelly, L., Morris, A. D., Chasman, D. I., Klungel, O. H., Ridker, P. M., Van Gilst, W. H., Simon, T., Nyberg, F., Palmer, C. N. A., Sadee, W., Van Der Harst, P., ... Maitland-Van Der Zee, A-H. (2013). Cholesteryl ester transfer protein (CETP) polymorphisms, statin use, and their impact on cholesterol levels and cardiovascular events. Pharmacoepidemiology and Drug Safety, 22(s1), 323-324. [648]. https://doi.org/10.1002/pds.3512
Jamal Uddin, M., Groenwold, R. H. H., De Boer, A., Belitser, S. V., Hoes, A. W., Roes, K. C. B., & Klungel, O. H. (2013). Application of instrumental variables method in pharmacoepidemiology: An example of beta2-agonist use and myocardial infarction. Pharmacoepidemiology and Drug Safety, 22(s1), 32-33. [61]. https://doi.org/10.1002/pds.3512
Groenwold, R. H., Van Staa, T. P., De Boer, A., & Klungel, O. H. (2013). Impact of censoring on estimates of adverse drug effects: A simulation study. Pharmacoepidemiology and Drug Safety, 22(s1), 219. [445]. https://doi.org/10.1002/pds.3512

2012

Scholarly publications

Peters, B. J. M., de Boer, A., Schalekamp, T., Klungel, O. H., & Maitland-van der Zee, A. H. (2012). Cardiovascular Pharmacogenetics. In Pharmacogenetics and Individualized Therapy (pp. 183-213). John Wiley and Sons Ltd. https://doi.org/10.1002/9781118116494.ch6
Lalmohamed, A., Bazelier, M. T., Van Staa, T. P., Uitdehaag, B. M., Leufkens, H. G., De Boer, A., & De Vries, F. (2012). Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. European Journal of Neurology. https://doi.org/10.1111/j.1468-1331.2012.03668.x
Lalmohamed, A., Vestergaard, P., Cooper, C., de Boer, A., Leufkens, H. G., van Staa, T. P., & de Vries, F. (2012). Timing of stroke in patients undergoing total hip replacement and matched controls: a nationwide cohort study. Stroke. https://doi.org/10.1161/STROKEAHA.112.668509
Lalmohamed, A., Vestergaard, P., Klop, C., Grove, E. L., de Boer, A., Leufkens, H. G., van Staa, T. P., & de Vries, F. (2012). Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Arch Intern Med. https://doi.org/10.1001/archinternmed.2012.2713
Lalmohamed, A., Vestergaard, P., Klop, C., Bazelier, M., de Boer, A., & de Vries, F. (2012). RISK OF GASTROINTESTINAL BLEEDINGS IN PATIENTS WITH TOTAL HIP/KNEE REPLACEMENTS AND MATCHED CONTROLS: A POPULATION-BASED COHORT STUDY IN DENMARK. Osteoporosis International, 23, S563-S564.
Harmsze, A. M., van Werkum, J. W., Hackeng, C. M., Ruven, H. J. T., Kelder, J. C., Bouman, H. J., Breet, N. J., Ten Berg, J. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2012). The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and Genomics, 22(3), 169-75. https://doi.org/10.1097/FPC.0b013e32834ff6e3
Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., Schunkert, H., Samani, N. J., Clarke, R., Hopewell, J. C., Thompson, J. F., Li, M., Thorleifsson, G., Newton-Cheh, C., Musunuru, K., ... de Boer, A. (2012). Erratum: Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study (The Lancet (2012) DOI:10.1016/S0140-6736(12) 60312-2). The Lancet, 380(9841).
Pouwels, S., De Boer, A., Lalmohamed, A., Klop, C., & De Vries, F. (2012). Risk of fracture in patients with Parkinson's disease. Bone, 50, 44-45. https://doi.org/10.1016/j.bone.2012.02.119
Duijnhoven, R. G., Straus, S. M. J. M., Raine, J., De Boer, A., Hoes, A. W., & De Bruin, M. L. (2012). Exposure to new medicines prior to market authorisation: Too few patients and insufficient follow-up. Pharmacoepidemiology and Drug Safety, 21, 224-225. https://doi.org/10.1002/pds.3324
Warnier, M. J., Blom, M., Bardai, A., Souverein, P. C., Hoes, A. W., Rutten, F., De Boer, A., De Bruin, M. L., & Tan, H. L. (2012). Patients with obstructive pulmonary disease have an increased risk of ecg documented out-of-hospital cardiac arrest. Pharmacoepidemiology and Drug Safety, 21, 265. https://doi.org/10.1002/pds.3324
Swerdlow, D. I., Holmes, M. V., Kuchenbaecker, K. B., Engmann, J. E. L., Shah, T., Sofat, R., Guo, Y., Chung, C., Peasey, A., Pfister, R., Mooijaart, S. P., Ireland, H. A., Leusink, M., Langenberg, C., Li, K., Palmen, J., Howard, P., Cooper, J. A., Drenos, F., ... Casas, J. P. (2012). The interleukin-6 receptor as a target for prevention of coronary heart disease: A mendelian randomisation analysis. The Lancet, 379(9822), 1214-1224. https://doi.org/10.1016/S0140-6736(12)60110-X
Saxena, R., Elbers, C. C., Guo, Y., Peter, I., Gaunt, T. R., Mega, J. L., Lanktree, M. B., Tare, A., Castillo, B. A., Li, Y. R., Johnson, T., Bruinenberg, M., Gilbert-Diamond, D., Rajagopalan, R., Voight, B. F., Balasubramanyam, A., Barnard, J., Bauer, F., Baumert, J., ... Keating, B. J. (2012). Erratum: Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci (American Journal of Human Genetics (2012) 90 (410-425)). American Journal of Human Genetics, 90(4), 753. https://doi.org/10.1016/j.ajhg.2012.03.001
Lalmohamed, A., Vestergaard, P., Klop, C., Bazelier, M., De Boer, A., & De Vries, F. (2012). Risk of gastrointestinal bleedings in patients with total hip/knee replacements and matched controls: A population-based cohort study in Denmark. Osteoporosis International, 23, 563-564. https://doi.org/10.1007/s00198-012-2005-y
Lalmohamed, A., Vestergaard, P., Klop, C., Pouwels, S., De Boer, A., & De Vries, F. (2012). Risk of gastrointestinal bleedings in patients with total hip/knee replacements and matched controls: A population-based cohort study in Denmark. Bone, 50, 186. https://doi.org/10.1016/j.bone.2012.02.590
Lalmohamed, A., Vestergaard, P., Pouwels, S., Klop, C., De Boer, A., & De Vries, F. (2012). Risk of venous thromboembolism in patients with total hip/knee replacements and matched controls: A population-based cohort study in Denmark. Bone, 50, 186. https://doi.org/10.1016/j.bone.2012.02.589
Lalmohamed, A., Vestergaard, P., Klop, C., Pouwels, S., De Boer, A., & De Vries, F. (2012). Risk of haemorrhagic stroke in patients with total hip/knee replacements and matched controls: A population-based cohort study in Denmark. Bone, 50, 185. https://doi.org/10.1016/j.bone.2012.02.588
Van Schie, R. M. F., Wessels, J. A. M., Van Hoorn, L. G. J., Verhoef, T. I., Schalekamp, T., Le Cessie, S., Van Der Meer, F. J. M., Rosendaal, F. R., Visser, L. E., Teichert, M., Hofman, A., Burhe, P. N., De Boer, A., & Maitland-Van Der Zee, A. H. (2012). Genetic variation in GATA-4 might affect the coumarin maintenance dose. Drug Metabolism and Drug Interactions, 27(3), 11. https://doi.org/10.1515/dmdi-2012-0025
Franken, M. G., Nilsson, F., Sandmann, F., De Boer, A., & Koopmanschap, M. A. (2012). A detailed comparison of dutch and swedish drug reimbursement decisions: What evidence is available, which criteria are used, and is the decision-making process transparent? Value in Health, 15(7), 287. https://doi.org/10.1016/j.jval.2012.08.534
Harmsze, A. M., van Werkum, J. W., Hackeng, C. M., Ruven, H. J. T., Kelder, J. C., Bouman, H. J., Breet, N. J., ten Berg, J. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2012). The influence of CYP2C19*2 and *17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting. Pharmacogenetics and Genomics, 22(3), 169-175. https://doi.org/10.1097/FPC.0b013e32834ff6e3
Saxena, R., Elbers, C. C., Guo, Y., Peter, I., Gaunt, T. R., Mega, J. L., Lanktree, M. B., Tare, A., Castillo, B. A., Li, Y. R., Johnson, T., Bruinenberg, M., Gilbert-Diamond, D., Rajagopalan, R., Voight, B. F., Balasubramanyam, A., Barnard, J., Bauer, F., Baumert, J., ... Keating, B. J. (2012). Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. American Journal of Human Genetics, 90(3), 410-425. https://doi.org/10.1016/j.ajhg.2011.12.022
Lanktree, M. B., Guo, Y., Murtaza, M., Glessner, J. T., Bailey, S. D., Onland-Moret, N. C., Lettre, G., Ongen, H., Rajagopalan, R., Johnson, T., Shen, H., Nelson, C. P., Klopp, N., Baumert, J., Padmanabhan, S., Pankratz, N., Pankow, J. S., Shah, S., Taylor, K., ... Keating, B. J. (2012). Erratum: Meta-analysis of dense genecentric association studies reveals common and uncommon variants associated with height ((The American Journal of Human Genetics (2010) 88 (6-18)). American Journal of Human Genetics, 90(6), 1116-1117. https://doi.org/10.1016/j.ajhg.2012.05.017
Lalmohamed, A., Welsing, P. M. J., Lems, W. F., Jacobs, J. W. G., Kanis, J. A., Johansson, H., De Boer, A., & De Vries, F. (2012). Calibration of FRAX ® 3.1 to the Dutch population with data on the epidemiology of hip fractures. Osteoporosis International, 23(3), 861-9. https://doi.org/10.1007/s00198-011-1852-2
Lalmohamed, A., Bazelier, M. T., Van Staa, T. P., Uitdehaag, B. M. J., Leufkens, H. G. M., De Boer, A., & De Vries, F. (2012). Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study. European Journal of Neurology, 19(7), 1007-1014. https://doi.org/10.1111/j.1468-1331.2012.03668.x
Voight, B. F., Peloso, G. M., Orho-Melander, M., Frikke-Schmidt, R., Barbalic, M., Jensen, M. K., Hindy, G., Hólm, H., Ding, E. L., Johnson, T., Schunkert, H., Samani, N. J., Clarke, R., Hopewell, J. C., Thompson, J. F., Li, M., Thorleifsson, G., Newton-Cheh, C., Musunuru, K., ... Kathiresan, S. (2012). Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. The Lancet, 380(9841), 572-80. https://doi.org/10.1016/S0140-6736(12)60312-2
Lalmohamed, A., Vestergaard, P., Klop, C., Grove, E. L., de Boer, A., Leufkens, H. G. M., van Staa, T. P., & de Vries, F. (2012). Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Archives of Internal Medicine, 172(16), 1229-35. https://doi.org/10.1001/archinternmed.2012.2713
van Schie, R. M. F., el Khedr, N., Verhoef, T. I., Teichert, M., Stricker, B. H., Hofman, A., Buhre, P. N., Wessels, J. A. M., Schalekamp, T., le Cessie, S., van der Meer, F. J. M., Rosendaal, F. R., de Boer, A., Maitland-van der Zee, A-H., & Visser, L. E. (2012). Validation of the acenocoumarol EU-PACT algorithms: similar performance in the Rotterdam Study cohort as in the original study. Pharmacogenomics, 13(11), 1239-45. https://doi.org/10.2217/pgs.12.101
Verhoef, T. I., Redekop, W. K., van Schie, R. MF., Bayat, S., Daly, A. K., Geitona, M., Haschke-Becher, E., Hughes, D. A., Kamali, F., Levin, L-Å., Manolopoulos, V. G., Pirmohamed, M., Siebert, U., Stingl, J. C., Wadelius, M., de Boer, A., Maitland-van der Zee, A-H., & EU-PACT Group (2012). Cost-effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics, 13(12), 1405-1417. https://doi.org/10.2217/pgs.12.124
Kleijnen, S., George, E., Goulden, S., d'Andon, A., Vitré, P., Osińska, B., Rdzany, R., Thirstrup, S., Corbacho, B., Nagy, B. Z., Leufkens, H. G., de Boer, A., & Goettsch, W. G. (2012). Relative effectiveness assessment of pharmaceuticals: similarities and differences in 29 jurisdictions. Value in Health, 15(6), 954-60. https://doi.org/10.1016/j.jval.2012.04.010
van Schie, R. M. F., Verhoef, T. I., Boejharat, S. B., Schalekamp, T., Wessels, J. A. M., le Cessie, S., Rosendaal, F. R., van der Meer, F. J. M., de Boer, A., & Maitland-van der Zee, A-H. (2012). Evaluation of the effect of statin use on the acenocoumarol and phenprocoumon maintenance dose. Drug Metabolism and Drug Interactions, 27(4), 229-34. https://doi.org/10.1515/dmdi-2012-0024
Lalmohamed, A., Vestergaard, P., Cooper, C., de Boer, A., Leufkens, H. G. M., van Staa, T. P., & de Vries, F. (2012). Timing of stroke in patients undergoing total hip replacement and matched controls: a nationwide cohort study. Stroke, 43(12), 3225-3229. https://doi.org/10.1161/STROKEAHA.112.668509
van Schie, R. M. F., Wessels, J. A. M., Verhoef, T. I., Schalekamp, T., le Cessie, S., van der Meer, F. J. M., Rosendaal, F. R., Visser, L. E., Teichert, M., Hofman, A., Buhre, P. N. M., de Boer, A., & Maitland-van der Zee, A-H. (2012). Evaluation of the effect of genetic variations in GATA-4 on the phenprocoumon and acenocoumarol maintenance dose. Pharmacogenomics, 13(16), 1917-1923. https://doi.org/10.2217/pgs.12.174
Verhoef, T. I., Zuurhout, M. J. L., van Schie, R. M. F., Redekop, W. K., van der Meer, F. J. M., le Cessie, S., Schalekamp, T., de Boer, A., & Maitland-van der Zee, A. H. (2012). The effect of omeprazole and esomeprazole on the maintenance dose of phenprocoumon. British Journal of Clinical Pharmacology, 74(6), 1068-1069. https://doi.org/10.1111/j.1365-2125.2012.04295.x
Verhoef, T. I., Redekop, W. K., Hegazy, H., de Boer, A., Maitland-van der Zee, A. H., & EU-PACT Group (2012). Long-term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. Journal of Thrombosis and Haemostasis, 10(12), 2610-2612. https://doi.org/10.1111/jth.12007
Verhoef, T. I., Redekop, W. K., Buikema, M. M., Schalekamp, T., Van Der Meer, F. J. M., Le Cessie, S., Wessels, J. A. M., Van Schie, R. M. F., De Boer, A., Teichert, M., Visser, L. E., Maitland-Van Der Zee, A. H., & EU-PACT Group (2012). Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. Journal of Thrombosis and Haemostasis, 10(4), 606-614. https://doi.org/10.1111/j.1538-7836.2012.04633.x
van Schie, R. M. F., Babajeff, A. M. V., Schalekamp, T., Wessels, J. A. M., le Cessie, S., de Boer, A., van der Meer, F. J. M., van Meegen, E., Verhoef, T. I., Rosendaal, F. R., Maitland-van der Zee, A. H., & EU-PACT Study Group (2012). An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. Journal of Thrombosis and Haemostasis, 10(5), 767-772. https://doi.org/10.1111/j.1538-7836.2012.04694.x
van Vliet-Ostaptchouk, J. V., van Haeften, T. W., Landman, G. W. D., Reiling, E., Kleefstra, N., Bilo, H. J. G., Klungel, O. H., de Boer, A., van Diemen, C. C., Wijmenga, C., Boezen, H. M., Dekker, J. M., van 't Riet, E., Nijpels, G., Welschen, L. M. C., Zavrelova, H., Bruin, E. J., Elbers, C. C., Bauer, F., ... 't Hart, L. M. (2012). Common variants in the type 2 diabetes KCNQ1 gene are associated with impairments in insulin secretion during hyperglycaemic glucose clamp. PLoS One, 7(3), e32148. https://doi.org/10.1371/journal.pone.0032148
Warnier, M. J., Rutten, F. H., Kors, J. A., Lammers, J. W. J., de Boer, A., Hoes, A. W., & de Bruin, M. L. (2012). Cardiac arrhythmias in adult patients with asthma. Journal of Asthma, 49(9), 942-6. https://doi.org/10.3109/02770903.2012.724132

Professional publications

De Boer, A., & Maitland-Van Der Zee, A. H. (2012). Implementatie van farmacogenetica in de klinische praktijk: dermatologisch perspectief. Nederlands Tijdschrift voor Dermatologie en Venereologie, 22(3), 171-174.

Other output

Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S., Hoes, A. W., Roes, K. C. B., De Boer, A., & Klungel, O. H. (2012). Evaluating propensity score balance measures in typical pharmacoepidemiological settings. Pharmacoepidemiology and Drug Safety, 21(S3), 36-37. [72]. https://doi.org/10.1002/pds.3324
Ali, M. S., Groenwold, R. H. H., Pestman, W. R., Belitser, S. V., Hoes, A. W., De Boer, A., & Klungel, O. H. (2012). Time-dependent propensity score and collider-stratification bias: Inhaled beta2-agonist and risk of coronary heart disease. Pharmacoepidemiology and Drug Safety, 21(S3), 252. [537]. https://doi.org/10.1002/pds.3324

2011

Scholarly publications

Pouwels, S., Lalmohamed, A., Souverein, P., Cooper, C., Veldt, B. J., Leufkens, H. G., De Boer, A., Van Staa, T., & De Vries, F. (2011). Use of proton pump inhibitors and risk of hip/femur fracture: A population-based case-control study. Osteoporosis International. https://doi.org/10.1007/s00198-010-1337-8
Harmsze, A. M., Van Werkum, J. W., Moral, F., Ten Berg, J. N. M., Hackeng, C. M., Klungel, O. H., De Boer, A., & Deneer, V. H. M. (2011). Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets, 22(2), 98-102. https://doi.org/10.3109/09537104.2010.530359
Butterworth, A. S., Braund, P., Farrall, M., Hardwick, R. J., Saleheen, D., Peden, J., Soranzo, N., Chambers, J. C., Sivapalaratnam, S., Kleber, M. E., Keating, B., Qasim, A., Klopp, N., Erdmann, J., Assimes, T. L., Ball, S. G., Balmforth, A. J., Barnes, T., Basart, H., ... Wallace, C. (2011). Large-scale gene-centric analysis identifies novel variants for coronary artery disease. PLoS Genetics, 7(9). https://doi.org/10.1371/journal.pgen.1002260
Van Zaane, B., Squizzato, A., Biere-Rafi, S., Souverein, P. C., Brandjes, D. P. M., Buller, H. R., Gerdes, V. E. A., & De Boer, A. (2011). Thyroid disease, antithyroid or thyreomimetic agents, and the risk of pulmonary embolism. Journal of Thrombosis and Haemostasis, 9, 413. https://doi.org/10.1111/j.1538-7836.2011.04380_2.x
Pouwels, S., Javaid, M., De Boer, A., & De Vries, F. (2011). Risk of fracture in patients with Myasthenia Gravis: The general practice research database. Bone, 48, 270. https://doi.org/10.1016/j.bone.2011.03.668
Biere-Rafi, S., Di Nisio, M., Gerdes, V., Porreca, E., Souverein, P., de Boer, A., Büller, H., & Kamphuisen, P. (2011). Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiology and Drug Safety, 20(6), 635-642. https://doi.org/10.1002/pds.2130
Harmsze, A. M., VanWerkum, J. W., Souverein, P. C., Bouman, H. J., Hackeng, C. M., Ruven, H. J. T., Ten Berg, J. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2011). Combined influence of PPIs, CCBs and CYP2C19∗2 on on-treatment platelet reactivitiy and on the occurrence of atherothrombotic events in patients undergoing coronary stent implantation. European Heart Journal, 32, 239-240. https://doi.org/10.1093/eurheartj/ehr322
Belitser, S., Martens, E. P., Pestman, W. R., Groenwold, R. H. H., De Boer, A., & Klungel, O. H. (2011). Measuring balance and model selection in propensity score methods. Pharmacoepidemiology and Drug Safety, 20(11), 1115-1129. https://doi.org/10.1002/pds.2188
Maitland-Van Der Zee, A-H., Van Wieren-De Wijer, D. B. M. A., De Boer, A., Kroon, A. A., De Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., Psaty, B. M., Van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2011). Genetic variation in the renin-angiotensin system, use of renin-angiotensin system inhibitors and the risk of myocardial infarction. Journal of the renin-angiotensin-aldosterone system, 12(3), 208-214. https://doi.org/10.1177/1470320310391834
Pouwels, S., Lalmohamed, A., Souverein, P., Cooper, C., Veldt, B. J., Leufkens, H. G., de Boer, A., van Staa, T., & de Vries, F. (2011). Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study. Osteoporosis International, 22(3), 903-10. https://doi.org/10.1007/s00198-010-1337-8
de Peuter, O. R., Souverein, P. C., Klungel, O. H., Büller, H. R., de Boer, A., & Kamphuisen, P. W. (2011). Non-selective vs. selective beta-blocker treatment and the risk of thrombo-embolic events in patients with heart failure. European Journal of Heart Failure, 13(2), 220-6. https://doi.org/10.1093/eurjhf/hfq176
Mattila, T., Stoyanova, V., Elferink, A., Gispen-de Wied, C., de Boer, A., & Wohlfarth, T. (2011). Insomnia medication: do published studies reflect the complete picture of efficacy and safety? European Neuropsychopharmacology, 21(7), 500-7. https://doi.org/10.1016/j.euroneuro.2010.10.005
Swen, J. J., Nijenhuis, M., de Boer, A., Grandia, L., Maitland-van der Zee, A. H., Mulder, H., Rongen, G. A. P. J. M., van Schaik, R. H. N., Schalekamp, T., Touw, D. J., van der Weide, J., Wilffert, B., Deneer, V. H. M., & Guchelaar, H-J. (2011). Pharmacogenetics: from bench to byte--an update of guidelines. Clinical Pharmacology and Therapeutics, 89(5), 662-673. https://doi.org/10.1038/clpt.2011.34
Harmsze, A. M., de Boer, A., Boot, H., Deneer, V. H. M., Heringa, M., Mol, P. G. M., Schalekamp, T., Verduijn, M. M., Verheugt, F. W. A., & le Comte, M. (2011). Interactie tussen clopidogrel en protonpompremmers. Nederlands Tijdschrift voor Geneeskunde, 155(28), A2442.
Bazelier, M., de Boer, A., & de Vries, F. (2011). Acid suppressants and hip fracture: duplicate publication bias? Bone, 49(4), 920; author reply 921. https://doi.org/10.1016/j.bone.2011.07.025
de Boer, A. (2011). When to publish measures of disproportionality derived from spontaneous reporting databases? British Journal of Clinical Pharmacology, 72(6), 909-911. https://doi.org/10.1111/j.1365-2125.2011.04087.x
Groenwold, R. H. H., de Vries, F., de Boer, A., Pestman, W. R., Rutten, F. H., Hoes, A. W., & Klungel, O. H. (2011). Balance measures for propensity score methods: a clinical example on beta-agonist use and the risk of myocardial infarction. Pharmacoepidemiology and Drug Safety, 20(11), 1130-1137. https://doi.org/10.1002/pds.2251
van den Hoek, H. L., Bos, W. J. W., de Boer, A., & van de Garde, E. M. W. (2011). Statins and prevention of infections: systematic review and meta-analysis of data from large randomised placebo controlled trials. BMJ - Clinical research, 343, d7281.
Peters, B. J. M., Pett, H., Klungel, O. H., Stricker, B. H. C., Psaty, B. M., Glazer, N. L., Wiggins, K. L., Bis, J. C., de Boer, A., & Maitland-van der Zee, A-H. (2011). Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis, 217(2), 458-464. https://doi.org/10.1016/j.atherosclerosis.2011.06.023
Peters, B. J. M., Harmsze, A. M., ten Berg, J. M., Maitland-van der Zee, A-H., Tjoeng, M. M., de Boer, A., & Deneer, V. H. M. (2011). CYP2C19 and ABCB1 genes and individualized treatment with clopidogrel. Pharmacogenomics, 12(2), 141-4. https://doi.org/10.2217/pgs.10.211
Blom, M. T., Bardai, A., van Munster, B. C., Nieuwland, M-I., de Jong, H., van Hoeijen, D. A., Spanjaart, A. M., de Boer, A., de Rooij, S. E., & Tan, H. L. (2011). Differential changes in QTc duration during in-hospital haloperidol use. PLoS One, 6(9), e23728. https://doi.org/10.1371/journal.pone.0023728
van Schie, R. M. F., de Boer, A., & Maitland-van der Zee, A. H. (2011). Implementation of pharmacogenetics in clinical practice is challenging. Pharmacogenomics, 12(9), 1231-1233. https://doi.org/10.2217/pgs.11.81
Varekamp, I., Verbeek, J. H. A. M., de Boer, A., & van Dijk, F. J. H. (2011). Effect of job maintenance training program for employees with chronic disease - a randomized controlled trial on self-efficacy, job satisfaction, and fatigue. Scandinavian Journal of Work, Environment & Health, 37(4), 288-97.
van Schie, R. M. F., Wessels, J. A. M., le Cessie, S., de Boer, A., Schalekamp, T., van der Meer, F. J. M., Verhoef, T. I., van Meegen, E., Rosendaal, F. R., Maitland-van der Zee, A-H., & EU-PACT Study Group (2011). Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. European Heart Journal, 32(15), 1909-1917. https://doi.org/10.1093/eurheartj/ehr116
Eussen, S. R. B. M., Bouvy, M. L., Rompelberg, C. J. M., van der Elst, M. E., Garssen, J., Oosterveld, M. H., de Boer, A., de Gier, J. J., van Kranen, H. J., & Klungel, O. H. (2011). Influence of the use of functional foods enriched with phytosterols/-stanols on adherence to statin therapy. Pharmacoepidemiology and Drug Safety, 20(8), 830-7. https://doi.org/10.1002/pds.2168
Deenen, M. J., Tol, J., Burylo, A. M., Doodeman, V. D., de Boer, A., Vincent, A., Guchelaar, H-J., Smits, P. H. M., Beijnen, J. H., Punt, C. J. A., Schellens, J. H. M., & Cats, A. (2011). Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clinical Cancer Research, 17(10), 3455-68. https://doi.org/10.1158/1078-0432.CCR-10-2209
De Peuter, O. R., Lip, G. Y., Souverein, P. C., Klungel, O. H., de Boer, A., Buller, H. R., & Kamphuisen, P. W. (2011). Time-trends in treatment and cardiovascular events in patients with heart failure: a pharmacosurveillance study. European Journal of Heart Failure, 13(5), 489-495.
Harmsze, A. M., Van Werkum, J. W., Souverein, P. C., Breet, N. J., Bouman, H. J., Hackeng, C. M., Ruven, H. J. T., Ten Berg, J. M., Klungel, O. H., De Boer, A., & Deneer, V. H. M. (2011). Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. Journal of Thrombosis and Haemostasis, 9(10), 1892-1901. https://doi.org/10.1111/j.1538-7836.2011.04483.x
Noguera, P., Posthuma-Trumpie, G. A., van Tuil, M., van der Wal, F. J., de Boer, A., Moers, A. P., & van Amerongen, A. (2011). Carbon nanoparticles in lateral flow methods to detect genes encoding virulence factors of Shiga toxin-producing Escherichia coli. Analytical and Bioanalytical Chemistry, 399(2), 831-8.
Harmsze, A. M., van Werkum, J. W., Moral, F., Ten Berg, J. N., Hackeng, C. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2011). Sulfonylureas and on-clopidogrel platelet reactivity in type 2 diabetes mellitus patients. Platelets, 22(2), 98-102.
Lanktree, M. B., Guo, Y., Murtaza, M., Glessner, J. T., Bailey, S. D., Onland-Moret, N. C., Lettre, G., Ongen, H., Rajagopalan, R., Johnson, T., Shen, H., Nelson, C. P., Klopp, N., Baumert, J., Padmanabhan, S., Pankratz, N., Pankow, J. S., Shah, S., Taylor, K., ... van der Schouw, Y. T. (2011). Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. American Journal of Human Genetics, 88(1), 6-18. http://www.ncbi.nlm.nih.gov/pubmed/21194676
Belitser, S. V., Martens, E. P., Pestman, W. R., Groenwold, R. H. H., de Boer, A., & Klungel, O. H. (2011). Measuring balance and model selection in propensity score methods. Pharmacoepidemiology and Drug Safety, 20(11), 1115-1129. https://doi.org/10.1002/pds.2188

Professional publications

Harmsze, A. M., De Boer, A., Boot, H., Deneer, V. H. M., Heringa, M., Mol, P. G. M., Schalekamp, T., Verduijn, M. M., Verheugt, F. W. A., & Le Comte, M. (2011). Interactie tussen clopidogrel en protonpomp remmers. Nederlands Tijdschrift voor Geneeskunde, 155(28), 1261-1269.
Harmsze, A. M., de Boer, A., Boot, H., Deneer, V. H. M., Heringa, M., Mol, P. G. M., Schalekamp, T., Verduijn, M. M., Verheugt, F. W. A., & le Comte, M. (2011). Interactie tussen clopidrogel en protonpompremmers. Nederlands Tijdschrift voor Geneeskunde, 155(A2442).
Harmsze, A. M., van Werkum, J. W., ten Berg, J. M., Ruven, H. J. T., Hackeng, C. M., Tjoeng, M. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2011). Effect van genetische variaties op de effectiviteit van clopidogrel. Pharmaceutisch Weekblad Scientific edition, 5(5), a1111.

Other output

Verhoef, T. I., Redekop, W. K., Schalekamp, T., Van Der Meer, F. J. M., Le Cessie, S., Wessels, J. A. M., Van Meegen, E., Van Schie, R. M. F., De Boer, A., & Maitland-Van Der Zee, A-H. (2011). Long-term effects of pharmacogenetics in acenocoumarol and phenproucomon. Pharmacoepidemiology and Drug Safety, 20, 329. https://doi.org/10.1002/pds.2206
Groenwold, R. H. H., De Vries, F., De Boer, A., Pestman, W. R., Rutten, F. H., Hoes, A. W., & Klungel, O. H. (2011). Balance measures for propensity score methods: A clinical example on beta-agonist use and the risk of myocardial infarction. Pharmacoepidemiology and Drug Safety, 20, 310. https://doi.org/10.1002/pds.2206
de Boer, A., Harmsze, A. M., Deneer, V. H. M., Maitland - van der Zee, A-H., Peters, B. J. M., Souverein, P. C., Van Werkum, J. W., ten Berg, J. M., Tjoeng, M. M., & Klungel, O. (2011). Interactions between CES2, CYP2C9, UGT1A6 and COX1 genetic variants and acetylsalicylic acid modify the risk of myocardial infarction. Basic & Clinical Pharmacology & Toxicology, 109, 102. https://doi.org/10.1111/j.1742-7843.2011.00722.x

2010

Scholarly publications

Egberts, A. C. G., & De Boer, A. (2010). Gescheiden farmaceutische budgetten: Dansen over ijsschotsen. Nederlands Tijdschrift voor Geneeskunde, 154(51-52), 2376-2378.
Harmsze, A. M., Deneer, V. H., Maitland-van Der Zee, A. H., De Boer, A., & Klungel, O. H. (2010). Genetische variaties beïnvloeden effectiviteit en veiligheid van geneesmiddelen. Nederlands Tijdschrift voor Geneeskunde, 154(28), 1329-1333.
Eussen, S., Van Der Elst, M., Klungel, O., Rompelberg, C., Garssen, J., Oosterveld, M., De Boer, A., De Gier, J., & Bouvy, M. (2010). A randomized controlled trial of the effect of a pharmaceutical care program on improving adherence to statin therapy: The statin intervention research project (STIPT). 35-36. https://doi.org/10.1002/pds.2019
Biere-Rafi, S., Gerdes, V., Hutten, B., Squizzato, A., Ageno, W., Souverein, P., De Boer, A., Buller, H. R., & Kamphuisen, P. (2010). Statin treatment reduces the incidence of recurrent pulmonary embolism: A population based case-control study. Blood, 116(21).
Biere-Rafi, S., Gerdes, V. E. A., Hutten, B. A., Squizzato, A., Ageno, W., Souverein, P. C., De Boer, A., Büller, H. R., & Kamphuisen, P. W. (2010). Statin treatment for primary and secondary prevention of pulmonary embolism: A population based case-control study. Pathophysiology of Haemostasis and Thrombosis, 37, 1. https://doi.org/10.1159/000318095
Harmsze, A. M., Robijns, K., Van Werkum, J. W., Breet, N. J., Hackeng, C. M., Ten Berg, J. M., Ruven, H. J. T., Klungel, O. H., De Boer, A., & Deneer, V. H. M. (2010). The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thrombosis and Haemostasis, 103(5), 920-925. https://doi.org/10.1160/TH09-08-0516
Pouwels, S., Lalmohamed, A., Leufkens, H. G., de Boer, A., Cooper, C., van Staa, T., & de Vries, F. (2010). Risk of Fracture and Bone Mineral Density in Stroke Response. Stroke, 41(1), E60-E60. https://doi.org/10.1161/STROKEAHA.109.569558
Eussen, S. R. B. M., Van Der Elst, M. E., Klungel, O. H., Rompelberg, C. J. M., Garssen, J., Oosterveld, M. H., De Boer, A., De Gier, J. J., & Bouvy, M. L. (2010). A pharmaceutical care program to improve adherence to statin therapy: A randomized controlled trial. Annals of Pharmacotherapy, 44(12), 1905-1913. https://doi.org/10.1345/aph.1P281
Taverne, K., de Groot, M., de Boer, A., & Klungel, O. (2010). Genetic polymorphisms related to the renin-angiotensin-aldosterone system and response to antihypertensive drugs. Expert Opinion on Drug Metabolism and Toxicology, 6(4), 439-60. https://doi.org/10.1517/17425250903571670
Pouwels, S., Lalmohamed, A., van Staa, T., Cooper, C., Souverein, P., Leufkens, H. G., Rejnmark, L., de Boer, A., Vestergaard, P., & de Vries, F. (2010). Use of organic nitrates and the risk of hip fracture: a population-based case-control study. Journal of Clinical Endocrinology and Metabolism, 95(4), 1924-31. https://doi.org/10.1210/jc.2009-2342
Wangge, G., Klungel, O. H., Roes, K. C. B., de Boer, A., Hoes, A. W., & Knol, M. J. (2010). Room for improvement in conducting and reporting non-inferiority randomized controlled trials on drugs: a systematic review. PLoS One, 5(10), e13550. https://doi.org/10.1371/journal.pone.0013550
Egberts, T., & de Boer, A. (2010). Gescheiden farmaceutische budgetten: dansen over ijsschotsen. Nederlands Tijdschrift voor Geneeskunde, 154(51-52), A3004.
Schalekamp, T., & de Boer, A. (2010). Pharmacogenetics of Oral Anticoagulant Therapy. Current Pharmaceutical Design, 16(2), 187-203.
Mattila, T. K., & de Boer, A. (2010). Influence of Intensive versus Conventional Glucose Control on Microvascular and Macrovascular Complications in Type 1 and 2 Diabetes Mellitus. Drugs, 70(17), 2229-2245. https://doi.org/10.2165/11585220-000000000-00000
Harmsze, A. M., van Werkum, J. W., ten Berg, J. M., Zwart, B., Bouman, H. J., Breet, N. J., van 't Hof, A. W., Ruven, H. J., Hackeng, C. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2010). CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. European Heart Journal, 31(24), 3046-3053. https://doi.org/10.1093/eurheartj/ehq321
Harmsze, A. M., Deneer, V. H., Maitland-van der Zee, A. H., de Boer, A., & Klungel, O. H. (2010). Genetische variaties beïnvloeden effectiviteit en veiligheid van geneesmiddelen. Nederlands Tijdschrift voor Geneeskunde, 154(A1503), A1503.
Peters, B. J. M., Rodin, A. S., de Boer, A., & Maitland-van der Zee, A-H. (2010). Methodological and statistical issues in pharmacogenomics. Journal of Pharmacy and Pharmacology, 62(2), 161-166. https://doi.org/10.1211/jpp.62.02.0002
Verhoef, T. I., Schalekamp, T., Redekop, W. K., de Boer, A., & Maitland-van der Zee, A-H. (2010). Clinical and economic consequences of pharmacogenetic-guided dosing of warfarin. Expert Review of Pharmacoeconomics and Outcomes Research, 10(4), 375-378. https://doi.org/10.1586/erp.10.42
Pouwels, S., Lalmohamed, A., Leufkens, H. G. M., de Boer, A., Cooper, C., van Staa, T. P., & de Vries, F. (2010). Response to Letter by Tsuda. Stroke, 41(1), e60-e60.
Peters, B. J. M., Rodin, A. S., Klungel, O. H., van Duijn, C. M., Stricker, B. H. C., van't Slot, R., de Boer, A., & Maitland-van der Zee, A-H. (2010). Pharmacogenetic interactions between ABCB1 and SLCO1B1 tagging SNPs and the effectiveness of statins in the prevention of myocardial infarction. Pharmacogenomics, 11(8), 1065-1076. https://doi.org/10.2217/pgs.10.81
Peters, B. J. M., Rodin, A. S., Klungel, O. H., Stricker, B. H. C., Bruno, H. C., de Boer, A., & Maitland-van der Zee, A. H. (2010). Variants of ADAMTS1 modify the effectiveness of statins in reducing the risk of myocardial infarction. Pharmacogenetics and Genomics, 20(12), 766-774.
Harmsze, A., van Werkum, J. W., Bouman, H. J., Ruven, H. J., Breet, N. J., Ten Berg, J. M., Hackeng, C. M., Tjoeng, M. M., Klungel, O. H., de Boer, A., & Deneer, V. H. (2010). Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation. Pharmacogenetics and Genomics, 20(1), 18-25. https://doi.org/10.1097/FPC.0b013e328333dafe
Verhoef, T. I., Redekop, W. K., Darba, J., Geitona, M., Hughes, D. A., Siebert, U., de Boer, A., Maitland-van der Zee, A-H., Barallon, R., Briz, M., Daly, A., Haschke-Becher, E., Kamali, F., Kirchheiner, J., Manolopoulos, V. G., Pirmohamed, M., Rosendaal, F. R., van Schie, R. M. F., Wadelius, M., & EU-PACT Group (2010). A systematic review of cost-effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics, 11(7), 989-1002. https://doi.org/10.2217/pgs.10.74
Dekkers, O. M., Romijn, J. A., de Boer, A., & Vandenbroucke, J. P. (2010). The risk for breast cancer is not evidently increased in women with hyperprolactinemia. Pituitary, 13(3), 195-198. https://doi.org/10.1007/s11102-009-0214-y
Wangge, G., Klungel, O. H., Roes, K. C. B., de Boer, A., Hoes, A. W., & Knol, M. J. (2010). Interpretation and inference in noninferiority randomized controlled trials in drug research. Clinical Pharmacology and Therapeutics, 88(3), 420-423. https://doi.org/10.1038/clpt.2010.134

Other output

De Peuter, O., Lip, G. Y. H., Souverein, P. C., Klungel, O. H., de Boer, A., Büller, H. R., & Kamphuisen, P. W. (2010). Time-trends in treatment and cardiovascular events in patients with heart failure: A pharmacosurveillance study. 39. https://doi.org/10.1159/000318096
Wangge, G., Klungel, O. H., Roes, K. C. B., De Boer, A., Hoes, A. W., & Knol, M. J. (2010). Room for improvements in conducting and reporting non-inferiority randomized controlled trials on drugs. 73-74. Abstract from 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management. https://doi.org/10.1002/pds.2019
De Peuter, O. R., Souverein, P. C., Klungel, O. H., Lip, G. Y., Buller, H. R., De Boer, A., & Kamphuisen, P. W. (2010). Non-selective beta-blockers decrease thrombotic events in patients with heart failure. 268. https://doi.org/10.1016/S0735-1097(10)60269-0
De Peuter, O. R., Lip, G. Y. H., Souverein, P. C., Klungel, O. H., De Boer, A., Buller, H. R., & Kamphuisen, P. W. (2010). Time-trends in treatment and cardiovascular events in patients with heart failure: A pharmacosurveillance study. 1052-1053. https://doi.org/10.1093/eurheartj/ehq290
Harmsze, A. M., Van Werkum, J. W., Taubert, D., Hackeng, C. M., Ruven, H. J., Ten Berg, J. M., Klungel, O. H., de Boer, A., & Deneer, V. H. M. (2010). Concomitant use of esomeprazole, but not pantoprazole, is associated with lower plasma concentrations of clopidogrel's active thiol metabolite and higher on-clopidogrel platelet aggregation. European Heart Journal, 31(S1), 968. https://doi.org/10.1093/eurheartj/ehq290
Warnier, M. J., de Bruin, M. L., Rutten, F. H., Hoes, A. W., & de Boer, A. (2010). Drug-Induced ECG Abnormalities in Patients with COPD. S65. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.
Peters, B. J. M., Pett, H., de Boer, A., Klungel, O. H., & Maitland-van der Zee, A. H. (2010). The PCSK9 E670G Polymorphism Modifies the Effectiveness of Statins in Reducing the Risk of Myocardial Infarction. S114. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.
Eussen, S. R. B. M., van der Elst, M. E., Klungel, O. H., Rompelberg, C. J., Garssen, J., Oosterveld, M., de Boer, A., de Gier, J. J., & Bouvy, M. L. (2010). A Randomized Controlled Trial of the Effect of a Pharmaceutical Care Program on Improving Adherence to Statin Therapy: The STatin Intervention Research ProjecT (STIPT). S35. Abstract from Abstracts of the 26th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 19-22 August 2010, Brighton, UK.

2009

Scholarly publications

Pouwels, S., Lalmohamed, A., Leufkens, B., De Boer, A., Cooper, C., Van Staa, T., & De Vries, F. (2009). Risk of hip/femur fracture after stroke: A population-based case-control study. Stroke. https://doi.org/10.1161/STROKEAHA.109.554055
Lalmohamed, A., Pouwels, S., Cooper, C., van Staa, T., Leufkens, B., Rejnmark, L., de Boer, A., Vestergaard, P., & de Vries, F. (2009). Use of Organic Nitrates and the Risk of Hip Fracture: A Population-Based Case-Control Study. Pharmacoepidemiology and Drug Safety, 18, S8-S9.
Lalmohamed, A., Pouwels, S., Cooper, C., van Staa, T., Leufkens, B., de Boer, A., & de Vries, F. (2009). Use of Protonpump Inhibitors and Risk of Hip Fracture. Pharmacoepidemiology and Drug Safety, 18, S17-S18.
Van Der Zee, A. H. M., Van Wieren-De Wijer, D. B. M. A., Stricker, B. H. C., De Boer, A., Kroon, A. A., Psaty, B. M., & Klungel, O. H. (2009). Reply. Journal of Hypertension, 27(6), 1328-1329. https://doi.org/10.1097/HJH.0b013e32832bb882
Klungel, O. H., & De Boer, A. (2009). Verdere studie nodig naar rol staties bij diabetes. Pharmaceutisch Weekblad, 144(7), 16-19.
De Peuter, O. R., Souverein, P. C., Klungel, O. H., De Boer, A., Büller, H. R., & Kamphuisen, P. W. (2009). Non-selective beta-blockers decrease thrombotic events in patients with heart failure. Journal of Thrombosis and Haemostasis, 7(S2), 215. http://hdl.handle.net/11370/9ad01c77-c6e3-4f17-a179-d48877bc82b2
Brassé, B. P., Roijers, J. F. M., Chahid, Y., Van Geest-Daalderop, J. H. H., De Vries-Goldschmeding, H., Van Wijk, E. M., De Boer, A., Egberts, A. C. G., & Schalekamp, T. (2009). VKORC1 en CYP2C9 genotype beinvloeden acenocoumarol antistolling: Interactie tussen genotypes en overantistolling. Pharmaceutisch Weekblad, 144(4), 4-8.
Bozkurt, O., De Boer, A., Grobbee, D. E., De Leeuw, P. W., Kroon, A. A., Schiffers, P., & Klungel, O. H. (2009). Variation in renin-angiotensin system and salt-sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. American Journal of Hypertension, 22(5), 545-551. https://doi.org/10.1038/ajh.2009.38
Peters, B. J. M., Klungel, O. H., de Boer, A., Ch Stricker, B. H., & Maitland-van der Zee, A-H. (2009). Pharmacogenetics of cardiovascular drug therapy. Clinical Cases in Mineral and Bone Metabolism, 6(1), 55-65.
van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A-H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., Psaty, B. M., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Interaction between the Gly460Trp alpha-adducin gene variant and diuretics on the risk of myocardial infarction. Journal of Hypertension, 27(1), 61-8. https://doi.org/10.1097/HJH.0b013e328317a74d
van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A-H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., Psaty, B. M., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Reasons for non-response in observational pharmacogenetic research. Pharmacoepidemiology and Drug Safety, 18(8), 665-71. https://doi.org/10.1002/pds.1764
Kars, M., Souverein, P. C., Herings, R. M. C., Romijn, J. A., Vandenbroucke, J. P., de Boer, A., & Dekkers, O. M. (2009). Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. Journal of Clinical Endocrinology and Metabolism, 94(8), 2729-34. https://doi.org/10.1210/jc.2009-0177
Bozkurt, Ö., de Boer, A., Grobbee, D. E., Kroon, A. A., Schiffers, P., de Leeuw, P., & Klungel, O. H. (2009). Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes. Journal of the renin-angiotensin-aldosterone system, 10(2), 101-108. https://doi.org/10.1177/1470320309104877
Pouwels, S., Lalmohamed, A., Leufkens, B., de Boer, A., Cooper, C., van Staa, T., & de Vries, F. (2009). Risk of hip/femur fracture after stroke: a population-based case-control study. Stroke, 40(10), 3281-5. https://doi.org/10.1161/STROKEAHA.109.554055
van Schie, R. M. F., Jorgensen, A. L., de Boer, A., Maitland-van der Zee, A-H., & EU-PACT Study Group (2009). Systematic review of pharmacogenetic warfarin dosing. Journal of General Internal Medicine, 24(10), 1171. https://doi.org/10.1007/s11606-009-1083-9
van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A. H., de Boer, A., Belitser, S. V., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., van Duijn, C. M., Stricker, B. H. C. H., & Klungel, O. H. (2009). Determinants of DNA yield and purity collected with buccal cell samples. European Journal of Epidemiology, 24(11), 677-82. https://doi.org/10.1007/s10654-009-9388-x
van Schie, R. M. F., Wadelius, M. I. A., Kamali, F., Daly, A. K., Manolopoulos, V. G., de Boer, A., Barallon, R., Verhoef, T. I., Kirchheiner, J., Haschke-Becher, E., Briz, M., Rosendaal, F. R., Redekop, W. K., Pirmohamed, M., & Maitland van der Zee, A-H. (2009). Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics, 10(10), 1687-1695. https://doi.org/10.2217/pgs.09.125
Peters, B. J. M., Klungel, O. H., de Boer, A., & Maitland-van der Zee, A-H. (2009). Genetic determinants of response to statins. Expert Review of Cardiovascular Therapy, 7(8), 977-983. https://doi.org/10.1586/erc.09.83
Schellens, J. H. M., Grouls, R., Guchelaar, H. J., Touw, D. J., Rongen, G. A., de Boer, A., & Van Bortel, L. M. (2009). The Dutch Vision of Clinical Pharmacology. Clinical Pharmacology and Therapeutics, 85(4), 366-368. https://doi.org/10.1038/clpt.2008.148
Peters, B. J., Klungel, O. H., Visseren, F. L., de Boer, A., & Maitland-van der Zee, A-H. (2009). Pharmacogenomic insights into treatment and management of statin-induced myopathy. Genome Medicine, 1(12), 120. https://doi.org/10.1186/gm120
Kars, M., Souverein, P. C., Herings, R. M. C., Romijn, J. A., Vandenbroucke, J. P., de Boer, A., & Dekkers, O. M. (2009). Estimated Age- and Sex-Specific Incidence and Prevalence of Dopamine Agonist-Treated Hyperprolactenemia. Journal of Clinical Endocrinology and Metabolism, 94(8), 2729-2734.
van Wieren-de Wijer, D. B. M. A., Maitland-van der Zee, A-H., de Boer, A., Stricker, B. H. C., Kroon, A. A., de Leeuw, P. W., Bozkurt, O., & Klungel, O. H. (2009). Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharmacy World & Science, 31(2), 158-164. https://doi.org/10.1007/s11096-008-9264-x
van Schie, R. M. F., Jorgensen, A. L., de Boer, A., & Maitland-van der Zee, A. H. (2009). Systematic Review of Pharmcogenetic Warfarin Dosing. Journal of General Internal Medicine, 24(10), 1171.
van Wieren-de Wijer, B. M. A., Maitland-van der Zee, A. H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M., Janssen, R. G. J. H., Psaty, B. M., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Interaction between the Fly460Trp α-adducin gene variant and diuretics on the risk of myocardial infarction. Journal of Hypertension, 27, 61-68.

Professional publications

Brassé, B. P., Roijers, J. F. M., Chahid, Y., Van Geest-Daalderop, J. H. H., De Vries-Goldschmeding, H., Van Wijk, E. M., De Boer, A., Egberts, A. C. G., & Schalekamp, T. (2009). Invloed van de genotypen VKORC1 en CYP2C9 op acenocoumarol-dosisbehoefte: Interactie tussen genotypen bepaalt overontstolling. Pharmaceutisch Weekblad, 144(4), 4-8.
Van Wijk, B. L. G., & De Boer, A. (2009). Generieke substitutie en therapietrouw. Pharmaceutisch Weekblad, 144(4), 2-3.
Klungel, O. H., & de Boer, A. (2009). Wel nadere studie nodig rol statines bij diabetes. Visie op statines blijft overeind. Pharmaceutisch Weekblad, februari, 16-20.
van Wijk, B. L. G., & de Boer, A. (2009). Generieke geneesmiddelensubstitutie en therapietrouw. Pharmaceutisch Weekblad, 3(1), 2-3.
Schalekamp, T., & de Boer, A. (2009). Farmacogenetica van cumarinederivaten. Genotypering helpt antistollingstherapie. Pharmaceutisch Weekblad, 23 oktober, 14-18.
Brassé, B. P., Chahid, Y., Roijers, J. F. M., van Geest-Daalderop, J. H. H., de Vries-Goldschmeding, H., van Wijk, E. M., de Boer, A., & Egberts, A. C. G. (2009). Invloed van de genotypen VKORC1en CYP2C9 op acenocoumarol-dosisbehoefte. Interactie tussen genotypen bepaalt overstolling. Pharmaceutisch Weekblad, 2009(3), 4-8.

Other output

Bozkurt, O., De Boer, A., Grobbee, D. E., Leeuw, P. W. D., Kroon, A. A., Schiffers, P., & Klungel, O. H. (2009). Variation in renin-angiotensin system and salt sensitivity genes and the risk of diabetes mellitus associated with the use of thiazide diuretics. 23. Abstract from 25th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, United States. https://doi.org/10.1002/pds.1806
Lalmohamed, A., Pouwels, S., Cooper, C., Van Staa, T., Leufkens, B., De Boer, A., & De Vries, F. (2009). (Young investigator award) Use of protonpump inhibitors and risk of hip fracture. 264. https://doi.org/10.1007/s00198-009-0923-0
Rafi, S., Di Nisio, M., Porreca, E., De Boer, A., Souverein, P. C., Buller, H. R., & Kamphuisen, P. W. (2009). Nonsteroidal anti-inflammatory drugs increase the risk of pulmonary embolism. 206.
Lalmohamed, A., Pouwels, S., Cooper, C., Van Staa, T., Leufkens, B., Rejnmark, L., De Boer, A., Vestergaard, P., & De Vries, F. (2009). Use of organic nitrates and the risk of hip fracture: A population-based case-control study. 8-9. https://doi.org/10.1002/pds.1806
Van Wieren-De Wijer, D. B. M. A., Maitland-Van Der Zee, A. H., De Boer, A., Kroon, A. A., De Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., Psaty, B. M., Van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Interaction between the G894TeNOS gene variant and calcium antagonists on the risk of myocardial infarction. 162-163. https://doi.org/10.1002/pds.1806
De Boer, A., Harmsze, A. M., Van Werkum, J. W., Deneer, V. D., Ruven, H. J., Klungel, O. H., Hackeng, C. M., & Ten Berg, J. M. (2009). Influence of proton pump inhibitors on the antiplatelet properties of two clopidogrel dosing regimens and the role of CYP2C19 genotype. 28. https://doi.org/10.1111/j.1742-7843.2009.00436.x
Eussen, S., Van Der Elst, M., Rompelberg, C., Garssen, J., Van Loveren, H., Bouvy, M., Oosterveld, M., De Boer, A., De Gier, J., & Klungel, O. (2009). Effects of phytosterols on pattern and effectiveness of statin use: Preliminary results of a post-marketing study. 128-129. https://doi.org/10.1002/pds.1806
De Peuter, O. R., Souverein, P. C., Klungel, O. H., de Boer, A., Büller, H. R., & Kamphuisen, P. W. (2009). Non-Selective ß-Blockers Decrease Thrombotic Events in Patients with Heart Failure. Pharmacoepidemiology and Drug Safety, 18, S114.
Lalmohamed, A., Pouwels, S., Cooper, C., van Staa, T. P., Leufkens, H. G. M., de Boer, A., & de Vries, F. (2009). Use of Protonpump Inhibitors and Risk of Hip Fracture. Pharmacoepidemiology and Drug Safety, 18, S17.
Eussen, S. R. B. M., van der Elst, M. E., Rompelberg, C. J., Garssen, J., Bouvy, M. L., Oostervelt, M. H., de Boer, A., de Gier, J. J., & Klungel, O. H. (2009). Effects of functional foods enriched with plant sterols/-stanols on effectiveness and pattern of statin therapy. Poster session presented at Internl Conf. on Pharmacoepidemiology and Therapeutic Risk Management, Rhode Island, USA.
van Wieren-de Wijer, B. M. A., Maitland-van der Zee, A. H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M. H., Janssen, R. G. J. H., Psaty, B. M., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2009). Interaction between the G894T eNOS Gene Variant and Calcium Antagonists on the Risk of Myocardial Infarction. Pharmacoepidemiology and Drug Safety, 18, S162.
Harmsze, A. M., van Werkum, J. W., Deneer, V. H. M., Ruven, H. J., Klungel, O. H., Hackeng, C. M., ten Berg, J. M., & de Boer, A. (2009). Influence of Proton Pump Inhibitors on the Anti-platelet Properties of Two Clopidogrel Dosing regimens and the Role of CYP2C19 Genotype. Pharmacoepidemiology and Drug Safety, 18, S131.
Lalmohamed, A., Pouwels, S., Cooper, C., van Staa, T. P., Leufkens, H. G. M., de Boer, A., & de Vries, F. (2009). Use of protonpump inhibitors and risk of hip fracture. Bone, 44(2), S396-S397.
Lalmohamed, A., Pouwels, S., Cooper, C., van Staa, T. P., Leufkens, H. G. M., Rejnmark, L., de Boer, A., Vestergaard, P., & de Vries, F. (2009). Use of Organic Nitrates and the Risk of Hip Fracture: A Population-Based Case-Control Study. Pharmacoepidemiology and Drug Safety, 18, S8.
Lalmohamed, A., Pouwels, S., Cooper, C., van Staa, T. P., Leufkens, H. G. M., Reijnmark, L., de Boer, A., Vestergaard, P., & de Vries, F. (2009). Use of organic nitrates and the risk of hip fracture: A population-based case-control study. Bone, 44(2), S397.
Eussen, S. R. B. M., van der Elst, M. E., Rompelberg, C. J., Garssen, J., van Loveren, H., Oosterveld, M., de Boer, A., Bouvy, M. L., de Gier, J. J., & Klungel, O. H. (2009). Effects of Phytosterols on Pattern and Effectiveness of Statin Use: Prreliminary Results of a Post-Marketing Study. Pharmacoepidemiology and Drug Safety, 18, S128.

2008

Scholarly publications

Swen, J. J., Wilting, I., De Goede, A. L., Grandia, L., Mulder, H., Touw, D. J., De Boer, A., Conemans, J. M. H., Egberts, T. C. G., Klungel, O. H., Koopmans, R., Van Der Weide, J., Wilffert, B., Guchelaar, H-J., & Deneer, V. H. M. (2008). Corrigendum: Pharmacogenetics: From bench to byte (Clinical Pharmacology and Therapeutics (2008) 83, 5, (781-787) DOI: 10.1038/sj.clpt.6100507). Clinical Pharmacology and Therapeutics, 84(1), 175. https://doi.org/10.1038/clpt.6100624
Swen, J. J., Wilting, I., de Goede, A. L., Grandia, L., Mulder, H., Touw, D. J., de Boer, A., Conemans, J. M. H., Egberts, T. C. G., Klungel, O. H., Koopmans, R., van der Weide, J., Wilffert, B., Guchelaar, H-J., & Deneer, V. H. M. (2008). Pharmacogenetics: from bench to byte. Clinical Pharmacology and Therapeutics, 83(5), 781-787. https://doi.org/10.1038/sj.clpt.6100507
Ahlers, S. J. G. M., van Gulik, L., van der Veen, A. M., van Dongen, H. P. A., Bruins, P., Belitser, S. V., de Boer, A., Tibboel, D., & Knibbe, C. A. J. (2008). Comparison of different pain scoring systems in critically ill patients in a general ICU. Critical Care, 12(1), R15. https://doi.org/10.1186/cc6789
Schellens, J. H. M., Grouls, R., Guchelaar, H. J., Touw, D. J., Rongen, G. A., de Boer, A., Van Bortel, L. M., & de Boer, A. (2008). The Dutch model for clinical pharmacology: collaboration between physician- and pharmacist--clinical pharmacologists. British Journal of Clinical Pharmacology, 66(1), 146-147. https://doi.org/10.1111/j.1365-2125.2008.03156.x
Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2008). Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal, 8(6), 400-7. https://doi.org/10.1038/sj.tpj.6500493
Schalekamp, T., Maitland-van der Zee, A-H., & de Boer, A. (2008). Pharmacogenomics of coumarin anticoagulants: are we underestimating the role of CYP2C9? Thrombosis and Haemostasis, 100(2), 175-176.
Schalekamp, T., Klungel, O. H., Souverein, P. C., & de Boer, A. (2008). Increased Bleeding Risk With Concurrent Use of Selective Serotonin Reuptake inhibitors and Coumarins. Archives of Internal Medicine, 168(2), 180-185. https://doi.org/10.1001/archinternmed.2007.32
Otte, W. M., van der Maas, F., & de Boer, A. (2008). Comparison of knowledge and accessibility to information sources of HIV/AIDS between blind and sighted populations in Nigeria. Aids care, 20(9), 1093-1097. https://doi.org/10.1080/09540120701842787
Schalekamp, T., Klungel, O. H., Souverein, P. C., & de Boer, A. (2008). Effect of oral antiplatelet agents on major bleeding in users of coumarins. Thrombosis and Haemostasis, 100(6), 1076-1083.
Bozkurt, O., Verschuren, W. M. M., van Wieren-de Wijer, B. M. A., Knol, M. J., de Boer, A., Grobbee, D. E., Geerlings, M. I., Heerdink, E. R., & Klungel, O. H. (2008). Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. Journal of Human Hypertension, 22(11), 774-780. https://doi.org/10.1038/jhh.2008.62
Peters, B. J. M., Maitland-van der Zee, A-H., Stricker, B. H. C., van Wieren-de Wijer, D. B. M. A., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P., Janssen, R. G. J. H., van Duijn, C. M., & Klungel, O. H. (2008). Effectiveness of statins in the reduction of the risk of myocardial infarction is modified by the GNB3 C825T variant. Pharmacogenetics and Genomics, 18(7), 631-636. https://doi.org/10.1097/FPC.0b013e3283023fb2
Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2008). Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or β-blocker use and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal, 6(1), 22-26.
Martens, E. P., de Boer, A., Pestman, W. R., Belitser, S. V., Stricker, B. H. C., & Klungel, O. H. (2008). Comparing treatment effects after adjustment with multivariable Cox proportional hazards regression and propensity score methods. Pharmacoepidemiology and Drug Safety, 17(1), 1-8. https://doi.org/10.1002/pds.1520
Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2008). Systematic differences in treatment effect estimates between propensity score methods and logistic regression. International Journal of Epidemiology, 37, 1142-1147.

Professional publications

Klungel, O., & De Boer, A. (2008). Primaire preventie met statines is zinvoller dan gerapporteerd. Pharmaceutisch Weekblad, 143(7), 14-15.
De Boer, A. (2008). Duidelijkheid na samenvoegen van studies. Pharmaceutisch Weekblad, 143(50), 22-25.
de Boer, A. (2008). Duidelijkheid na combinatie studies. COPD-middel veilig voor hart en vaten. Pharmaceutisch Weekblad, 50, 22-26.
Klungel, O. H., & de Boer, A. (2008). Reacties Onderwaardering. Pharmaceutisch Weekblad, 16, 10.
Klungel, O. H., & de Boer, A. (2008). Publieksmedia zaaien nieuwe onrust onder statinegebruikers. Primaire preventie zinvoller dan gemeld. Pharmaceutisch Weekblad, 7, 14-16.

Other output

Klungel, O. H., van Wieren-de Wijer, B. M. A., de Boer, A., Kroon, A. A., Psaty, B. M., van Duijn, C., Stricker, B. H. C., & Maitland-van der Zee, A. H. (2008). Renin-Angiotensin System Polymorphisms, Use of ACE Inhibitors and the Risk of Myocardial Infarction. S4. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
Bozkurt, O., de Boer, A., Grobbee, D. E., Kroon, A. A., Schiffers, P. M., de Leeuw, P. W., & Klungel, O. H. (2008). Renin-Angiotensin-System Polymorphisms, Use of Angiotensin Receptor Blockers and the Risk of Diabetes. S264. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
Harmsze, A. M., van Werkum, J. W., Deneer, V. H. M., Ruven, H. J., Klungel, O. H., Hackeng, C. M., ten Berg, J. M., & de Boer, A. (2008). The Effect of Seven Genetic Variants on the Response to Clopidogrel. S5. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
van Wieren-de Wijer, B. M. A., Maitland-van der Zee, A. H., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M., Janssen, R. J., van Duijn, C. M., Stricker, B. H. C., & Klungel, O. H. (2008). Interactions between the Gly460Trp alpha-adducin gene variant and diuretics and the risk of myocardial infarction among treated hypertensive patients. 296. Abstract from Dutch Society of Clinical Pharmacology an Biopharmacy Meeting.
Peters, B. J. M., Maitland-van der Zee, A. H., Stricker, B. H. C., van Wieren-de Wijer, B. M. A., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M., Janssen, R. G. J. H., van Duijn, C. M., & Klungel, O. H. (2008). Effectiveness of Statins in the Reduction of the Risk of Myocardial Infarction Is Modified by the GNB3 C825T Variant. S263. Abstract from 24th International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

2007

Scholarly publications

Van Wijk, B. L. G., Avorn, J., Solomon, D. H., Klungel, O. H., Heerdink, E. R., de Boer, A., & Brookhart, A. M. (2007). Herstarten van antihypertensiva. Pharmaceutisch Weekblad, 142(38), 118-120.
Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2007). Diuretic-gene interaction and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal, 7(5), 346-52. https://doi.org/10.1038/sj.tpj.6500428
Schalekamp, T., Brassé, B. P., Roijers, J. F. M., van Meegen, E., van der Meer, F. J. M., van Wijk, E. M., Egberts, A. C. G., & de Boer, A. (2007). VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clinical Pharmacology and Therapeutics, 81(2), 185-193. https://doi.org/10.1038/sj.clpt.6100036
van Wijk, B. L. G., Avorn, J., Solomon, D. H., Klungel, O. H., Heerdink, E. R., de Boer, A., & Brookhart, A. M. (2007). Rates and determinants of reinitiating antihypertensive therapy after prolonged stoppage: a population-based study. Journal of Hypertension, 25(3), 689-697. https://doi.org/10.1097/HJH.0b013e3280148a58
Schelleman, H., Klungel, O. H., Witteman, J. C. M., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2007). Pharmacogenetic interactions of three candidate gene polymorphisms with ACE-inhibitors or β-blockers and the risk of atherosclerosis. British Journal of Clinical Pharmacology, 64(1), 57-66. https://doi.org/10.1111/j.1365-2125.2007.02848.x
Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Yazdanpanah, M., Danser, A. H. J., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2007). Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. European Journal of Human Genetics, 15(4), 478-484. https://doi.org/10.1038/sj.ejhg.5201789
Schalekamp, T., van Geest-Daalderop, J. H. H., Kramer, M. H. H., van Holten-Verzantvoort, A. T. M., & de Boer, A. (2007). Coumarin anticoagulants and co-trimoxazole: avoid the combination rather than manage the interaction. European Journal of Clinical Pharmacology, 63(4), 335-343. https://doi.org/10.1007/s00228-007-0268-6
Gumbs, P. D., Verschuren, W. M. M., Souverein, P. C., Mantel-Teeuwisse, A. K., de Wit, G. A., de Boer, A., & Klungel, O. H. (2007). Society already achieves economic benefits from generic substitution but fails to do the same for therapeutic substitution. British Journal of Clinical Pharmacology, 64(5), 680-685. https://doi.org/10.1111/j.1365-2125.2007.02958.x
Bozkurt, O., de Boer, A., Grobbee, D. E., Heerdink, E. R., Burger, H., & Klungel, O. H. (2007). Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Molecular Diagnosis & Therapy, 11(5), 291-302.
van der Elst, M. E., Bouvy, M. L., de Blaey, C. J., & de Boer, A. (2007). Effect of Drug Combinations On Admission For Recurrent Myocardial Infarction. Heart, 93(10), 1226-1230. https://doi.org/10.1136/hrt.2006.098053
Frankfort, S. V., Appels, B. A., de Boer, A., Tulner, L. R., van Campen, J. P. C. M., Koks, C. H. W., Beijnen, J. H., & Schmand, B. A. (2007). Identification of responders and reactive domains to rivastigmine in Alzheimer's disease. Pharmacoepidemiology and Drug Safety, 16(5), 545-551. https://doi.org/10.1002/pds.1345
Bozkurt, O., de Boer, A., Grobbee, D. E., Heerdink, E. R., Burger, H., & Klungel, O. H. (2007). Pharmacogenetics of glucose-lowering drug treatment: a systematic review. Molecular Diagnosis & Therapy, 11(8), 291-302.
https://dspace.library.uu.nl/bitstream/handle/1874/27324/bozkurt_07_pharmacogeneticsofglucoselowering.pdf?sequence=1
Gumbs, P. D., Verschuren, M. W. M., Mantel-Teeuwisse, A. K., de Wit, A. G., de Boer, A., & Klungel, O. H. (2007). Economic evaluations of cholesterol-lowering drugs: a critical and systematic review. PharmacoEconomics, 25(3), 187-199.
https://dspace.library.uu.nl/bitstream/handle/1874/396837/gumbs_07_economicevaluationsofcholesterol.pdf?sequence=1

Other output

van Wieren-de Wijer, B. M. A., Maitland-van der Zee, A. H., de Boer, A., Stricker, B. H. C., & Klungel, O. H. (2007). Interactions between the Gly460Trp Alpha-Adducin Gene Variant and Diuretics and the Risk of Myocardial Infarction among Treated Hypertensive Patients. S24. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
van Wijk, B. L. G., Avorn, J., Solomon, D. H., Klungel, O. H., Heerdink, E. R., de Boer, A., & Brookhart, A. M. (2007). Rates and Determinants of Reinitiating Antihypertensive Therapy after Prolonged Stoppage. S199. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
Schalekamp, T., Klungel, O. H., Souverein, P. C., & de Boer, A. (2007). Effect of Oral Antiplatelet Drugs on Major Bleeding among Users of Coumarin Anticoagulants. S50. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2007). An Important Advantage of Propensity Score Methods Compared to Logistic Regression Analysis. S114. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.
Peters, B. J. M., Maitland-van der Zee, A. H., Stricker, B. H. C., van Wieren-de Wijer, B. M. A., de Boer, A., Kroon, A. A., de Leeuw, P. W., Schiffers, P. M., Janssen, R., van Duijn, C. M., & Klungel, O. H. (2007). Effectiveness of Statins is modified by the GNB3 C825T variant. The PHARMO-genetics study. Abstract from Unknown event, Asilomar, USA.
Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2007). The Use of the Overlapping Coefficient in Propensity Score Analysis. S1. Abstract from 23rd International Conference on Pharmacoepidemiology & Therapeutic Risk Management.

2006

Scholarly publications

Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., de Wit, G. A., Hofman, A., Trienekens, P. H., Stricker, B. H. C., de Boer, A., & Klungel, O. H. (2006). Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: The Rotterdam Study. Drugs and Aging, 23(9), 733-741. https://doi.org/10.2165/00002512-200623090-00003
Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). Generic substitution of antihypertensive drugs: does it affect adherence? Annals of Pharmacotherapy, 40(1), 15-20. https://doi.org/10.1345/aph.1G163
Schalekamp, T., Boink, G. J. J., Visser, L. E., Stricker, B. H. C., de Boer, A., & Klungel, O. H. (2006). CYP2C9 genotyping in acenocoumarol treatment: is it a cost-effective addition to international normalized ratio monitoring? Clinical Pharmacology and Therapeutics, 79(6), 511-520. https://doi.org/10.1016/j.clpt.2006.03.008
Schalekamp, T., Brassé, B. P., Roijers, J. F. M., Chahid, Y., van Geest-Daalderop, J. H. H., de Vries-Goldschmeding, H., van Wijk, E. M., Egberts, A. C. G., & de Boer, A. (2006). VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation. Clinical Pharmacology and Therapeutics, 80(1), 13-22. https://doi.org/10.1016/j.clpt.2006.04.006
Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). A comparison of two multiple-characteristic decision-making models for the comparison of antihypertensive drug classes: Simple Additive Weighting (SAW) and Technique for Order Preference by Similarity to an Ideal Solution (TOPSIS). American journal of cardiovascular drugs : drugs, devices, and other interventions, 6(4), 251-258.
Schalekamp, T., Smit, C., van Geest-Daalderop, J. H. H., de Vries-Goldschmeding, H., & de Boer, A. (2006). Discrepancies between medication records of anticoagulation clinics and pharmacy records. Pharmacoepidemiology and Drug Safety, 15(11), 823-828. https://doi.org/10.1002/pds.1286
van der Elst, M. E., Bouvy, M. L., de Blaey, C. J., & de Boer, A. (2006). Improving pharmacotherapy after myocardial infarction by group academic detailing using feedback data on a patient level. Pharmacotherapy, 26(2), 254-259. https://doi.org/10.1592/phco.26.2.254
Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2006). Diuretic-gene interaction and the risk of myocardial infarction and stroke. The Pharmacogenomics Journal, 1-7.
https://dspace.library.uu.nl/bitstream/handle/1874/27460/schelleman_06_diureti-geneinteractionandtherisk.pdf?sequence=2
Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2006). Instrumental Variables. Application and limitations. Epidemiology, 17(3), 260-267. https://doi.org/10.1097/01.ede.0000215160.88317.cb
Schelleman, H., Klungel, O. H., van Duijn, C. M., Witteman, J. C. M., Hofman, A., de Boer, A., & Stricker, B. H. C. (2006). Drug-gene interaction between the insertion/deletion polymorphism of the angiotensin-converting enzyme gene and antihypertensive therapy. Annals of Pharmacotherapy, 40(2), 212-218. https://doi.org/10.1345/aph.1G316
Mantel-Teeuwisse, A. K., Klungel, O. H., Hofman, A., Verschuren, W. M. M., Trienekens, P. H., Porsius, A. J., Stricker, B. H. C., & de Boer, A. (2006). Prescribing behaviour according to Dutch and European guidelines on the management of hypercholesterolaemia (1992-1999). British Journal of Clinical Pharmacology, 61(5), 592-600. https://doi.org/10.1111/j.1365-2125.2006.02634.x
Frankfort, S. V., Appels, B. A., De Boer, A., Tulner, L. R., Van Campen, J. P. C. M., Koks, C. H. W., & Beijnen, J. H. (2006). Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting. International Journal of Clinical Practice, 60(6), 646-654. https://doi.org/10.1111/j.1368-5031.2006.00970.x
Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). Initial non-compliance with antihypertensive monotherapy is followed by complete discontinuation of antihypertensive therapy. Pharmacoepidemiology and Drug Safety, 15(8), 587-93. https://doi.org/10.1002/pds.1239
de Boer, A. (2006). Pharmacogenomics: Methods and Protocol. Annals of Pharmacotherapy, 40, 1001-1002.
Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). Refill persistence with chronic medication assessed from a pharmacy database was influenced by method of calculation. Journal of Clinical Epidemiology, 59(1), 11-17. https://doi.org/10.1016/j.jclinepi.2005.05.005
Schelleman, H., Klungel, O. H., Witteman, J. C. M., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2006). The influence of the alpha-adducin G460W polymorphism and angiotensinogen M235T polymorphism on antihypertensive medication and blood pressure. European Journal of Human Genetics, 14, 860-866.
https://dspace.library.uu.nl/bitstream/handle/1874/27452/schelleman_06_theinfluenceofthealphaadducing460wpolymorphism.pdf?sequence=2
Maitland-Van Der Zee, A-H., Jukema, J. W., Zwinderman, A. H., Hallman, D. M., De Boer, A., Kastelein, J. J. R., & De Knijff, P. (2006). Apolipoprotein-E polymorphism and response to pravastatin in men with coronary artery disease (REGRESS). Acta Cardiologica, 61(3), 327-331. https://doi.org/10.2143/AC.61.3.2014836
https://dspace.library.uu.nl/bitstream/handle/1874/27448/maitland_06_apolipoproteinepolymorphism.pdf?sequence=2

Professional publications

Bijl, D., & de Boer, A. (2006). Geven COX-2-remmers een betere verlichting van artroseklachten dan paracetamol? Reumatologen Vademecum, 9(9).
https://dspace.library.uu.nl/bitstream/handle/1874/27335/boer_06_gevencox2remmerseenbetereverlichting.pdf?sequence=1

Other output

Bozkurt, O., Verschuren, M. W. M., de Boer, A., Grobbee, D. E., Geerlings, M. I., Heerdink, E. R., Stricker, B. H. C., & Klungel, O. H. (2006). Interaction between Genetic Polymorphisms in the Renin-Angiotensin-System and the Risk of Diabetes Associated with the Use of ACE Inhibitors. S135. Abstract from Unknown event, Asilomar, USA.
van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2006). A Comparison of Two Multiple Characteristics Decision Making Techniques for the Comparison of Antihypertensive Drugs: Simple additive Weighting and Technique for Order Preference by Similarity to an Ideal Solution. S224. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., van der Elst, M. E., Klungel, O. H., Bouvy, M. L., de Blaey, C. J., & de Boer, A. (2006). Acute Effects of Discontinuation of Statin Treatment on the Occurrence of a First Myocardial Infarction. S247. Abstract from Unknown event, Asilomar, USA.
Frankfort, S. V., Appels, B. A., de Boer, A., Tulner, LR., van Campen, J. P. C. M., Koks, C. H. W., & Beijnen, J. H. (2006). Treatment effects of rivastigmine on cognition, performance of daily living activities and behavior in Alzheimer's disease in an outpatient geriatric setting. Abstract from Unknown event, Asilomar, USA.
Schelleman, H., Klungel, O. H., Witteman, J. C. M., Breteler, M. M. B., Danser, J. H. J., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2006). Angiotensinogen M235T Polymorphism and the Risk of Myocardial Infarction and Stroke among Hypertensive Patients on ACE-Inhibitors or beta-Blockers. S144. Abstract from Unknown event, Asilomar, USA.
Bozkurt, O., Verschuren, W. M. M., de Boer, A., Grobbee, D. E., Geerlings, M. I., Heerdink, E. R., Stricker, B. H. C., & Klungel, O. H. (2006). Genetic polymorphisms in the ras and risk of diabetes associated with the use of ACE inhibitors: the Doetinchem study. 119. Abstract from Unknown event, Asilomar, USA.
Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., Smets, Y. F. C., Westendorp, R. G. J., & Klungel, O. H. (2006). Instrumental Variables and Survival Outcomes: The Effect of Pancreas-Kidney versus Kidney Transplantation on Mortality. S93. Abstract from Unknown event, Asilomar, USA.
Schelleman, H., Klungel, O. H., Witteman, J. C. M., van Duijn, C. M., Hofman, A., Breteler, M. M. B., de Boer, A., & Stricker, B. H. C. (2006). Diuretic-Gene Interactions and the Risk of Myocardial Infarction and Stroke. S17. Abstract from Unknown event, Asilomar, USA.

2005

Scholarly publications

Florentinus, S. R., Heerdink, E. R., de Boer, A., van Dijk, L., & Leufkens, H. G. M. (2005). Erratum: The trade-off between cardiovascular and gastrointestinal effects of rofecoxib (Pharmacoepidemiology and Drug Safety (2005) (14)). Pharmacoepidemiology and Drug Safety, 14(9). https://doi.org/10.1002/pds.1139
Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & De Boer, A. (2005). Compliantie, adherentie en persistentie bij antihypertensiva: Apotheker zou therapietrouw moeten bevorderen. Pharmaceutisch Weekblad, 140(48), 1543-1545.
Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., De Boer, A., & Klungel, O. H. (2005). Medicamenteuze behandling van hypercholesterolemie kosteneffectief. Pharmaceutisch Weekblad, 140(32), 982-983.
van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & De Boer, A. (2005). Rate and determinants of 10-year persistence with antihypertensive drugs. Journal of Hypertension, 23(11), 2101-2107. https://doi.org/10.1097/01.hjh.0000187261.40190.2e
Maitland-Van Der Zee, A. H., Klungel, O. H., Stricker, B. H. C., & De Boer, A. (2005). Farmacogenetica van statines. Hart Bulletin, 36(6), 159-161.
Wu, H. L., Nijssen, L. E., Van Der Salm, A., Denee, T. R., De Boer, A., & Klungel, O. H. (2005). Statines bij het acuut coronair syndroom. Pharmaceutisch Weekblad, 140(32), 995-997.
Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., De Boer, A., & Klungel, O. H. (2005). Kosteneffectiviteit van statines. Pharmaceutisch Weekblad, 140(32), 982-983.
Ufer, M., Schalekamp, T., & De Boer, A. (2005). Effects of CYP2C9 polymorphisms on phenprocoumon anticoagulation status [1] (multiple letters). Clinical Pharmacology and Therapeutics, 77(4), 335-336. https://doi.org/10.1016/j.clpt.2005.01.012
Van Wijk, B. L., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2005). Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Annals of Pharmacotherapy, 39(2), 319-28. https://doi.org/10.1345/aph.1E027
Schillevoort, I., Herings, R. M. C., Hugenholtz, G. W. K., de Boer, A., Nolen, W. A., Roos, R. A. C., & Leufkens, H. G. M. (2005). Antipsychotic-induced extrapyramidal syndromes in psychiatric practice: a case-control study. Pharmacy World & Science, 27(4), 285-289. https://doi.org/10.1007/s11096-004-5797-9
Frankfort, S. V., Appels, B. A., de Boer, A., Tulner, L. R., van Campen, J. P. C. M., Koks, C. H. W., & Beijnen, J. H. (2005). Discontinuation of rivastigmine in routine clinical practice. International Journal of Geriatric Psychiatry, 20(12), 1167-71. https://doi.org/10.1002/gps.1411
van der Elst, M. E., Bouvy, M. L., de Blaey, C. J., & de Boer, A. (2005). Preventive drug use in patients with a history of nonfatal myocardial infarction during 12-year follow-up in The Netherlands: a retrospective analysis. Clinical Therapeutics, 27(11), 1806-1814. https://doi.org/10.1016/j.clinthera.2005.11.003
Maitland-van der Zee, A. H., Klungel, O. H., & de Boer, A. (2005). Genetic Polymorphisms and Response to HMG-CoA Reductase Inhibitors. In M. K. Raizada, J. F. R. Paton, S. Kasparov, & M. J. Katovich (Eds.), Contemporary Cardiology: Cardiovascular Genomics (pp. 95-114). Humana Press.
https://dspace.library.uu.nl/bitstream/handle/1874/11671/maitland_geneticpolymorphismsandresponsetohmg_coa.pdf?sequence=2
Schelleman, H., Stricker, B. H. C., Verschuren, W. M. M., de Boer, A., Kroon, A. A., de Leeuw, P. W., Kromhout, D., & Klungel, O. H. (2005). Interactions between five candidate genes and antihypertensive drug therapy on blood pressure. The Pharmacogenomics Journal, 6(1), 22-26. https://doi.org/10.1038/sj.tpj.6500339
Hommerson, P., Nedeljkovic, S. I., Klungel, O. H., de Boer, A., Ostojic, M. C., Grujic, M. Z., Vojvodic, N. M., Bloemberg, B. P. M., & Kromhout, D. (2005). Cardiovascular drug use and differences in the incidence of cardiovascular mortality in elderly Serbian men. Pharmacy World & Science, 27(2), 124-128. https://doi.org/s11096-004-1559-y
Florentinus, S. R., Heerdink, E. R., de Boer, A., van Dijk, L., Leufkens, H. G. M., & de Boer, A. (2005). The trade-off between cardiovascular and gastrointestinal effects of rofecoxib. Pharmacoepidemiology and Drug Safety, 14(7), 437-441. https://doi.org/10.1002/pds.1123
Frankfort, S. V., Appels, B. A., de Boer, A., Tulner, LR., van Campen, J. P. C. M., Koks, C. H. W., & Beijnen, J. H. (2005). Discontinuation of rivastigmine in routine clincal practice. International Journal of Geriatric Psychiatry, 20, 1167-1171.
https://dspace.library.uu.nl/bitstream/handle/1874/11877/Boer_05_Discontinuationofrivastigmineinroutine.pdf?sequence=2
Mantel-Teeuwisse, A. K., Klungel, O. H., Schalekamp, T., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2005). Suboptimal choices and dosing of statins at start of therapy. British Journal of Clinical Pharmacology, 60(1), 83-89.
https://dspace.library.uu.nl/bitstream/handle/1874/11872/boer_05_MantelSuboptimalChoicesandDosing.pdf?sequence=2
Schelleman, H., Klungel, O. H., van Duijn, C. M., Witteman, J. C. M., Hofman, A., de Boer, A., & Stricker, B. H. C. (2005). Insertion/deletion polymorphism of the ACE gene and adherence to ACE inhibitors. British Journal of Clinical Pharmacology, 59(4), 483-485. https://doi.org/10.1111/j.1365-2125.2004.02332.x

Professional publications

Van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & De Boer, A. (2005). apothekers en therapietrouw. Pharmaceutisch Weekblad, 140(48), 1543-1545.
Vader, C. I., Grouls, R. J. E., Korsten, H. H. M., Ackerman, E. W., Schönberger, J. P. A. M., De Boer, A., & Leufkens, H. G. M. (2005). Toegenomen risico op AF na CABG. Pharmaceutisch Weekblad, 140(11), 375-378.
Klungel, O. H., Grobbee, D. E., & De Boer, A. (2005). Onderbouwd voorschrijven van antihypertensiva. Geneesmiddelenbulletin, 39(2), 13-24.
Vader, C. I., Grouls, R. J. E., Korsten, H. H. M., Ackerman, E. W., Schonberger, J. P., de Boer, A., & Leufkens, H. G. M. (2005). Boezemfibrilleren na bypassoperatie. Pharmaceutisch Weekblad, 11, 375-378.
https://dspace.library.uu.nl/bitstream/handle/1874/11878/Boer_05_Boezembribrillerennabypassoperatie.pdf?sequence=2
Wu, H. L., Nijssen, L. E., van der Salm, A., Denee, T. R., de Boer, A., & Klungel, O. H. (2005). Statines bij acuut coronair syndroom. Pharmaceutisch Weekblad, 32, 995-997.
https://dspace.library.uu.nl/bitstream/handle/1874/11870/Boer_05_Statinesbijacuutcoronairsyndroom.pdf?sequence=2
de Boer, A. (2005). Hoe nu verder met de COX-2-remmers. Geneesmiddelenbulletin, 39, 121-129.
https://dspace.library.uu.nl/bitstream/handle/1874/11874/Boer_05_HoenuverdermetdeCOX.pdf?sequence=2
Gumbs, P. D., Verschuren, W. M. M., Mantel-Teeuwisse, A. K., de Boer, A., & Klungel, O. H. (2005). Medicamenteuze behandeling van hypercholesterolemie kosteneffectief. Pharmaceutisch Weekblad, 32, 982-983.
https://dspace.library.uu.nl/bitstream/handle/1874/11875/boer_05_GumbsMedicamenteuzebehandelingvanhypercholesterolemie.pdf?sequence=2

Other output

Florentinus, S. R., Heerdink, E. R., de Boer, A., van Dijk, L., & Leufkens, H. G. M. (2005). The Trade-Off between Cardiovascular and Gastrointestinal Effects of Rofecoxib. S97. Abstract from Unknown event, Asilomar, USA.
Schelleman, H., Stricker, B. H. C., Verschuren, W. M. M., de Boer, A., Kroon, A. A., de Leeuw, P. W., Kromhout, D., & Klungel, O. H. (2005). Drug-Gene Interaction between Five Candidate Genes and the Response to Antihypertensive Drug Therapy on Blood Pressure. S124. Abstract from Unknown event, Asilomar, USA.
Schelleman, H., Klungel, O. H., Witteman, J. C. M., Hofman, A., van Duijn, C. M., de Boer, A., & Stricker, B. H. C. (2005). The Influence of the alpha-Adducin G460W Polymorphism, Angiotensinogen M235T Polymorphism, and Angiotensin Converting Enzyme I/D Polymorphism on Blood Pressure Response to Antihypertensive Medication. S51. Abstract from Unknown event, Asilomar, USA.
van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2005). 10 Year Persistence in Use of Antihypertensive Drugs. S197. Abstract from Unknown event, Asilomar, USA.
Martens, E. P., Pestman, W. R., de Boer, A., Belitser, S., & Klungel, O. H. (2005). Lower and Upper Bounds on the Correlation between Treatment and Instrumental Variable Limit the Applicability of the Method. S40. Abstract from Unknown event, Asilomar, USA.
Schalekamp, T., van Alphen, A., van Geest, A., van Holten, A., Koot, J., & de Boer, A. (2005). Co-Trimocazole and Coumarin Anticoagulants: A Troublesome Combination. S50. Abstract from Unknown event, Asilomar, USA.
van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2005). Non-compliance with antihypertensive drugs is associated with discontinuation of antihypertensive drugs.. 137. Abstract from Unknown event, Asilomar, USA.

2004

Scholarly publications

Florentinus, S. R., Heerdink, E. R., Klungel, O. H., De Boer, A., Kastelein, J. J. P., Wolfe, S. M., Cohen, J. S., Olsson, G. O., & Fox, J. C. (2004). Should rosuvastatin be withdrawn from the market? [1] (multiple letters). Lancet, 364(9445), 1577-1580. https://doi.org/10.1016/S0140-6736(04)17301-7
Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Veenstra, D. L., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2004). Pharmacoeconomic evaluation of testing for angiotensin-converting enzyme genotype before starting beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics, 14(1), 53-60. https://doi.org/10.1097/00008571-200401000-00006
Schalekamp, T., van Geest-Daalderop, J. H. H., de Vries-Goldschmeding, H., Conemans, J., Bernsen Mj, M. J., & de Boer, A. (2004). Acenocoumarol stabilization is delayed in CYP2C93 carriers. Clinical Pharmacology and Therapeutics, 75(5), 394-402. https://doi.org/10.1016/j.clpt.2003.12.017
Florentinus, S. R., Heerdink, E. R., Klungel, O. H., & de Boer, A. (2004). Should rosuvastatin be withdrawn from the market? The Lancet, 364(9445), 1577; author reply 1578-9. https://doi.org/10.1016/S0140-6736(04)17301-7
Maitland-van, D. Z. A-H., Klungel, O. H., & de Boer, A. (2004). Pharmacogenetics in health-care practice. Pharmacy World & Science, 26(5), 253-5.
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2004). Decrease of antiparkinsonian drugs before start of an antipsychotic in patients on levodopa treatment? Pharmacy World & Science, 26(5), 277-281.
Maitland-van der Zee, A-H., Klungel, O. H., Leufkens, H. G. M., de Boer, A., Stricker, B. H. C., Hofman, A., Witteman, J. C. M., van Duijn, C. M., & Kastelein, J. J. P. (2004). Effectiveness of HMG-CoA reductase inhibitors is modified by the ACE insertion deletion polymorphism. Atherosclerosis, 175(2), 377-379. https://doi.org/10.1016/j.atherosclerosis.2004.04.009
van Eijk, M. E. C., Paes, A. H. P., Porsius, A., Avorn, J., & de Boer, A. (2004). Pre-randomization decisions and group stratification in a randomized controlled trial to improve prescribing. Pharmacy World & Science, 26(4), 227-231.
https://dspace.library.uu.nl/bitstream/handle/1874/11895/Boer_04_EijkPre_randomizationdecisionsandgroupstratification.pdf?sequence=2
Mantel-Teeuwisse, A. K., Verschuren, W. M. M., Klungel, O. H., de Boer, A., & Kromhout, D. (2004). Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands. British Journal of Clinical Pharmacology, 58(3), 310-316. https://doi.org/10.1111/j.1365-2125.2004.02152.x
Maitland-van der Zee, A. H., Klungel, O. H., & de Boer, A. (2004). Pharmcogenetics in health-care practice. Pharmacy World & Science, 26, 253-255.
https://dspace.library.uu.nl/bitstream/handle/1874/11888/boer_04_MaitlandPharmcogeneticsinhealth_carepractice.pdf?sequence=2
Mantel-Teeuwisse, A. K., Klungel, O. H., Egberts, T. C. G., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2004). Failure to continue lipid-lowering drug use following the withdrawal of cerivastatin. Drug Safety, 27(1), 63-70.
https://dspace.library.uu.nl/bitstream/handle/1874/396967/boer_04_MantelFailuretoContinueLipid_LoweringDrugUse.pdf?sequence=1
Schelleman, H., Klungel, O. H., Kromhout, D., de Boer, A., Stricker, B. H. C., & Verschuren, W. M. M. (2004). Prevalence and determinants of undertreatment of hypertension in the Netherlands. Journal of Human Hypertension, 18(5), 317-324. https://doi.org/10.1038/sj.jhh.1001672
Klungel, O. H., Martens, E. P., Psaty, B. M., Grobbee, D. E., Sullivan, S. D., Stricker, B. H. C., Leufkens, H. G. M., & de Boer, A. (2004). Methods to assess intended effects of drug treatment in observational studies are reviewed. Journal of Clinical Epidemiology, 57(12), 1223-1231. https://doi.org/10.1016/j.jclinepi.2004.03.011
de Maat, M. M. R., de Boer, A., Koks, C. H. W., Mulder, J. W., Meenhorst, P. L., van Gorp, E. C. M., Mairuhu, A. T. A., Huitema, A. D. R., & Beijnen, J. H. (2004). Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. Journal of Clinical Pharmacy and Therapeutics, 29(2), 121-130. https://doi.org/10.1111/j.1365-2710.2003.00541.x
Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Verschuren, W. M. M., Witteman, J. C. M., Stijnen, T., Hofman, A., Breteler, M. M. B., Leufkens, H. G. M., & de Boer, A. (2004). Comparison of two methodologies to analyze exposure to statins in an observational study on effectiveness. Journal of Clinical Epidemiology, 57(3), 237-242. https://doi.org/10.1016/j.jclinepi.2003.07.011
van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2004). The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. Journal of Hypertension, 22, 1831-1837.
https://dspace.library.uu.nl/bitstream/handle/1874/11879/boer_04_WijkvanTheAssociationBetweenCompliance.pdf?sequence=2
Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Veenstra, D. L., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2004). Pharmacoeconomic evaluation of testing for angiotensinconverting enzyme genotype before starting ß-hydrocy-ß-methylglutaryl coenzyme A reductase inhibitor therapy in men. Pharmacogenetics, 14, 53-60.
https://dspace.library.uu.nl/bitstream/handle/1874/11889/boer_04_MaitlandPharmacoeconomicEvaluation.pdf?sequence=2
Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2004). Long term persistence with statin treatment in daily medical practice. Heart, 90(9), 1065-1066. https://doi.org/10.1136/hrt.2003.026187
Florentinus, S. R., Heerdink, E. R., Klungel, O. H., & de Boer, A. (2004). Should rosuvastatin be withdrawn from the market? The Lancet, 364, 1577-1580.
https://dspace.library.uu.nl/bitstream/handle/1874/11893/boer_04_FlorentinusShouldRosuvastatinBeWithdrawn.pdf?sequence=2
Schelleman, H., Stricker, B. H. C., De Boer, A., Kroon, A. A., Verschuren, M. W. M., Van Duijn, C. M., Psaty, B. M., & Klungel, O. H. (2004). Drug-Gene Interactions between Genetic Polymorphisms and Antihypertensive Therapy. Drugs, 64(16), 1801-1816.
https://dspace.library.uu.nl/bitstream/handle/1874/11882/boer_04_SchellemanDrug_GeneInteractions_between.pdf?sequence=2
Schalekamp, T., Oosterhof, M., van Meegen, E., van Der Meer, F. J. M., Conemans, J., Hermans, M., Meijerman, I., & de Boer, A. (2004). Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. Clinical Pharmacology and Therapeutics, 76(5), 409-417. https://doi.org/10.1016/j.clpt.2004.08.006

Other output

Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Veenstra, D. L., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2004). Pharmacoecomic evaluation of testing for angiotensin converting enzyme (ACE) genotype before starting HMG-COA reductase therapy in men. 115. Abstract from Unknown event, Asilomar, USA.
Martens, E. P., de Boer, A., Pestman, W. R., Belitser, S., & Klungel, O. H. (2004). Comparing Intended Treatment Effects after Adjustment with a Multivariable Cox Proportional Hazards Model and Propensity Score Methods in an Observational Study. S16. Abstract from Unknown event, Asilomar, USA.
van der Elst, M. E., Bouvy, M. L., de Blaey, C. J., & de Boer, A. (2004). Preventive Drug Treatment after Myocardial Infarction. S36. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Klungel, O. H., Hofman, A., Verschuren, W. M. M., Trienekens, P. H., Porsius, A. J., Stricker, B. H. C., & de Boer, A. (2004). The Need To Change Prescibing Behaviour According to Dutch and European Guidelines on the Management of Hypercholesterolemia. S28. Abstract from Unknown event, Asilomar, USA.
van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2004). Comparison of Different Methods To Calculate Persistance of Drug Use by Using Pharmacy Records. S44. Abstract from Unknown event, Asilomar, USA.
Schelleman, H., Klungel, O. H., van Duijn, C. M., Witteman, J. C. M., Hofman, A., de Boer, A., & Stricker, B. H. C. (2004). Insertion/Deletion Ploymorphism of the Ace Gene and Antihypertensive Response to Ace-Inhibitors. S108. Abstract from Unknown event, Asilomar, USA.
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2004). The effectiveness of HMG-COA reductase inhibitors is affected by ACE insertion deletion polymorphism. 361. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2004). Determinants of persistence with statin use in daily medical practice. 361. Abstract from Unknown event, Asilomar, USA.
Lievers, C. J. A., de Boer, A., Stricker, B. H. C., de Wijer, B. M. A., Kroon, A. A., de Leeuw, P. W., van Duijn, C. M., Verschuren, W. M. M., & Klungel, O. H. (2004). Interactions between Genetic Polymorphisms and Antiypertensive Drugs in the Treatment of Hypertension. S109. Abstract from Unknown event, Asilomar, USA.
van Wijk, B. L. G., Klungel, O. H., Heerdink, E. R., & de Boer, A. (2004). Non-Compliance with Antihypertensive Drugs Is Associated with Discontinuation of Antihypertensive Drugs. S47. Abstract from Unknown event, Asilomar, USA.

2003

Scholarly publications

Maitland-Van der Zee, A. H., & De Boer, A. (2003). Farmacogenetica: farmacotherapie aanpassen aan het genotype. Geneesmiddelenbulletin, 37(3), 25-30.
Maitland-van der Zee, A-H., Stricker, B. H. C., Klungel, O. H., Mantel-Teeuwisse, A. K., Kastelein, J. J. P., Hofman, A., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2003). Adherence to and dosing of beta-hydroxy-beta-methylglutaryl coenzyme A reductase inhibitors in the general population differs according to apolipoprotein E-genotypes. Pharmacogenetics, 13(4), 219-223. https://doi.org/10.1097/00008571-200304000-00006
Tamminga, W. J., Wemer, J., Oosterhuis, B., de Boer, A., Vranckx, S., Drenth, B. F. H., de Zeeuw, R. A., de Leij, L. F. M. H., & Jonkman, J. H. G. (2003). Polymorphic drug metabolism (CYP2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. European Journal of Clinical Pharmacology, 59(1), 57-64. https://doi.org/10.1007/s00228-003-0562-x
Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., van der Kuip, D. A. M., Witteman, J. C. M., Hofman, A., Leufkens, H. G. M., & de Boer, A. (2003). Repeated nitrate prescriptions as a potential marker for angina pectoris. A comparison with medical information from the Rotterdam Study. Pharmacy World & Science, 25(2), 70-72.
Ramnath, A. N., Naber, H. R., de Boer, A., & Leusink, J. A. (2003). No benefit of intraoperative whole blood sequestration and autotransfusion during coronary artery bypass grafting: results of a randomized clinical trial. Journal of Thoracic and Cardiovascular Surgery, 125(6), 1432-1437.
van der Elst, M. E., Buurma, H., Bouvy, M. L., & de Boer, A. (2003). Drug therapy for prevention of recurrent myocardial infarction. Annals of Pharmacotherapy, 37(10), 1465-77. https://doi.org/10.1345/aph.1C450
Tamminga, W. J., Wemer, J., Oosterhuis, B., de Boer, A., Vranckx, S., Drenth, B. F. H., de Zeeuw, R. A., de Leij, L. F. M. H., & Jonkman, J. H. G. (2003). Polymorphic drug metabolism (CY2D6) and utilisation of psychotropic drugs in hospitalised psychiatric patients: a retrospective study. European Journal of Clinical Pharmacology, 59, 57-64.
https://dspace.library.uu.nl/bitstream/handle/1874/27419/boer_03_polymorphicdrugmetabolism.pdf?sequence=1
van der Elst, M. E., Buurma, H., Bouvy, M. L., & de Boer, A. (2003). Drug Therapy for Prevention of Recurrent Myocardial Infarction. Cardiology, 37, 1465-1477.
https://dspace.library.uu.nl/bitstream/handle/1874/27509/elst_03_drugtherapyforpreventionofrecurrent.pdf?sequence=1
de Maat, M. M. R., Post, T. M., Jonker, D. M., Mulder, J. W., Meenhorst, P. L., van Gorp, E. C. M., Koks, C. H. W., de Boer, A., & Beijnen, J. H. (2003). Pharmacotherapy of Hospitalised HIV-Infected Patients in a General Hospital during 1990, 1997 and 2001. Clinical Drug Investigation, 23(1), 45-53. https://doi.org/10.2165/00044011-200323010-00006
Mantel-Teeuwisse, A. K., Verschuren, W. M. M., Klungel, O. H., Kromhout, D., Lindemans, A. D., Avorn, J., Porsius, A. J., & de Boer, A. (2003). Undertreatment of hypercholesterolaemia: a population-based study. British Journal of Clinical Pharmacology, 55, 389-397.
https://dspace.library.uu.nl/bitstream/handle/1874/27515/mantel_03_undertreatmentofhypercholesterolemia.pdf?sequence=2
Wirds, J. W., Duyn, A. E. J., Geraerts, S. D., Preijer, E., Van Diemen-Steenvoorde, J. A. A. M., Van Leeuwen, J. H. S., Haas, F. J. L. M., Gerritsen, W. B. M., De Boer, A., & Leusink, J. A. (2003). S100 protein content of umbilical cord blood in healthy newborns in relation to mode of delivery. Archives of Disease in Childhood Fetal and Neonatal Edition, 88(1), F67-9.
https://dspace.library.uu.nl/bitstream/handle/1874/14954/wirds_03_S100protein.pdf?sequence=2
van der Elst, M. E., Cisneros-Gonzalez, N., de Blaey, C. J., Buurma, H., & de Boer, A. (2003). Oral Antithrombotic Use Among Myocardial Infarction Patients. Annals of Pharmacotherapy, 37(1), 143-146.
https://dspace.library.uu.nl/bitstream/handle/1874/27517/elst_03_oralantithrombotic.pdf?sequence=1
Maitland-van der Zee, A. H., & de Boer, A. (2003). Farmacogenetica: geneesmiddelentherapie aangepast aan het genotype van de patiënt? Geneesmiddelenbulletin, 37(3), 25-30.
https://dspace.library.uu.nl/bitstream/handle/1874/29422/maitland_03_farmacogenetica.pdf?sequence=2
de Boer, A. (2003). Medicatiebeleid en farmaco-epidemiologie. De apotheker: uw therapeut. Pharmaceutisch Weekblad, 138(5), 176-179.
https://dspace.library.uu.nl/bitstream/handle/1874/27416/boer_03_medicatiebeleidenfarmacoepidemiologie.pdf?sequence=1

Professional publications

De Boer, A. (2003). Individualisering. Pharmaceutisch Weekblad, 138(41), 1425.
Klungel, O. H., Mantel-Teeuwisse, A. K., & De Boer, A. (2003). Geslachtsverschillen in de epidemiologie, risico en behandeling. Farmacotherapie van hypertensie en hypercholesterolemie. Pharmaceutisch Weekblad, 138(40), 1383-1389.
de Boer, A. (2003). Klassensubstitutie van geneesmiddelen. In Medicamenteuze therapie (pp. 171-176). Boerhaave Commissie voor Postacademisch Onderwijs in de Gene.
https://dspace.library.uu.nl/bitstream/handle/1874/29420/boer_03_klassensubstitutievangeneesmiddelen.pdf?sequence=1
Klungel, O. H., Mantel-Teeuwisse, A. K., & de Boer, A. (2003). Medicamenteuze behandeling van hypertensie en hypercholesterolemie. Sekseverschillen in epidemiologie, risico en therapie. Pharmaceutisch Weekblad, 138(40), 1383-1389.
https://dspace.library.uu.nl/bitstream/handle/1874/27485/klungel_03_sekseverschilleninepidemiologie.pdf?sequence=1

Other output

Kastelein, J. J. P., Hofman, A., van Duijn, C. M., Witteman, J. C. M., de Boer, A., Klungel, O. H., Leufkens, H. G. M., Maitland-van der Zee, A. H., Veenstra, D. L., & Stricker, B. H. C. (2003). Economic evaluation of testing for angiotensin converting enzyme(ACE) genotype before starting HMG.CoA reductase therapy in men.. S67-S68. Abstract from Unknown event, Asilomar, USA.
Hofman, A., van Duijn, C. M., Witteman, J. C. M., de Boer, A., Klungel, O. H., Leufkens, H. G. M., Maitland-van der Zee, A. H., & Stricker, B. H. C. (2003). Pharmacoeconomic Evaluation of Testing for Angiotensin Converting Enzym (ACE) Genotype before Starting HMG-COA Reductase Therapy in Men. S67. Abstract from Unknown event, Asilomar, USA.
Schelleman, H., Klungel, O. H., Verschuren, W. M. M., de Boer, A., Stricker, B. H. C., & Kromhout, D. (2003). Prevelance and Determinants of Undertreatment of Hypertension in the Netherlands. Pharmacoepidemiology and Drug Safety, 12(1), S100.
Kastelein, J. J. P., Hofman, A., van Duijn, C. M., Witteman, J. C. M., Breteler, M. M. B., de Boer, A., Klungel, O. H., Maitland-van der Zee, A. H., & Stricker, B. H. C. (2003). The effectiveness of HMG-CoA Reductase Inhibitors is affected by ACE Insertion/Deletion polymorphism. Abstract from Unknown event, Asilomar, USA.
Kromhout, D., de Boer, A., Klungel, O. H., Verschuren, W. M. M., Schelleman, H., & Stricker, B. H. C. (2003). Prevalence and Determinants of Undertreatment of Hypertension in the Netherlands. S. Abstract from Unknown event, Asilomar, USA.
Gorecka, K., de Boer, A., Vleck, J., Stolk, R. P., Grobbee, D. E., & Klungel, O. H. (2003). Statins and the Risk of Diabetes Mellitus: Utrecht Diabetes Epidemiology Studies (UDES). S71. Abstract from Unknown event, Asilomar, USA.
Seidell, J. C., Kastelein, J. J. P., de Knijff, P., Zwinderman, A. H., de Boer, A., Maitland-van der Zee, A. H., Jukema, J. W., & Hallman, D. M. (2003). Influence of Apolipoprotein-E polymorphism on coronary artery disease and on efficacy of HMG-CoA reductase inhibitors in men. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Goettsch, W. G., Klungel, O. H., de Boer, A., & Herings, R. M. C. (2003). Discontinuation of Statin Use in Daily Medical Practice. S76. Abstract from Unknown event, Asilomar, USA.
de Boer, A., Herings, R. M. C., Mantel-Teeuwisse, A. K., Goettsch, W. G., & Klungel, O. H. (2003). Discontinuation of Satin Use in Daily Medical Practice. S76. Abstract from Unknown event, Asilomar, USA.

2002

Scholarly publications

Lau, H. S., Muller, J. M., Eskes, P. F., Lenters, E., Van der Westerlaken, M. M. L., & De Boer, A. (2002). Een retrospectief onderzoek: Perinatale infecties: Voorkomen en behandeling. Pharmaceutisch Weekblad, 137(20), 746-747.
Bosman, A. A. P., Van der Zee, A. H. M., Klungel, O. H., Leufkens, H. G. M., & De Boer, A. (2002). Laveren tussen hoog en laag. Pharmaceutisch Weekblad, 137(9), 329-332.
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & De Boer, A. (2002). Time trends in lipid lowering drug use in the Netherlands. Has the backlog of candidates for treatment been eliminated? British Journal of Clinical Pharmacology, 53(4), 379-385. https://doi.org/10.1046/j.1365-2125.2002.01562.x
Lu, M-L., Shen, W. W., Schillevoort, I., De Boer, A., Roos, R. A. C., Jansen, P. A. F., & Leufkens, H. G. M. (2002). Comment: Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine [3] (multiple letters). Annals of Pharmacotherapy, 36(7-8), 1292-1293.
van de Vijver, D. A. M. C., Hugtenburg, J. G., & De Boer, A. (2002). Epi van ziektes kinderen. Pharmaceutisch Weekblad, 137(18), 639-643.
Schillevoort, I., van Puijenbroek, E. P., de Boer, A., Roos, R. A. C., Jansen, P. A. F., & Leufkens, H. G. M. (2002). Extrapyramidal syndromes associated with selective serotonin reuptake inhibitors: a case-control study using spontaneous reports. International Clinical Psychopharmacology, 17(2), 75-79.
Schillevoort, I., de Boer, A., van der Weide, J., Steijns, L. S. W., Roos, R. A. C., Jansen, P. A. F., & Leufkens, H. G. M. (2002). Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics, 12(3), 235-240.
Van De Vijver, D., Roos, R., Jansen, P., Porsius, A., & De Boer, A. (2002). Antipsychotics and Parkinson's disease: association with disease and drug choice during the first 5 years of antiparkinsonian drug treatment. European Journal of Clinical Pharmacology, 58(2), 157-161. https://doi.org/10.1007/s00228-002-0441-x
Maitland-van der Zee, A. H., Klungel, O. H., Stricker, B. H. C., Monique Verschuren, W. M., Kastelein, J. J. P., Leufkens, H. G. M., & de Boer, A. (2002). Genetic polymorphisms: importance for response to HMG-CoA reductase inhibitors. Atherosclerosis, 163(2), 213-22. https://doi.org/10.1016/S0021-9150(01)00725-0
Stolk, L. M. L., Degraeuwe, P. L. J., Nieman, F. H. M., de Wolf, M. C., & de Boer, A. (2002). Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Therapeutic Drug Monitoring, 24(4), 527-531.
https://dspace.library.uu.nl/bitstream/handle/1874/29345/boer_02_populationpharmacokineticsandrelationship.pdf?sequence=1
van de Vijver, D. A., Roos, R. A., Jansen, P. A., Porsius, A. J., & de Boer, A. (2002). Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records. Pharmacoepidemiology and Drug Safety, 10(6), 549-554. https://doi.org/10.1002/pds.624
Jansen, M. M. P. M., Heymer, F., Leusink, J. A., & de Boer, A. (2002). The quality of nutrition at an intensive care unit. Nutrition Research, 22, 411-422.
https://dspace.library.uu.nl/bitstream/handle/1874/29346/boer_02_thequalityofnutritionatanintensivecareunit.pdf?sequence=1
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Breteler, M. M. B., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). The effectiveness of hydroxy-methylglutaryl coenzyme A reductase inhibitors (statins) in the elderly is not influenced by apolipoprotein E genotype. Pharmacogenetics, 12(8), 647-653. https://doi.org/10.1097/00008571-200211000-00009
https://dspace.library.uu.nl/bitstream/handle/1874/29425/maitland_03_theeffectivenessofhydroxy-methylglutaryl.pdf?sequence=2
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2002). Influence of benzodiazepines on antiparkinsonian drug treatment in levodopa users. Acta Neurologica Scandinavica, 105(1), 8-12.
https://dspace.library.uu.nl/bitstream/handle/1874/27981/vijver_02_influenceofbenzodiazepinesonantiparkinsoniandrug.pdf?sequence=2
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Breteler, M. M. B., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). The effectiveness of Hydroxy-Methylglutaryl Coenzyme A reductase inhibitors in the elderly is not influenced by Apolipoprotein E-genotypes. Pharmacogenetics, 12(8), 647-653.
https://dspace.library.uu.nl/bitstream/handle/1874/29404/maitland_02_theeffectivenessofhydroxymethylglutaryl.pdf?sequence=2
van Eijk, M. E. C., Belitser, S. V., Porsius, A. J., & de Boer, A. (2002). Evaluation of patient outcomes in an area where prescribing of anticholinergic antidepressants was influenced by academic detailing. Pharmacy World & Science, 24(4), 144-148.
https://dspace.library.uu.nl/bitstream/handle/1874/29315/eijk_02_evaluationofpatientoutcomes.pdf?sequence=1
Mantel-Teeuwisse, A. K., Klungel, O. H., Herings, R. M. C., van Puijenbroek, E. P., Porsius, A. J., & de Boer, A. (2002). Myopathy due to statin/fibrate use in the Netherlands. Annals of Pharmacotherapy, 36(12), 1957-1960.
Klungel, O. H., Heckbert, S. R., de Boer, A., Leufkens, H. G. M., Sullivan, S. D., Fishman, P. A., Veenstra, D. L., & Psaty, B. M. (2002). Lipid-lowering drug use and cardiovascular events after myocardial infarction. Annals of Pharmacotherapy, 36(5), 751-757. https://doi.org/10.1345/aph.1A308
de Maat, M. M. R., Frankfort, S. V., Mathôt, R. A. A., Mulder, J. W., Meenhorst, P. L., van Gorp, E. C. M., Koks, C. H. W., Hoetelmans, R. M. W., de Boer, A., & Beijnen, J. H. (2002). Discrepancies Between Medical and Pharmacy Records for Patients on Anti-HIV Drugs. Annals of Pharmacotherapy, 36(3), 410-415.
https://dspace.library.uu.nl/bitstream/handle/1874/29382/maat_02_discrepanciesbetweenmedicalandpharmacy.pdf?sequence=2
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2002). Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. British Journal of Clinical Pharmacology, 54(2), 168-170.
https://dspace.library.uu.nl/bitstream/handle/1874/27876/vijver_02_startofaselectiveserotoninreuptakeinhibitor.pdf?sequence=2

Professional publications

Lau, H. S., Muller, J. M., Eskes, P. F., Lenters, E., Van der Westerlaken, M. M. L., & De Boer, A. (2002). Perinatale infecties. Pharmaceutisch Weekblad, 137(20), 746-747.
Bosman, A. A. P., Van der Zee, A. H. M., Klungel, O. H., Leufkens, B., & De Boer, A. (2002). Cholesterol als risicofactor van een hersenberoerte. Pharmaceutisch Weekblad, 137(9), 329-332.
van de Vijver, D. A. M. C., Hugtenburg, J. G., & de Boer, A. (2002). Wat hebben en gebruiken onze kleine klantjes. Pharmaceutisch Weekblad, 137(18), 639-643.
https://dspace.library.uu.nl/bitstream/handle/1874/27888/vijver_02_epidemiologievanziektenengebruikvanreceptgeneesmiddele.pdf?sequence=2

Other output

Mantel-Teeuwisse, A. K., Klungel, O. H., Egberts, A. C. G., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2002). Patterns of lipid lowering drug use after the withdrawal of cerivastatin. 234 P011-235. Abstract from Unknown event, Asilomar, USA.
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Breteler, M. M. B., van Duijn, C. M., & de Boer, A. (2002). The effectiveness of HMG-CoA Refuctase Inhibitors is affected by ACE Insertion/Deletion polymorphism. s10-s11. Abstract from Unknown event, Asilomar, USA.
Hommerson, P., Nedeljkovic, S., Klungel, O. H., de Boer, A., Ostojic, M., Grujic, M. Z., & Kromhout, D. (2002). Cardiovascular drug use and differences in the incidence of cardiovascular mortality in elderly men. The serbian cohort of the seven countries study. S106-S106. Abstract from Unknown event, Asilomar, USA.
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Mantel-Teeuwisse, A. K., Kastelein, J. J. P., Hofman, A., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). Adherence to and dosing of HMG-CoA reductase inhibitors differs according to apolipoprotein E-genotypes. s15. Abstract from Unknown event, Asilomar, USA.
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Mantel-Teeuwisse, A. K., Leufkens, H. G. M., van Duijn, C. M., & de Boer, A. (2002). The use of statins in the general population differ according to APOE-genotypes. 559. Abstract from Unknown event, Asilomar, USA.
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Leufkens, H. G. M., van Duijn, C. M., van Broekhoven, C., & de Boer, A. (2002). The effectiveness of HMG-CoA reductase inhibitors in an elderly population is independent of Apolipoprotein E-genotypes. 548P. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Verboom, M., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2002). Comparison of a Parkinson's Disease Guideline with Early Antiparkinsonian Ddrug Treatment in Dutch Daily Practice. S75 166-S76. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Verboom, M., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2002). Comparison of a Parkinson's disease guideline with early antiparkinsonian drug treatment in Dutch daily practice. S75-S75. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Egberts, A. C. G., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2002). Patterns of lipid lowering drug use after the withdrawal of cerivastatin.. 559P. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Verschuren, W. M. M., Klungel, O. H., Porsius, A. J., & de Boer, A. (2002). Determinants of undertreatment of hypercholesterolemia in a population-based study in the Netherlands. 557P. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2002). Patterns of lipid lowering drug use after withdrawal of cerivastatin. S68-S68. Abstract from Unknown event, Asilomar, USA.
Maitland-van der Zee, A. H., Stricker, B. H. C., Klungel, O. H., Kastelein, J. J. P., Hofman, A., Witteman, J. C. M., Breteler, M. M. B., van Duijn, C. M., & de Boer, A. (2002). The effectiveness of HMG-CoA reduction inhibitors is affected by ACE insertion/delection polymorphism. S10-S10. Abstract from Unknown event, Asilomar, USA.

2001

Scholarly publications

Fournier, A., Oprisiu, R., Michel Achard, J., Klungel, O. H., Leufkens, H. G. M., De Boer, A., Longstreth Jr., W. T., Kaplan, R. C., Smith, N. L., & Psaty, B. M. (2001). Differences between primary vs secondary prevention trials regarding the stroke protective effect of antihypertensive drugs [3] (multiple letters). Archives of Internal Medicine, 161(17), 2152-2153. https://doi.org/10.1001/archinte.161.17.2152
van Eijk, M. E. C., Avorn, J., Porsius, A. J., & de Boer, A. (2001). Reducing prescribing of highly anticholinergic antidepressants for elderly people: randomised trial of group versus individual academic detailing. BMJ (Clinical research ed.), 322(7287), 654-657.
https://dspace.library.uu.nl/bitstream/handle/1874/319410/van_eijk_01_reducing.mht_1_.pdf?sequence=1
Klungel, O. H., Stricker, B. H., Breteler, M. M., Seidell, J. C., Psaty, B. M., & de Boer, A. (2001). Is drug treatment of hypertension in clinical practice as effective as in randomized controlled trials with regard to the reduction of the incidence of stroke? Epidemiology, 12(3), 339-344.
Mantel-Teeuwisse, A. K., Kloosterman, J. M., Maitland-van der Zee, A. H., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Drug-Induced lipid changes: a review of the unintended effects of some commonly used drugs on serum lipid levels. Drug Safety, 24(6), 443-56.
van de Vijver, D. A., Stricker, B. H., Breteler, M. M., Roos, R. A., Porsius, A. J., & de Boer, A. (2001). Evaluation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. Pharmacy World & Science, 23(4), 148-52.
van Eijk, M. E., Krist, L. F., Avorn, J., Porsius, A., & de Boer, A. (2001). Do the research goal and databases match? A checklist for a systematic approach. Health Policy, 58(3), 263-274.
van Dongen, E. P., Schepens, M. A., Morshuis, W. J., ter Beek, H. T., Aarts, L. P., de Boer, A., & Boezeman, E. H. (2001). Thoracic and thoracoabdominal aortic aneurysm repair: use of evoked potential monitoring in 118 patients. Journal of Vascular Surgery, 34(6), 1035-1040. https://doi.org/10.1067/mva.2001.119397
Schillevoort, I., de Boer, A., Herings, R. M., Roos, R. A., Jansen, P. A., & Leufkens, H. G. (2001). Antipsychotic-induced extrapyramidal syndromes: Risperidone compared with low- and high-potency conventional antipsychotic drugs. European Journal of Clinical Pharmacology, 57(4), 327-331. https://doi.org/10.1007/s002280100302
https://dspace.library.uu.nl/bitstream/handle/1874/27881/schillevoort_01_antipsychoticinducedextrapyramidalsyndromes.pdf?sequence=2
Mantel-Teeuwisse, A. K., Klungel, O. H., & de Boer, A. (2001). Lipid abnormalities induced by novel antipsychotic drugs. Drug Safety, 24(13), 1017-1018.
https://dspace.library.uu.nl/bitstream/handle/1874/29287/mantel_01_lipidabnormalities.pdf?sequence=2
Klungel, O. H., Heckbert, S. R., Longstreth, W. T., Furberg, C. D., Kaplan, R. C., Smith, N. L., Lemaitre, R. N., Leufkens, H. G., de Boer, A., & Psaty, B. M. (2001). Antihypertensive Drug Therapies and the Risk of Ischemic Stroke. Archives of Internal Medicine, 161(1), 37-43.
https://dspace.library.uu.nl/bitstream/handle/1874/388234/klungel_01_antihypertensivedrugtherapies.pdf?sequence=1
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M., Porsius, A., & de Boer, A. (2001). Comparison of different methods to estimate prevalence of drug use by using pharmacy records. Journal of Clinical Epidemiology, 54(11), 1181-1186.
Schillevoort, I., de Boer, A., Herings, R. M., Roos, R. A., Jansen, P. A., & Leufkens, H. G. (2001). Risk of extrapyramidal syndromes with haloperidol, risperidone, or olanzapine. Annals of Pharmacotherapy, 35(12), 1517-1522.
https://dspace.library.uu.nl/bitstream/handle/1874/27879/schillevoort_01_riskofextrapyramidalsyndromes.pdf?sequence=2
van Vliet, J., Leusink, J. A., de Jongh, B. M., & de Boer, A. (2001). A comparison between two types of central venous catheters in the prevention of catheter-related infections: the importance of performing all the relevant cultures. Clinical Intensive Care, 12(3), 135-140.
https://dspace.library.uu.nl/bitstream/handle/1874/27778/boer_01_acomparisonbetweentwotypesofcentralvenouscatheters.pdf?sequence=1
van de Vijver, D. A. M. C., Stricker, B. H. C., Breteler, M. M. B., Roos, R. A. C., Porsius, A. J., & de Boer, A. (2001). Evalutation of antiparkinsonian drugs in pharmacy records as a marker for Parkinson's disease. Pharmacy World & Science, 23(4), 148-152.
https://dspace.library.uu.nl/bitstream/handle/1874/27943/vijver_01_evaluationofantiparkinsoniandrugs.pdf?sequence=2
Klungel, O. H., Leufkens, H. G. M., de Boer, A., Longstreth, W. T., Kaplan, R. C., Smith, N. L., & Psaty, B. M. (2001). Differences Between Primary vs Secondary Prevention Trials Regarding the STroke Protective Effect of Antihypertensive Drugs. Archives of Internal Medicine, 161.
https://dspace.library.uu.nl/bitstream/handle/1874/27950/klungel_01_differencesbetweenprimaryvssecondary.pdf?sequence=1
Mantel-Teeuwisse, A. K., Kloosterman, J. M. E., Maitland-van der Zee, A. H., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Drug-Induces Lipid Changes. Drug Safety, 24(6), 443-456.
Maitland-van der Zee, A. H., Klungel, O. H., Kloosterman, J. M. E., Seidell, J. C., Leufkens, H. G. M., & de Boer, A. (2001). The association between antihypertensive drug therapies and plasma lipid levels in the general population. Journal of Human Hypertension, 15, 701-705.
https://dspace.library.uu.nl/bitstream/handle/1874/27955/maitland_01_theassociationbetweenantihypertensivedrug.pdf?sequence=2
Maitland-van der Zee, A. H., de Boer, A., & Leufkens, H. G. M. (2001). Pharmacogenetics and the role of the pharmacist. Journal of Research in Pharmaceutical Economics, 11(3/4), 143-150.
https://dspace.library.uu.nl/bitstream/handle/1874/29309/maitland_01_pharmacogeneticsandtheroleofthepharmacist.pdf?sequence=2

Other output

van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2001). Start of Antipsychotic Drugs in New Patients with Parkinson's Disease. S20-S21. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2001). Use of antipsychotics in parkinson's disease in daily practice. Conceptuur, 28, 24.
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2001). Influence of Benzodiazepines on Antiparkinsonian Drug Treatment in Patients with Parkinson's Disease. S21. Abstract from Unknown event, Asilomar, USA.
Schillevoort, I. E. R. M., de Boer, A., van der Weide, J., Steijns, L. S. W., Roos, R. A. C., & Jansen, P. A. F. (2001). Antipsychotic-induced extrapyramidal syndromes and CYP2D6 genotype: a case control study. S155-S156. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2001). Time trends in lipid lowering drug use in The Netherlands. Has the backlog of candidates for treatment been eliminatied. S72-S72. Abstract from Unknown event, Asilomar, USA.
Schillevoort, I. E. R. M., van Puijenbroek, E. P., de Boer, A., Roos, R. A. C., & Jansen, P. A. F. (2001). Extrapyramidal syndromes associated with SSRI-use. S140-S141. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Lindemans, A. D., Verschuren, W. M. M., Klungel, O. H., Porsius, A. J., & de Boer, A. (2001). Undertreatment of hypercholesterolemia in a population-based study in The Netherlands. S73-S73. Abstract from Unknown event, Asilomar, USA.

2000

Scholarly publications

Klungel, O. H., Paes, A. H. P., Seidell, J. C., Kuijvenhoven, M. M., & De Boer, A. (2000). Sekseverschillen bij de medicamenteuze behandeling van hypertensie door de huisarts. Huisarts en Wetenschap, 43(7), 303-305.
Klungel, O. H., De Boer, A., Seidell, J. C., Lloyd-Jones, D. M., & Levy, D. (2000). Overestimation of the number of individuals with hypertension who are eligible for treatment according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [4] (multiple letters). Archives of Internal Medicine, 160(10), 1540.
Klungel, O. H., Paes, A. H. P., Seidell, J. C., Kuijvenhoven, M. M., & De Boer, A. (2000). Geslachtsverschillen behandeling hypertensie. Huisarts en Wetenschap, 43(7), 303-305.
Maitland-van der Zee, A. H., Klungel, O. H., Leufkens, H. G. M., & De Boer, A. (2000). Farmacotherapie en genotype. Pharmaceutisch Weekblad, 135(11), 378-379.
Teeuwisse, A., Klungel, O., Porsius, A., & De Boer, A. (2000). Doelmatigheid van cholesterolverlagende geneesmiddelen. Pharmaceutisch Weekblad, 135(4), 106.
Klungel, O. H., Paes, A. H. P., De Boer, A., Kuyvenhoven, M. M., Seidell, J. C., & Bakker, A. (2000). Sex differences in the medication choice for hypertension in general practice: A study with written case simulations. Pharmacy World and Science, 22(4), 140-146. https://doi.org/10.1023/A:1008713714549
Van Eijk, M. E. C., Bahri, P., Dekker, G., Herings, R. M. C., Porsius, A., Avorn, J., & De Boer, A. (2000). Use of prevalence and incidence measures to describe age-related prescribing of antidepressants with and without anticholinergic effects. Journal of Clinical Epidemiology, 53(6), 645-651. https://doi.org/10.1016/S0895-4356(99)00194-8
Sang Lau, H., Riezebos, J., Abas, V., Porsius, A. J., & De Boer, A. (2000). A nation-wide study on the practice of euthanasia and physician-assisted suicide in community and hospital pharmacies in the Netherlands. Pharmacy World and Science, 22(1), 3-9. https://doi.org/10.1023/A:1008705223595
Klungel, O. H., de Boer, A., Paes, A. H., Nagelkerke, N. J., Seidell, J. C., & Bakker, A. (2000). Influence of correction for within-person variability in blood pressure on the prevalence, awareness, treatment, and control of hypertension. American Journal of Hypertension, 13(1 ), 88-91. https://doi.org/10.1016/S0895-7061(99)00101-6
Klungel, O. H., de Boer, A., & Seidell, J. C. (2000). Overestimation of the number of individuals with hypertension who are eligible for treatment according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Archives of Internal Medicine, 160(10), 1540.
Lau, H. S., Florax, C., Porsius, A. J., & De Boer, A. (2000). The completeness of medication histories in hospital medical records of patients admitted to general internal medicine wards. British Journal of Clinical Pharmacology, 49(6), 597-603.
van Dongen, E. P., ter Beek, H. T., Aarts, L. P., Schepens, M. A., Morshuis, W. J., Benning, F. J., de Boer, A., & Boezeman, E. H. (2000). The effect of two low-dose propofol infusions on the relationship between six-pulse transcranial electrical stimulation and the evoked lower extremity muscle response. Acta Anaesthesiologica Scandinavica, 44(7), 799-803.
Klungel, O. H., de Boer, A., Paes, A. H., Herings, R. M., Seidell, J. C., & Bakker, A. (2000). Influence of question structure on the recall of self-reported drug use. Journal of Clinical Epidemiology, 53(3), 273-277. https://doi.org/10.1016/S0895-4356(99)00167-5
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2000). Start of antidepressant drugs in Parkinson's disease: association with the disease and its course. International Journal of Geriatric Psychiatry, 2, 148-152.
van Dongen, E. P., ter Beek, H. T., Aarts, L. P., Schepens, M. A., Morshuis, W. J., Benning, F. J., de Boer, A., & Boezeman, E. H. (2000). The effect of two low-dose propofol infusions on the relationship between six-pulse transcranial electrical stimulation and the evoked lower extremety muscle response. Acta Anaesthesiologica Scandinavica, 44, 799-803.
https://dspace.library.uu.nl/bitstream/handle/1874/27756/boer_00_theeffectoftwolow_dosepropofoinfusions.pdf?sequence=1
Maitland-van der Zee AH, N. V., de Boer A, N. V., Leufkens, H. G., & de Boer, A. (2000). The interface between pharmacoepidemiology and pharmacogenetics. European Journal of Pharmacology, 410(2-3), 121-130.
Klungel, O. H., Stricker, B. H., Breteler, M. M., Seidell, J. C., & de Boer, A. (2000). Onderbehandeling van hypertensie en het risico op beroerte bij de oudste ouderen. Tijdschrift voor Gerontologie en Geriatrie, 31(3), 119-122.
Klungel, O. H., Leufkens, H. G. M., & de Boer, A. (2000). Prediction or assessment of the number of averted events by treatment of hypertension. BMJ - Clinical research. http://www.bmj.com/cgi/eletters/320/7236/680#7077
Klungel, O. H., Leufkens, H. G. M., & de Boer, A. (2000). Estimation of the absolute benefit of drug treatment of hypertension in the general population. Hypertension. http://hyper.ahajournals.org/cgi/eletters/35/2/539
Klungel, O. H., Kaplan, R. C., Heckbert, S. R., Smith, N. L., Lemaitre, R. N., Longstreth, W. T., Leufkens, H. G., de Boer, A., & Psaty, B. M. (2000). Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. Stroke, 31(2), 420-424.
https://dspace.library.uu.nl/bitstream/handle/1874/407045/klungel_00_controlofbloodpressureandriskofstroke.pdf?sequence=1
Klungel, O. H., de Boer, A., Paes, A. H., Nagelkerke, N. J., Seidell, J. C., & Bakker, A. (2000). Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure. Journal of Clinical Epidemiology, 53(11), 1158-1163.

Professional publications

Klungel, O. H., Stricker, B. H. C., Breteler, M. M. B., Seidell, J. C., & De Boer, A. (2000). Ondrrbehandeling van hypertensie en het risico op hersenberoerte bij ouderen. Tijdschrift voor Gerontologie en Geriatrie, 31(3), 119-122.
Klungel, O. H., Paes, A. H. P., Seidell, J. C., Kuijvenhoven, M. M., & de Boer, A. (2000). Sekseverschillen bij de medicamentueze behandeling van hypertensie door de huisarts. Huisarts en Wetenschap, 43(7), 303-305.
Vonk, R., Conemans, J. M. H., Hermens, W. A. J. J., Bernsen, J., Brouwer, M., & de Boer, A. (2000). Is kennis van het cytochroom-genotype CY2D6 en CYP2C19 van belang voor de behandeling van de psychiatrische patient? Ark, 9(1), 14-19.
Mantel-Teeuwisse, A. K., Klungel, O. H., Porsius, A. J., & de Boer, A. (2000). Cholesterolverlagers en doelmatigheid. Pharmaceutisch Weekblad, 135(4), 108.
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porius, A. J., & de Boer, A. (2000). Selective serotonin reuptake inhibitor (SSRI) therapy is associated with an increase in antiparkinsonian drug treatment in patients on levodopa. British Journal of Clinical Pharmacology, 50, 486-487.
Klungel, O. H., de Boer, A., & Leufkens, H. G. M. (2000). Effectiviteit van geneesmiddelen in de dagelijkse praktijk. Conceptuur, 22, 10-11.
Maitland-van der Zee, A. H., Klungel, O. H., Leufkens, H. G. M., & de Boer, A. (2000). Geneesmiddeltherapie en het genotype van de patiënt. Pharmaceutisch Weekblad, 135, 378-379.
van de Vijver, D. A. M. C., Roos, A. C., Jansen, P. A. F., Porius, A. J., & de Boer, A. (2000). Start of a Selective Serotonin Reuptake Inhibitor (SSRI) and Increase of Antiparkinsonian Drug Treatment in Patients on Levodopa. Pharmacoepidemiology and Drug Safety, 9, S11-S12.

Other output

van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2000). Selective serotonin reuptake inhibitor (SSRI) therapy is associated with an increase in antiparkinsonian drug treatment in patients on levodopa. 486P-486P. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2000). Start of selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. S11-S12. Abstract from Unknown event, Asilomar, USA.
Mantel-Teeuwisse, A. K., Klungel, O. H., Verschuren, W. M. M., Porsius, A. J., & de Boer, A. (2000). Comparison of different methods to estimate prevalence of drug use by using pharmacy records. S1-S1. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., Stricker, B. H. C., Seidell, J. C., Breteler, M. M. B., Psaty, B. M., & de Boer, A. (2000). Effectiviteit van medicamenteuze behandeling van hypertensie in de reductie van de incidentie van hersenberoerte in de algemene bevolking. 29-29. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2000). Start van een selectieve serotonine heropname remmer (SSRI) en toename van parkinsonmedicatie in levodopa gebruikers. 12-12. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., Stricker, B. H. C., Seidell, J. C., Breteler, M. M. B., Psaty, B. M., & de Boer, A. (2000). Effectiviness of the pharmacological treatment of hypertension in the reduction of the incidence of stroke in the general population. 394P-395P. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Roos, R. A. C., Jansen, P. A. F., Porsius, A. J., & de Boer, A. (2000). Start van een selectieve serotonine heropname remmer (SSRI) en toename van parkinsonisme in levodopa gebruikers. Tijdschrift voor sociale geneeskunde, 78.
Klungel, O. H., Heckbert, S. R., Longstreth, W. T., Furberg, C. D., Smith, N. L., Kaplan, R. C., Lemaitre, R. N., Leufkens, H. G. M., de Boer, A., & Psaty, B. M. (2000). Antihypertensive drug therapies and the risk of ischemic stroke. 720-720. Abstract from Unknown event, Asilomar, USA.

1999

Scholarly publications

Teeuwisse, A. K., Porsius, A. J., & De Boer, A. (1999). Kwaliteit von behandeling von patienten met hypercholesterolemie: De weerbarstige praktijk. Pharmaceutisch Weekblad, 134(48), 1680-1683.
De Boer, A. (1999). Problemen bij de interpretatie van geneesmiddelenonderzoek. Farmacotherapie en 'evidence-based medicine'. Pharmaceutisch Weekblad, 134(5), 167-171.
De Boer, A. (1999). Farmacotherapie en 'evidence-based medicine': Problemen bij de interpretatie van geneesmiddelenonderzoek. Pharmaceutisch Weekblad, 134(5 SPEC. ISS.), 167-168.
Bouvy, M. L., Heerdink, E. R., Klungel, O. H., De Boer, A., Stuurman-Bieze, A. G. G., & Leufkens, H. G. (1999). Women with angina pectoris receive less antiplatelet treatment than men. British Journal of General Practice, 49(441), 299-300.
Klungel, O. H., De Boer, A., Paes, A. H. P., Herings, R. M. C., Seidell, J. C., & Bakker, A. (1999). Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharmacy World and Science, 21(5), 217-220. https://doi.org/10.1023/A:1008741321384
Klungel, O. H., De Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1999). Cardiovascular diseases and risk factors in a population-based study in The Netherlands: Agreement between questionnaire information and medical records. Netherlands Journal of Medicine, 55(4), 177-183. https://doi.org/10.1016/S0300-2977(99)00045-5
van Dongen, E. P., ter Beek, H. T., Schepens, M. A., Morshuis, W. J., Haas, F. J., de Boer, A., Boezeman, E. H., & Aarts, L. P. (1999). The relationship between evoked potentials and measurements of S-100 protein in cerebrospinal fluid during and after thoracoabdominal aortic aneurysm surgery. Journal of Vascular Surgery, 30(2), 293-300. https://doi.org/10.1016/S0741-5214(99)70140-0
van Dongen, E. P., ter Beek, H. T., Schepens, M. A., Morshuis, W. J., de Boer, A., Aarts, L. P., & Boezeman, E. H. (1999). Effect of nitrous oxide on myogenic motor potentials evoked by a six pulse train of transcranial electrical stimuli: a possible monitor for aortic surgery. British Journal of Anaesthesia, 82(3), 323-8.
Klungel, O. H., Paes, A. H. P., de Boer, A., Kuyvenhoven, M. M., Seidell, J. C., & Bakker, A. (1999). Sex differences in the medication choice for hypertension in general practice. A study written case simulations. In Studies on the quality of the pharmacological treatment of hypertension in the general population.
Bouvy, M. L., Heerdink, E. R., Klungel, O. H., de Boer, A., Stuurman-Bieze, A. G. G., & Leufkens, H. G. M. (1999). Women with angina pectoris receive less antiplatelet treatment then men. British Journal of General Practice, 49, 299-300.
van Dongen, E. P., ter Beek, H. T., Schepens, M. A., Morshuis, W. J., Haas, F. J. L. M., de Boer, A., Boezeman, E. H., & Aarts, L. P. (1999). The relationship between evoked potential and measurements of S-100 protein in cerebrospinal fluid during and after thoracoabdominal aortic aneurysm surgery. Journal of Vascular Surgery, 30, 293-300.
van Dongen, E. P., ter Beek, H. T., Schepens, M. A., Morshuis, W. J., Langemeijer, H. J., de Boer, A., & Boezeman, E. H. (1999). Within-patient variability of myogenic motor-evoked potentials to multipulse transcranial electrical stimulation during two levels of partial neuromuscular blockade in aortic surgery. Anesthesia and Analgesia, 88(1), 22-27.
van Dongen, E. P., ter Beek, H. T., Schepens, M. A., Morshuis, W. J., de Boer, A., Aarts, L. P., & Boezeman, E. H. (1999). Effect of nitrous oxide on myogenic motor potentials evoked by a six pulse train of transcanial electrical stimuli: a possible monitor for aortic surgery. British Journal of Anaesthesia, 82, 323-328.
Klungel, O. H., Stricker, B. H. C., Paes, A. H. P., Seidell, J. C., Bakker, A., Voko, Z., Breteler, M. M. B., & de Boer, A. (1999). Excess Stroke Among Hypertensive Men and Women Attributable to Undertreatment of Hypertension. Stroke, 30, 1312-1318.
van Dongen, E. P., ter Beek, H. T., Schepens, M. A., Morshuis, W. J., de Boer, A., Aarts, L. P., & Boezeman, E. H. (1999). Within patient variability of lower extremity muscle responses to transcranial electrical stimulation with pulse trains in aortic surgery. Clinical Neurophysiology, 110(6), 1144-1148.

Professional publications

van de Vijver, D. A. M. C., & De Boer, A. (1999). Effect van selegeline op mortaliteit bij de ziekte van Parkinson. Pharmaceutisch Weekblad, 134(46), 1602-1603.
De Boer, A., Peterse, E. E. M., Teeuwisse, A. K., & Porsius, A. J. (1999). Farmacotherapie van hyperlipidemie. Pharmaceutisch Weekblad, 134(48), 1667-1671.
De Boer, A. (1999). Problemen bij het interpreteren van geneesmiddelonderzoek: Farmacotherapie en evidence based medicine. Pharmaceutisch Weekblad, 134(5), 167-171.
Klungel, O. H., Seidell, J. C., Paes, A. H. P., & de Boer, A. (1999). Onderbehandeling van hypertensie: voorkomen, gevolgen en determinanten. Cardiologie, 6, 556-560.
de Boer, A., Peterse, E. E. M., Mantel-Teeuwisse, A. K., & Porsius, A. J. (1999). De medicamenteuze behandeling van hyperlipidemie. Pharmaceutisch Weekblad, 134(48), 1667-1671.
van de Vijver, D. A. M. C., & de Boer, A. (1999). Een omstreden geneesmiddel. Effect van selegiline op mortaliteit in patiënten met de ziekte van Parkinson. Pharmaceutisch Weekblad, 134, 1602-1603.
de Boer, A. (1999). Farmacotherapie en 'evidence-based medicine'. Pharmaceutisch Weekblad, 134(5), 167-171.
Mantel-Teeuwisse, A. K., Porsius, A. J., & de Boer, A. (1999). Kwaliteit van behandeling van patiënten met hypercholesterolemie. Pharmaceutisch Weekblad, 134(48), 1680-1683.

Other output

Klungel, O. H., Kaplan, R. C., Heckbert, S. R., Smith, N. L., Lemaitre, R. N., Longstreth, W. T., Leufkens, H. G. M., de Boer, A., & Psaty, B. M. (1999). Control of blood pressure and risk of stroke among pharmacologically treated hypertensive patients. 1-807-1-808. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., Stricker, B. H. C., Seidell, J. C., Breteler, M. M. B., Psaty, B. M., & de Boer, A. (1999). Effectiveness of the pharmacological treatment of hypertension under everyday circumstances with regard to the reduction of the incidence of stroke. 355-356. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Stricker, B. H. C., Breteler, M. M. B., Roos, R. A. C., Porsius, A. J., & de Boer, A. (1999). Validity of pharmacy records for identification of patients with Parkinson's disease. S175-S175. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Roos, R. A. C., Porsius, A. J., & de Boer, A. (1999). Estimation of incidence and prevalence of Parkinson's disease in elderly using pharmacy records. 779-780. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Herings, R. M. C., Roos, R. A. C., Porsius, A. J., & de Boer, A. (1999). Higher use of psychotropic drugs among patients with Parkinson's disease. 62-62. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Stricker, B. H. C., Breteler, M. M. B., Roos, R. A. C., Porsius, A. J., & de Boer, A. (1999). Validity of pharmacy records for identification of patients with Parkinson's disease. 779P-779P. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Stricker, B. H. C., Breteler, M. M. B., Roos, R. A. C., Porsius, A. J., & de Boer, A. (1999). Validity of pharmacy records for classification of Parkinson's disease. 20-21. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., Stricker, B. H. C., Seidell, J. C., Breteler, M. M. B., Psaty, B. M., & de Boer, A. (1999). Effectiveness of the pharmacological treatment of hypertension in the reduction of the incidence of stroke in the general population. 394P-395P. Abstract from Unknown event, Asilomar, USA.
van Eijk, M. E. C., Porsius, A. J., Avorn, J., & de Boer, A. (1999). Continuing medical education, individual academic detailing versus peer review group approach: can it alter antidepressant prescribing?. S177-S177. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., Roos, R. A. C., Porsius, A. J., & de Boer, A. (1999). Estimation of incidence and prevelance of Parkinson's disease elderly using pharmacy records. S175-S175. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., Stricker, B. H. C., Paes, A. H. P., Seidell, J. C., Bakker, A., Voko, Z., Breteler, M. M. B., & de Boer, A. (1999). Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. 129-130. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., de Boer, A., Herings, R. M. C., Roos, R. A. C., & Porsius, A. J. (1999). Increased use of psychotropic drugs by patients with Parkinson's disease. 476P-476P. Abstract from Unknown event, Asilomar, USA.

1998

Scholarly publications

Klungel, O. H., & De Boer, A. (1998). SEKSEVERSCHILLEN IN DE FARMACOLOGISCHE BEHANDELING VAN HYPERTENSIE: AANZIENLIJKE ONDERBEHANDEKING BIJ MANNEN EN VROUWEN AANGETOOND. Pharmaceutisch Weekblad, 133(23), 872-876.
Klungel, O. H., Seidell, J. C., De Boer, A., & Marques-Vidal, P. (1998). Assessment of control of hypertension in the population (multiple letters) [1]. Journal of Hypertension, 16(3), 395-396.
Turton, E. P. L., De Boer, A., Van Dongen, H. P. A., Leusink, J. A., & Moll, F. L. (1998). Ruptured aortic aneurysms [1]. European Journal of Vascular and Endovascular Surgery, 16(6), 543.
Klungel, O. H., Seidell, J. C., De Boer, A., Colhoun, H., Dong, W., & Poulter, N. (1998). Overestimation of the prevalence of hypertension in the population (multiple letters) [2]. Journal of Hypertension, 16(11), 1702-1703.
Klungel, O. H., & De Boer, A. (1998). Geslachtsverschillen bij de behandeling van hypertensie. Pharmaceutisch Weekblad, 133(23), 872-876.
Klungel, O. H., Seidell, J. C., & de Boer, A. (1998). Assessment of control of hypertension in the population. Journal of Hypertension, 16(3), 395-6.
van Dongen, H. P., Leusink, J. A., Moll, F. L., Brons, F. M., & de Boer, A. (1998). Ruptured abdominal aortic aneurysms: factors influencing postoperative mortality and long-term survival. European Journal of Vascular and Endovascular Surgery, 15(1), 62-66.
ter Riet, G., de Craen, A. J., de Boer, A., & Kessels, A. G. (1998). Is placebo analgesia mediated by endogenous opioids? A systematic review. Pain, 76(3), 273-275.
Klungel, O. H., de Boer, A., Paes, A. H., Seidell, J. C., & Bakker, A. (1998). Sex differences in antihypertensive drug use: determinants of the choice of medication for hypertension. Journal of Hypertension, 16(10), 1545-1553. https://doi.org/10.1097/00004872-199816100-00021
Klungel, O. H., Seidell, J. C., & de Boer, A. (1998). Overestimation of the prevalence of hypertension in the population. Journal of Hypertension, 16(11), 1702-3.
ter Riet, G., de Craen, A. J. M., de Boer, A., Kessels, J., & de Boer, A. (1998). Do Endorphins Mediate Placebo Analgesia? A Critical Commentary on One of the Seminal Papers. Forschende Komplementarmedizin, 5 Suppl S1, 12-14. https://doi.org/21069
de Boer, A., Van Dongen, H. P. A., Leusink, J. A., & Moll, F. L. (1998). Ruptured aortic aneurysms [correspondence]. European Journal of Vascular and Endovascular Surgery, 16, 543-543.
Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., Nagelkerke, N. J. D., & Bakker, A. (1998). Undertreatment of hypertension in a population-based study in The Netherlands. Journal of Hypertension, 16, 1371-1378.

Professional publications

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1998). Aanzienlijke onderbehandeling vrouwen aangetoond. Pharmaceutisch Weekblad, 133, 872-876.

Other output

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., Nagelkerke, N. J. D., & Bakker, A. (1998). Estimating the prevalence of hypertension corrected for the effect of within-Person-variability. S172-S172. Abstract from Unknown event, Asilomar, USA.
van de Vijver, D. A. M. C., de Boer, A., Herings, R. M. C., Roos, R. A. C., & Porsius, A. J. (1998). Patients with Parkinson's disease use more psychotropic drugs. S173-S173. Abstract from Unknown event, Asilomar, USA.
Bouvy, M. L., Heerdink, E. R., Klungel, O. H., de Boer, A., & Leufkens, H. G. M. (1998). Women with angina pectoris receive less anti-platelet treatment than men. S176-S176. Abstract from Unknown event, Asilomar, USA.

1997

Scholarly publications

Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1997). Sex‐based differences in the pharmacological treatment of hypertension: Insights from health services research. Journal of Hypertension, 15(12). https://doi.org/10.1097/00004872-199715120-00023
Crijns, M. B., Klaver, C., De Boer, A., Van Hees, C., Vermeer, B. J., Vandenbroucke, J., & Bergman, W. (1997). Ultraviolet exposure and the development of banal and atypical naevi - A cross-sectional study on Curacao and in The Netherlands. Melanoma Research, 7(5), 407-416.
McAlister, F. A., Klungel, O. H., De Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1997). Sex-based differences in the pharmacological treatment of hypertension: Insights from health services research (multiple letters) [1]. Journal of Hypertension, 15(12 I), 1527-1528. https://doi.org/10.1097/00004872-199715120-00022
Egeland, T., Hoff-Olsen, P., Magnus, O., De Boer, A., Oosterwijk, J. C., Rigters- Aris, C., & McDonough, P. G. (1997). Excessive use of a single donor? And inadvertent consangunity [4] (multiple letters). Fertility and Sterility, 67(6), 1181-1183.
Hofsté, W. J., Linssen, C. A., Boezeman, E. H., Hengeveld, J. S., Leusink, J. A., & de-Boer, A. (1997). Delirium and cognitive disorders after cardiac operations: relationship to pre- and intraoperative quantitative electroencephalogram. International Journal of Clinical Monitoring and Computing, 14(1), 29-36.
van der Werff, Y. D., van der Houwen, H. K., Heijmans, P. J., Duurkens, V. A., Leusink, H. A., van Heesewijk, H. P., & de Boer, A. (1997). Postpneumonectomy pulmonary edema. A retrospective analysis of incidence and possible risk factors. Chest, 111(5), 1278-1284.
Klungel, O. H., de Boer, A., Paes, A. H., Seidell, J. C., & Bakker, A. (1997). Sex differences in the pharmacological treatment of hypertension: a review of population-based studies. Journal of Hypertension, 15(6), 591-600. https://doi.org/10.1097/00004872-199715060-00004
Wesselink, R. M., de Boer, A., Morshuis, W. J., & Leusink, J. A. (1997). Cardio-pulmonary-bypass time has important independent influence on mortality and morbidity. European Journal of Cardio-thoracic Surgery, 11(6), 1141-5.
de Boer, A., Sang Lau, H., & Porsius, A. (1997). Physician-assisted death and pharmacy practice in the Netherlands. New England Journal of Medicine, 337(15), 1091-1092. https://doi.org/10.1056/NEJM199710093371518
Shackleton, D. P., Westendorp, R. G., Kasteleijn-Nolst Trenité, D. G., de Boer, A., & Herings, R. M. (1997). Dispensing epilepsy medication: a method of determining the frequency of symptomatic individuals with seizures. Journal of Clinical Epidemiology, 50(9), 1061-8. https://doi.org/10.1016/S0895-4356(97)00116-9
Crijns, M. B., Klaver, C., de Boer, A., Van Hees, C., Vermeer, B. J., Vandenbroucke, J., & Bergman, W. (1997). Ultraviolet exposure and the development of banal and atypical naevi--a cross-sectional study on Curaçao and in The Netherlands. Melanoma Research, 7(5), 407-16.
Shackleton, D. P., Westendorp, R. G. J., Kasteleijn-Nolst Trenité, T. G. A., de Boer, A., & Herings, R. M. C. (1997). Epileptic medication: a road to determining the number of individuals with seizures. Journal of Clinical Epidemiology, 50, 1061-1068.
Lau, H. S., de Boer, A., Beuning, K. S., & Porsius, A. (1997). Validation of pharmacy records in drug exposure assessment. Journal of Clinical Epidemiology, 50(5), 619-625.
de Boer, A., Oosterwijk, J. C., & Rigters-Aris, C. A. E. (1997). Excessive use of a single donor? And inadvertent consanguinity. Fertility and Sterility, 67, 1181-1185.
Wesselink, R. M. J., de Boer, A., Morshuis, W. J., & Leusink, J. A. (1997). Cardiopulmonary-bypass time has important independent influence on mortality and morbidity. European Journal of Cardio-thoracic Surgery, 11, 1141-1145.
Crijns, M. B., Klaver, C. W., de Boer, A., van Hees, C. L. M., Vermeer, B. J., Vandenbroucke, J. P., & Bergman, W. (1997). Ultraviolet exposure and the development of banal and atypical naevi - a cross-sectio-nal study on Curaçao and in the Netherlands. Melanoma Research, 7, 407-416.
de Boer, A., & Porsius, A. J. (1997). Why do scientists still study and discuss homeopathy? Pharmacy World & Science, 19(4), 176-177.

Professional publications

De Boer, A. (1997). Epidemiologie van ziekten bij kinderen. Pharmaceutisch Weekblad, 132(14), 425-428.
de Boer, A. (1997). Gebruik van prestatieverhogende middelen op sportscholen in Nederland. Pharmaceutisch Weekblad, 132, 1366-1370.
Linssen, C. A. M., Leusink, J. A., & de Boer, A. (1997). Algemeen welbevinden van patiënten na open-hartchirurgie. Intensive Care Review, 12, 199-203.
de Boer, A. (1997). De waarde van pharmacoeconomics voor beslissingen in de farmacotherapie. In D. D. Breimer, A. W. Broekmans, & H. G. M. Leufkens (Eds.), Pharmaco-economics (pp. 11-16)

Other output

van Eijk, M. E. C., Muris, M., de Boer, A., & Porsius, A. J. (1997). Pharmacotherapy consultation groups; inventory of prognostic factors influencing the outcome of measures to improve pharmacotherapy. S98-S98. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1997). Undertreatment of hypertension in The Netherlands 1987 - 1995. S25-S25. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1997). Influence of correction for within-person variability on the prevelance estimation of hypertension treatment and undertreatment of hypertension. S25-S25. Abstract from Unknown event, Asilomar, USA.
van Eijk, M. E. C., Bahri, P., Herings, R. M. C., de Boer, A., & Porsius, A. J. (1997). Influence of age on the prescribing of antidepressants with or without anticholinergic effects. S47-S47. Abstract from Unknown event, Asilomar, USA.

1996

Scholarly publications

Jonker, D. M., Dik, E., Willems, M., & De Boer, A. (1996). De behandeling van posttraumatische dystrofie: Een literatuuroverzicht. Pharmaceutisch Weekblad, 131(34), 977-983.
Gansevoort, R. T., Sluiter, W. J., Herings, R. M. C., De Boer, A., Stricker, B. H. C., Leufkens, H. G. M., & Porsius, A. (1996). ACE-REMMERS VERGROTEN HET RISICO OP HYPOGLYKEMIE BIJ DIABETICI [2]. Nederlands Tijdschrift voor Geneeskunde, 140(19), 1042-1044.
Herings, R. M. C., De Boer, A., Stricker, B. H. C., Leufkens, H. G. M., & Porsius, A. J. (1996). ACE-REMMERS VERGROTEN HET RISICO OP HYPOGLYKEMIE BIJ DIABETICI. Nederlands Tijdschrift voor Geneeskunde, 140(8), 432-436.
Lau, H. S., Beuning, K. S., Postma-Lim, E., Klein-Beernink, L., de Boer, A., & Porsius, A. J. (1996). Non-compliance in elderly people: evaluation of risk factors by longitudinal data analysis. Pharmacy World & Science, 18(2), 63-8.
Tissot van Patot, H. A., Leusink, J. A., Roodenburg, J., de Jongh, B. M., Lau, H. S., de Boer, S., & de Boer, A. (1996). Selective decontamination of the digestive tract: effect of cessation of routine application at an ICU. Pharmacy World & Science, 18(5), 171-177. https://doi.org/10.1007/BF00820728
Lau, H. S., Beuning, K. S., Postma-Lin, E., Klein-Beernink, L., de Boer, A., & Porsius, A. J. (1996). Non-compliance in the elderly: evaluation of risk factors by longitudinal data analysis. Pharmacy World & Science, 18, 63-68.
Herings, R. M., Stricker, B. H., de Boer, A., Bakker, A., Sturmans, F., & Stergachis, A. (1996). Current use of thiazide diuretics and prevention of femur fractures. Journal of Clinical Epidemiology, 49(1), 115-119. https://doi.org/10.1016/0895-4356(95)00552-8

Professional publications

Gansevoort, R. T., Sluiter, W. J., Herings, R. M. C., De Boer, A., Stricker, B. H. C., Leufkens, H. G. M., & Porsius, A. (1996). ACE eremmers verhogen het risico op hypoglycaemieen bij diabetes patienten. Nederlands Tijdschrift voor Geneeskunde, 140(19), 1042-1044.
Herings, R. M. C., De Boer, A., Stricker, B. H. C., Leufkens, H. G. M., & Porsius, A. J. (1996). ACE remmers verhogen het risico op hypoglycemie. Nederlands Tijdschrift voor Geneeskunde, 140(8), 432-436.
Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1996). Man/vrouw verschillen in de behandeling van hypertensie: internationale trends. Tijdschrift voor Sociale Gezondheidszorg, 4, 51-51.
Jonker, D., Dik, E., Willems, M., & de Boer, A. (1996). De behandeling van posttraumatische dystrofie: een literatuur overzicht. Pharmaceutisch Weekblad, 131, 977-83.
Heymans, F. J. M., van der Werf, Y. D., van Heesewijk, H. P. M., Duurkens, V. A. M., Brutel de la Rivière, A., Leusink, J. A., van der Houwen, H. K., & de Boer, A. (1996). Postpneumectomie-longoedeem; een retrospectief onderzoek naar incidentie en mogelijke risicofactoren. Nederlands Tijdschrift voor Geneeskunde, 140, 1054-1055.
Klungel, O. H., de Boer, A., Paes, A. H. P., Seidell, J. C., & Bakker, A. (1996). Onderbehandeling van hypertensie bij mannen en vrouwen: een dwarsdoorsnede populatie-onderzoek in Nederland. Tijdschrift voor Sociale Gezondheidszorg, 4, 26-26.
de Boer, A. (1996). Vrouwelijke hormonen en het risico op thrombo-embolische ziekten en kanker. In Vrouwelijke hormonen in de dagelijkse praktijk (pp. 35-40). Schering.
Herings, R. M. C., de Boer, A., Stricker, B. H. C., Leufkens, H. G. M., & Porsius, A. J. (1996). ACE-remmers vergroten het risico op hypoglycemie bij diabetici. Nederlands Tijdschrift voor Geneeskunde. Studenteneditie, 140, 432-436.
Herings, R. M. C., Stricker, B. H. C., & de Boer, A. (1996). Verhoogd risico op ernstige hypoglycemie na verandering van insuline preparaten. Tijdschrift voor Sociale Gezondheidszorg, 4, 70-70.
Herings, R. M. C., de Boer, A., Leufkens, H. G. M., & Urquhart, J. (1996). Selectief voorschrijven van orale anticonceptiva in relatie tot het optreden van veneuze thrombo-embolieën. Tijdschrift voor Sociale Gezondheidszorg, 4, 36-37.
Brons, F. M., Dongen, H. M. P., Leusink, J. A., & de Boer, A. (1996). Korte en lange termijn levensverwachting van patienten met een geruptureerd aneurysma aorta abdominalis na hospitalisatie. Tijdschrift voor Sociale Gezondheidszorg, 4, 53-53.
Van Dongen, H. P. A., Leusink, J. A., Moll, F. L., Brons, F. M., & de Boer, A. (1996). Behandelingsresultaten bij patiënten met een gebarsten aneurysma van de aorta abdominalis. Nederlands Tijdschrift voor Geneeskunde, 140, 140-140.
Leusink, J. A., de Jongh, B. M., Tissot van Patot, H., Rodenburg, J., & de Boer, A. (1996). Infecties bij langdurig beademde patiënten. Nederlands Tijdschrift voor Geneeskunde, 140, 1054-1054.
Lau, H. S., de Boer, A., Klerkx, M. B., & Porsius, A. J. (1996). De volledigheid van de medicatiehistorie in de medische status in het ziekenhuis. Tijdschrift voor Sociale Gezondheidszorg, 4, 70-70.
Lau, H. S., de Boer, A., Abas, V., & Porsius, A. J. (1996). Een landelijk onderzoek naar de frequentie van verzoeken om verstrekking van euthanasie middelen in openbare en ziekenhuisapotheken en de afhandeling daarvan. Tijdschrift voor Sociale Gezondheidszorg, 4, 15-16.
de Boer, A., van Haren, S. F., Hartgens, F., de Boer, D., & Porsius, A. J. (1996). Onderzoek naar het gebruik van prestatieverhogende middelen bij bodybuilders in Nederland. NeCeDo, 1-55.
de Boer, A. (1996). Why do we still study and discuss homeopathy. EPSA Newsletter, 3, 6-7.
de Boer, A., van Haren, S. F., Hartgens, F., de Boer, D., & Porsius, A. J. (1996). Onderzoek naar het gebruik van prestatie verhogende middelen bij bodybuilders in Nederland. NeCeDo.
Shackleton, D. P., Westendorp, R. G. J., Kasteleijn-Nolst Trenité, T. G. A., de Boer, A., & Vandenbroucke, J. P. (1996). Sterfte in een cohort epilepsie patiënten met een langdurige follow-up. Tijdschrift voor Sociale Gezondheidszorg, 4, 40-41.
Shackleton, D. P., Westendorp, R. G. J., Kasteleijn-Nolst Trenité, T. G. A., de Boer, A., & Herings, R. M. C. (1996). Epilepsie medicatie: een methode om het aantal individuen met aanvallen te bepalen. Tijdschrift voor Sociale Gezondheidszorg, 4, 45-45.
Leusink, J. A., Van Dongen, H. P. A., Moll, F. L., Brons, F. M., & de Boer, A. (1996). Het gebarsten abdominale aorta-aneurysma: complicaties en mortaliteit bij 309 patiënten. Intensive Care Review, 11, 131-140.
de Boer, A., & Leufkens, H. G. M. (1996). De ontwikkelingsgeneeskundige besparing vanuit de optiek van de farmacoepidemiologie. Innovator, 4, 16-17.
van der Houwen, H. K., van der Werf, Y. D., Heijmans, P. J. M., Duurkens, V. A. M., Leusink, J. A., van Heesewijk, H. P. M., & de Boer, A. (1996). Postpneumectomie longoedeem en fresh frozen plasma (FFP) transfusies. Tijdschrift voor Sociale Gezondheidszorg, 4, 28-29.

Other output

Herings, R. M. C., de Boer, A., Urquhart, J., & Leufkens, H. G. M. (1996). Non-causal explanations for the increased risk of venous thromboembolism among users of third generation oral anticonceptives. S88-S88. Abstract from Unknown event, Asilomar, USA.
Shackleton, D. P., Westendorp, R. G. J., Kasteleijn-Nolst, T., de Boer, A., & Herings, R. M. C. (1996). Epileptic medication: a road to determining the number of individuals with seizures. S89-S89. Abstract from Unknown event, Asilomar, USA.
Lau, H. S., de Boer, A., Beuning, K. S., & Porsius, A. J. (1996). Validation of pharmacy records as a measure of drug exposure. S60-S60. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., Paes, A. H. P., de Boer, A., Seidell, J. C., & Bakker, A. (1996). Sex differences in the treatment of hypertension; international trends. S57-S57. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., Paes, A. H. P., de Boer, A., Seidell, J. C., & Bakker, A. (1996). Undertreatment of hypertension in men and women: a population based survey in the Netherlands. S57-S57. Abstract from Unknown event, Asilomar, USA.
Klungel, O. H., Paes, A. H. P., de Boer, A., Schut-Meijwes, F. B., Seidell, J. C., & Bakker, A. (1996). Gender differences in self-reported antihypertensive drug use in the Netherlands. 165-167. Abstract from Unknown event, Asilomar, USA.
Herings, R. M. C., de Boer, A., & Stricker, B. H. C. (1996). Increased hypoglycaemia risk after changing insulin formulations. S89-S89. Abstract from Unknown event, Asilomar, USA.
Lau, H. S., Klerkx, M. B., de Boer, A., & Porsius, A. J. (1996). Completeness of medication histories in hospital medical records. S60-s60. Abstract from Unknown event, Asilomar, USA.

1995

Scholarly publications

Veninga, C. C. M., Denig, P., Haaijer-Ruskamp, F. M., Dijkers, F. W., Meyboom-de Jong, B., de Vries, C. S., Timmer, J. W., de Jong-van den Berg, L., van Eijk, M. E. C., de Boer, A., van Hemert, T. J. E., van der Horn, J. A., Steerneman, A. G. M., de Jong-van den Berg, L. T. W., de Wit, M. E. C., Stricker, B. H. C., Porsius, A. J., Peters, E. T. J., van der Werf, G. T., ... Stewart, R. (1995). Abstracts of papers and posters. Pharmacy World & Science, 17(9), 3-7. https://doi.org/10.1007/BF01901737
Van Haeften, T. W., Kong, N., Bates, A., Ryder, R. E. J., Feher, M. D., Amiel, S., Davie, A. P., Wildenborg, I. H. M., Veenstra, J., Van der Voort, P. H. J., Verdegaal, W. P., Silberbusch, J., Herings, R. M. C., De Boer, A., Stricker, B. H. C., Leufkens, H. G. M., & Porsius, A. J. (1995). ACE inhibitors and hypoglycaemia [13]. The Lancet, 346(8967), 125-127. https://doi.org/10.1016/S0140-6736(95)92148-6
Herings, R. M. C., Stricker, B. H. C., De Boer, A., Bakker, A., & Sturmans, F. (1995). Benzodiazepines and the risk of falling leading to femur fractures: Dosage more important than elimination half-life. Archives of Internal Medicine, 155(16), 1801-1807. https://doi.org/10.1001/archinte.155.16.1801
Herings, R. M., de Boer, A., Stricker, B. H., Bakker, A., & Sturmans, F. (1995). A rapid method to estimate the incidence rate and prevalence of insulin-dependent diabetes mellitus in children 0-19 years of age. Pharmacy World & Science, 17(1), 17-19. https://doi.org/10.1007/BF01875553
de Boer, A., Oosterwijk, J. C., & Rigters-Aris, C. A. (1995). Determination of a maximum number of artificial inseminations by donor children per sperm donor. Fertility and Sterility, 63(2), 419-21.
de Boer, A., & van Griensven, J. M. (1995). Drug interactions with thrombolytic agents. Current perspectives. Clinical Pharmacokinetics, 28(4), 315-26. https://doi.org/10.2165/00003088-199528040-00004
Herings, R. M., de Boer, A., Stricker, B. H., Leufkens, H. G., & Porsius, A. (1995). Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. The Lancet, 345(8959), 1195-8.
Crijns, M. B., Klaver, C. C., de Boer, A., Van Hees, C. L., Vermeer, B. J., Vandenbroucke, J. P., & Bergman, W. (1995). A comparative study of atypical and melanocytic naevi on the tropical island Curaçao and in The Netherlands. Melanoma Research, 5(3), 161-7.

1994

Scholarly publications

van Berkel, J., Filius, P. M. G., Dik, E., & De Boer, A. (1994). Long term health effects of breast augmentation: A review. Pharmacoepidemiology and Drug Safety, 3(5), 265-273.
Ganesh, S., Sier, C. F., Griffioen, G., Vloedgraven, H. J., de Boer, A., Welvaart, K., van de Velde, C. J., van Krieken, J. H., Verheijen, J. H., & Lamers, C. B. (1994). Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Research, 54(15), 4065-71.
van Hees, C. L., de Boer, A., Jager, M. J., Bleeker, J. C., Kakebeeke, H. M., Crijns, M. B., Vandenbroucke, J. P., & Bergman, W. (1994). Are atypical nevi a risk factor for uveal melanoma? A case-control study. Journal of Investigative Dermatology, 103(2), 202-5.

1993

Scholarly publications

Van Der Kuy, P. H. M., Meulendijk, A. J. M., Kraaijenga, J. J., & De Boer, A. (1993). HEEFT EEN PATIENT MET CARA RECHT OP EEN BETABLOKKER? EEN META-ANALYSE VAN HET EFFECT VAN CELIPROLOL OP HET GEFORCEERDE EXPIRATOIRE 1-SECONDE-VOLUME. Pharmaceutisch Weekblad, 128(44), 1293-1297.
Houghton, A., Blaney, D., De Boer, A., & Herings, R. M. C. (1993). Oral contraceptives without prescription [14]. The Lancet, 342(8877), 993.
Kroon, C., De Boer, A., Kroon, J. M., Schoemaker, H. C., Briet, E., & Cohen, A. F. (1993). Comparison of the bioavailability of heparin and low molecular weight heparin(oids) after subcutaneous administration in healthy volunteers. British Journal of Clinical Pharmacology, 35(5).
De Boer, A., & Waller, P. C. (1993). Frequency of adverse drug reactions [3]. British Journal of Clinical Pharmacology, 36(1), 89-91.
Lansink, M., de Boer, A., Dijkmans, B. A., Vandenbroucke, J. P., & Hazes, J. M. (1993). The onset of rheumatoid arthritis in relation to pregnancy and childbirth. Clinical and Experimental Rheumatology, 11(2), 171-174.
van Schaardenburg, D., Hazes, J. M., de Boer, A., Zwinderman, A. H., Meijers, K. A., & Breedveld, F. C. (1993). Outcome of rheumatoid arthritis in relation to age and rheumatoid factor at diagnosis. Journal of Rheumatology, 20(1), 45-52.
de Boer, A., Kluft, C., Gerloff, J., Dooijewaard, G., Günzler, W. A., Beier, H., van der Meer, F. J., & Cohen, A. F. (1993). Pharmacokinetics of saruplase, a recombinant unglycosylated human single-chain urokinase-type plasminogen activator and its effects on fibrinolytic and haemostatic parameters in healthy male subjects. Thrombosis and Haemostasis, 70(2), 320-5.
De Boer, A., Kluft, C., Kasper, F. J., Kroon, J. M., Schoemaker, H. C., Breimer, D. D., Soons, P. A., & Cohen, A. F. (1993). Interaction study between nifedipine and recombinant tissue-type plasminogen activator in healthy subjects. British Journal of Clinical Pharmacology, 36(2), 99-104.
Bavinck, J. N., De Boer, A., Vermeer, B. J., Hartevelt, M. M., van der Woude, F. J., Claas, F. H., Wolterbeek, R., & Vandenbroucke, J. P. (1993). Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. British Journal of Dermatology, 129(3), 242-9.
de Boer, A., & Herings, R. M. (1993). Oral contraceptives without prescription. The Lancet, 342(8877), 993.

Professional publications

Van Der Kuy, P. H. M., Meulendijk, A. J. M., Kraaijenga, J. J., & De Boer, A. (1993). Meta-analyse van de effectiviteit van celiprolol bij astma. Pharmaceutisch Weekblad, 128(44), 1293-1297.

1992

Scholarly publications

Cohen, A. F., Burggraaf, K., De Boer, A., & Kluft, C. (1992). Clearance of plasminogen activators - a major determinant of plasma concentration: Therapeutic and diagnostic implications. Annals of the New York Academy of Sciences, 667, 443-449. https://doi.org/10.1111/j.1749-6632.1992.tb51646.x
Danhof, M., de Boer, A., Magnani, H. N., & Stiekema, J. C. (1992). Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis, 22(2), 73-84.
de Boer, A., Kluft, C., Kroon, J. M., Kasper, F. J., Schoemaker, H. C., Pruis, J., Breimer, D. D., Soons, P. A., Emeis, J. J., & Cohen, A. F. (1992). Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator. Thrombosis and Haemostasis, 67(1), 83-87.
Krulder, J. W., de Boer, A., van den Besselaar, A. M., Cohen, A. F., Schoemaker, H. C., Briët, E., & Meinders, A. E. (1992). Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion. A study in healthy volunteers. Thrombosis and Haemostasis, 68(1), 30-2.
de Boer, A., Kroon, J. M., Kroon, C., van Vliet, A., Schoemaker, H. C., Breimer, D. D., Donoghue, S., & Cohen, A. F. (1992). Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man. Thrombosis and Haemostasis, 68(1), 24-9.
Cohen, A. F., Burggraaf, K., de Boer, A., & Kluft, C. (1992). Clearance of plasminogen activator--a major determinant of plasma concentration: therapeutic and diagnostic implications. Annals of the New York Academy of Sciences, 667, 443-9.
Kroon, C., ten Hove, W. R., de Boer, A., Kroon, J. M., van der Pol, J. M., Harthoorn-Lasthuizen, E. J., Schoemaker, H. C., van der Meer, F. J., & Cohen, A. F. (1992). Highly variable anticoagulant response after subcutaneous administration of high-dose (12,500 IU) heparin in patients with myocardial infarction and healthy volunteers. Circulation, 86(5), 1370-5.
de Boer, A., Kluft, C., Dooijewaard, G., Kasper, F. J., Kroon, J. M., Breimer, D. D., Stiekema, J. C., & Cohen, A. F. (1992). Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. Thrombosis and Haemostasis, 68(5), 550-5.

1991

Scholarly publications

Dooijewaard, G., de Boer, A., Turion, P. N., Cohen, A. F., Breimer, D. D., & Kluft, C. (1991). Physical exercise induces enhancement of urokinase-type plasminogen activator (u-PA) levels in plasma. Thrombosis and Haemostasis, 65(1), 82-6.
de Boer, A., Stiekema, J. C., Danhof, M., Moolenaar, A. J., & Breimer, D. D. (1991). Interaction of ORG 10172, a low molecular weight heparinoid, and digoxin in healthy volunteers. European Journal of Clinical Pharmacology, 41(3), 245-50. https://doi.org/10.1007/BF00315437
Kroon, C., de Boer, A., Kroon, J. M., Schoemaker, H. C., van den Meer, F. J., Cohen, A. F., & Schoenmaker, H. C. (1991). Influence of skinfold thickness on heparin absorption. The Lancet, 337(8747), 945-6.
de Boer, A., Stiekema, J. C., Danhof, M., & Breimer, D. D. (1991). Influence of chlorthalidone on the pharmacokinetics and pharmacodynamics of Org 10172 (Lomoparan), a low molecular weight heparinoid, in healthy volunteers. Journal of Clinical Pharmacology, 31(7), 611-7.
De Boer, A., Stiekema, J. C., Danhof, M., & Breimer, D. D. (1991). The influence of Org 10172, a low molecular weight heparinoid, on antipyrine metabolism and the effect of enzyme induction on the response to Org 10172. British Journal of Clinical Pharmacology, 32(1), 23-9.
de Boer, A., Stiekema, J. C., Danhof, M., van Dinther, T. G., Boeijinga, J. K., Cohen, A. F., & Breimer, D. D. (1991). Studies of interaction of a low-molecular-weight heparinoid (Org 10172) with cloxacillin and ticarcillin in healthy male volunteers. Antimicrobial Agents and Chemotherapy, 35(10), 2110-2115.
de Boer, A., Danhof, M., Cohen, A. F., Magnani, H. N., & Breimer, D. D. (1991). Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. Thrombosis and Haemostasis, 66(2), 202-7.
Soons, P. A., De Boer, A., Cohen, A. F., & Breimer, D. D. (1991). Assessment of hepatic blood flow in healthy subjects by continuous infusion of indocyanine green. British Journal of Clinical Pharmacology, 32(6), 697-704.

1990

Scholarly publications

De Boer, A., Kroon, J. M., Kroon, C. C. M., Van Vliet, A., Breimer, D. D., Donoghue, S., & Cohen, A. F. (1990). Synergistic effect of a new thromboxane antagonist (GR32191) and heparin on bleeding time in healthy male volunteers. British Journal of Clinical Pharmacology, 29(5).
Soons, P. A., Uchida, E., De Boer, A., Schoemaker, H. C., Breimer, D. D., & Cohen, A. F. (1990). Effects of exercise and i.v. propranolol on liver blood flow in healthy subjects, estimated with a continuous infusion of indocyanine green. British Journal of Clinical Pharmacology, 29(5).
Kroon, C. C. M., De Boer, A., Van Der Meer, F. J. M., Edelbroek, P. M., Schoemaker, H., & Cohen, A. F. (1990). Interactions between single dose acenocoumarol and cimetidine or pentobarbitone: validation of a single dose model to predict interactions in steady state. British Journal of Clinical Pharmacology, 29(5).
De Boer, A., Kluft, C., & Cohen, A. F. (1990). Life style and blood fibrinolytic activity: A comment on clearance of plasminogen activators. Fibrinolysis, 4(SUPPL. 2), 61-63.
De Boer, A., Danhof, M., Cohen, A. F., Magnani, H. N., & Breimer, D. D. (1990). Interactions study of the low molecular weight heparinoid Org 10172 (lomoparan®) and acetylsalicylic acid in healthy male volunteers. European Journal of Pharmacology, 183(2), 641. https://doi.org/10.1016/0014-2999(90)93567-A
Stiekema, J. C., de Boer, A., Danhof, M., Kroon, C., Broekmans, A. W., van Dinther, T. G., Voerman, J., & Breimer, D. D. (1990). Interaction of the combined medication with the new low-molecular-weight heparinoid Lomoparan (Org 10172) and acenocoumarol. Haemostasis, 20(3), 136-46.
Kroon, C., de Boer, A., Hoogkamer, J. F., Schoemaker, H. C., van der Meer, E. J., Edelbroek, P. M., & Cohen, A. F. (1990). Detection of drug interactions with single dose acenocoumarol: new screening method? International journal of clinical pharmacology, therapy, and toxicology, 28(8), 355-360.